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ABSTRACT 
 
Background: Pulmonary arterial hypertension (PAH) is a recognised complication of SLE. 
The risk of developing PAH in SLE may be increased in a subset of patients with 
antiphospholipid antibodies.   
Aims: To estimate the point prevalence of PAH, to evaluate screening tests and to identify 
risk factors for PAH in a large cohort of SLE patients 
Methods: A prospective cross-sectional study of 288 patients with SLE using resting 
transthoracic echocardiography to estimate the systolic pulmonary artery pressures (sPAP) 
and to assess cardiac morphology and function. We assessed potential risk factors such as the 
presence of lung disease, autoantibodies and anti-phospholipid syndrome (APS). We 
evaluated screening tests such as pulmonary function tests, six minute walk test and 
biomarkers. 
Results: Twelve out of 283 patients had PAH with sPAP >30 mm Hg (range 31-59 mmHg). 
Only 3 patients had sPAP >40 mm Hg. The only significant risk factor for PAH was lupus 
anticoagulant (p=0.005).  
Conclusion: The point prevalence of PAH was 4.2% in our cohort of patients with SLE. The 
significant association of lupus anticoagulant and presence of APS in PAH cases suggests 
that thrombosis may play an important role in the development of PAH with SLE patients.  
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CHAPTER 1   INTRODUCTION 
 
1.1. Systemic lupus erythematosus (SLE) 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease with multiple systemic 
manifestations causing significant increase in morbidity and mortality(1;2). The overall 
standardised mortality ratio (SMR) which is the ratio of deaths observed to deaths expected 
was 2.4 in a large multicenter international lupus cohort of 9,547 patients with an average 
follow up of 8.1 years. In particular the SMR for SLE patients with renal disease and 
infections were 7.9 and 5 respectively in this cohort.  Though skin and joint involvement are 
usually the presenting features, other system involvement such as haematological, renal and 
central nervous system can result in serious organ damage. Cardiovascular and respiratory 
involvement is not uncommon, and they can occur together resulting in symptom mimicry, 
delayed diagnosis and rapidly progressive disease.  
More than 90% patients who develop SLE are women in 20-50 year age group, but the level 
of activity in men is broadly similar. Though the actual cause of SLE is unknown, genetic 
susceptibility, hormonal and environmental factors may play a role in the development of 
SLE. 
1.1.1 Epidemiology 
The worldwide SLE prevalence range is 3-241/100,000(3-5) and incidence range is 0.37- 
8.7/100,000(5-7). The study methods, the country and ethnicity studied, sex, and case 
definitions are among several reasons that explain this wide variability. A community based 
study on adult women from Birmingham, UK reported a point prevalence of 1 in 2000 and an 
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incidence of 6.8 per 100,000(5). SLE more often affects women than men, supporting a role 
for sex hormones in the pathogenesis of SLE. The female to male ratio is 6-18:1, which 
depends on ethnicity and age of onset of SLE. The sex ratio is less than 10:1 females to males 
in younger and older patients. SLE affects any age between 18 months to 89 years but more 
frequently presents in the  in 20-50 year age group. More than 90% patients who develop 
SLE include females in the reproductive age group, and this has several implications for the 
management of SLE around pregnancy. It is well recognised that ethnic groups differ in 
incidence, prevalence, disease course, and outcomes such as organ damage and mortality in 
SLE. In a UK study, the Afro-Caribbean and Asian ethnicity had 5-6 times higher incidence 
and 2-5 times higher prevalence of SLE. In a US study(8), African Americans had two times 
higher incidence of SLE. The non-Caucasians with SLE are more likely to have severe 
disease course, renal and neurologic involvement(9), damage accrual and higher mortality 
rates(10;11). 
1.1.2 Etiopathogenesis 
Over the last 60 years since the advent of anti-nuclear antibody (ANA) and following the 
description of LE cell phenomenon, it has been proposed that the etiology of SLE includes 
autoantibodies produced in response to genetic, hormonal and environmental factors.  
1.1.2.1 Etiology 
Several genes have been identified to be acting in additive fashion to confer susceptibility to 
SLE(12;13). Both genetic and allelic heterogeneity are involved in the initiation of SLE. The 
familial aggregation of SLE, high sibling recurrence risk ratio (14)and increased SLE 
concordance rate in monozygotic twins (24-69%) being almost 10 times higher than that seen 
in dizygotic twins (2-9%) supports the genetic factors involved in SLE(15;16). The genetic 
linkage studies have identified multiple regions with loci that increase risk of lupus. The 
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homozygous hereditary complement deficiencies particularly of C1q,C2 and C4 increases the 
risk of SLE as these complement gene products participate in the rapid clearance of apoptotic 
debris(17). The risk for developing SLE associated with hereditary C1q, C4 and C2 
deficiency are >90%, 75% and 10% respectively(18). The C1q genes are located in 
chromosome 1, and C4 and C2 genes are located within Major Histocompatibility Antigen 
(MHC) class III region of chromosome 6.Other alleles of importance in the pathogenesis of 
SLE are HLA-DR2, HLA-DR3(19) and Fcgamma receptor genes(20;21). 
The environmental factors that are implicated in SLE risk include drugs, Ultraviolet (UV) 
rays in sunlight, heavy metals, chemicals, infections and lifestyle including diet.  
Procainamide and Hydralazine are among 100 other drugs implicated in lupus risk which 
modifies epigenetic mechanisms that control gene expression in T cells such as inhibition of 
deoxyribo-nucleic acid (DNA) methylation and induce autoreactivity(22). DNA methylation 
is a mechanism by which cells regulate gene transcription and DNA hypomethylation could 
result in abnormal gene expression implicated in the pathogenesis of SLE. UV rays increases 
apoptosis of keratinocytes, expression of autoantigens such as Ro, La, Sm and RNP on 
apoptotic cell surface(23) and impaired clearance of apoptotic cells. Crystalline silica and 
mercury are among the several metals and chemicals associated with SLE(24;25). The 
production of autoantibodies and subsequent development of SLE following infections such 
as Epstein-Barr virus (EBV)(26), Cytomegalovirus (CMV), herpes viruses and parvovirus 
B19 infections have been shown to be associated with SLE. 
The role of oestrogen in SLE disease expression has been considered as SLE is predominant 
in females and the disease onset often follows puberty. Though oestrogen acts through 
oestrogen receptors in T and B cells(27), the exact mechanism by which oestrogen exerts its 
role in pathogenesis is unclear. The use of oestrogen containing contraceptive pill(28) and 
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postmenopausal oestrogen replacement therapy(29) are associated with increased risk of 
developing SLE. 
1.1.2.2 Pathogenesis of SLE 
T cell abnormalities: The disruption of immune tolerance in SLE results in the escape of 
pathogenic autoreactive T cells into the peripheral circulation, where they recognize 
autoantigens (including DNA, histones and small ribonuclear proteins) presented by antigen 
presenting cells. The autoreactive T cells assist autoantibody production by autoreactive B 
cells as well as produce cytokines that promote autoantibody production(30). The SLE T cells 
display an activated phenotype and aberrant T cell receptor (TCR) are found in large 
proportion of SLE patients. The pathologic alterations in signal transduction across the TCR 
play a role in SLE pathogenesis(31). 
B cell abnormalities: The abnormalities in B cells include alterations in phenotype, life span, 
function and signal transduction. Phenotypically the naïve B-cells are replaced by activated 
plasma cells that are long lived. Autoreactive B cells in SLE produce autoantibodies through 
isotype switching and affinity maturation unlike in normal individuals where the 
autoantibodies are usually IgM isotype that does not undergo isotype switching or affinity 
maturation. The autoantibody production by B cells is mediated by both T cell dependent and 
T-cell independent mechanisms. In SLE, the failure of peripheral tolerance with the presence 
of autoreactive T cells and follicular dendritic cells presenting autoantigens results in survival 
and expansion of autoreactive B cells producing autoantibodies(32). The T cell independent 
mechanisms include Toll like receptors-9 and interleukin-10 (IL-10) and subsequently 
mediated by B cell receptor (BCR) and B cell activating factor (BAFF)(33). The autoreactive 
B cells efficiently present the autoantigen to T cells and modulate the activity of T cells to 
secrete cytokines that contributes to SLE pathogenesis. The intrinsic defects in B cells lead to 
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aberrant signal transduction across BCR resulting in B cell hyperactivity. The increased 
production of BAFF by dendritic cells also stimulates B cell survival and maturation. The 
activated B cells also secrete proinflammatory cytokines such as IL-6 and IL-10. 
Role of cytokines: Several cytokines have been linked to SLE pathogenesis and the key 
cytokines among those studied in SLE include Interferon-alpha, IL-6, IL-10 and TNF-
alpha(34). The high disease activity in SLE has been associated with increased expression of 
genes regulated by Interferon-alpha (IFN-alpha) in peripheral blood cells (“IFN 
signature”)(35). The cytokine IL-6 contributes to SLE pathogenesis through its action on B 
cells. B-cells abnormally respond to IL-6 by virtue of spontaneous surface expression of IL-6 
receptors. High levels of IL-6 correlate with SLE disease severity(36). The increased 
production of IL-10 has been shown in SLE patients(37), and serum levels of IL-10 are also 
correlated with disease severity(38).  The promotion of B- cell proliferation and 
differentiation by IL-10 promotes autoantibody production. The association of TNF-alpha 
gene polymorphism with SLE has been demonstrated (39)but the precise role of TNF-alpha 
in SLE is not yet clear. 
Defective Apoptosis: Apoptosis or programmed cell death is an active, tightly regulated 
physiological process leading to destruction of self-reactive lymphocytes. This is followed by 
the rapid clearance of apoptotic cells and fragments by mononuclear phagocytic cells. The 
disruption of either of these processes promotes development of autoimmunity. Apoptosis 
prevents the exposure and release of intracellular components such as nucleosomes 
(containing DNA) into the extracellular microenviroment that would lead to an inflammatory 
response and promote autoimmunity(23).The clearance of apoptotic cells are mediated by 
complements such as C1q, C3 and C4 as well as C-reactive protein (CRP). In SLE, the 
altered maturation of phagocytes results in defective clearance of apoptotic cells(40). The 
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congenital or acquired complement component deficiency seen in SLE patients also promotes 
defective apoptosis. In SLE, massive apoptotic rates of cells overwhelm the phagocytic cells 
and thus possibly unmask potential autoantigens. Conversely, lower rates of apoptosis of 
autoreactive cells in SLE can also augment the autoimmune response. Thus the defective 
apoptosis with both increased and decreased rates of apoptosis play a role in SLE 
pathogenesis. In addition, the autoantibodies found in SLE may also bind to apoptotic cell 
surface and the resulting antibody mediated phagocytosis may trigger secretion of pro-
inflammatory cytokines(41). 
The variation in its initial presentation in each patient with SLE is as diverse as the 
etiopathogenesis of SLE. However, some clinical features have been frequently associated 
with pathogenic autoantibodies in SLE such as anti double stranded DNA (dsDNA), 
extractable nuclear antigen antibody (ENA) such as anti Ro, anti La, anti Sm and anti RNP. 
For instance, anti-dsDNA is 97% specific for SLE and strongly associated with lupus 
nephritis. Similarly, renal, haematologic or vasculitis features are attributed to pathogenic 
autoantibodies forming immune complex deposits and activating complement. 
1.1.2.3 Autoantibodies and Immune Complexes 
SLE is an autoimmune disease characterized by autoantibodies and over a hundred 
autoantibodies have been described in sera of SLE patients(42). Only a few of these 
autoantibodies are measured in clinical practice. Antinuclear antibody is the commonest 
autoantibody found in more than 95% of lupus patients.  Anti-ssDNA (single stranded DNA), 
anti- dsDNA (double stranded DNA), anti Ro, anti-poly ADP ribose polymerase, anti- 
histone/nucleosome antibodies and anti-phospholipid antibodies are found in more than 25% 
of SLE patients. Anti-dsDNA is found in 50-78% of lupus patients with specificity of 97% 
for SLE(43). Anti-Ro antibodies are present in 30-40% and approximately 50% of those with 
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anti-Ro positivity also have anti-La antibodies(44). Anti-Sm antibodies are highly specific 
and found in 25-40% of Afro-Caribbeans and Asians but only in 10-30% of Caucasian lupus 
patients. The prevalence of anti-Sm is three times higher in Afro-Caribbeans compared to 
Caucasians(45). Lupus anticoagulant and anticardiolipin antibodies are the antiphospholipid 
antibodies that are present in 34% and 44% of lupus patients respectively(46). Anti-RNP 
(ribonucleoprotein) is present in 20-50% of lupus patients. These antibodies are non-organ 
specific such as ANA but organ specific antibodies may be also found such as anti-neuronal 
antibody. Pathogenic antibodies such as anti-dsDNA are a useful marker preceding a flare of 
lupus nephritis.  The majority of these autoantibodies have been detected up to 9.4 years 
(mean 3.3 years) prior to the diagnosis or onset of lupus disease(47;48). 
Immune complexes are formed when these autoantibodies react with target antigens. The 
clearance of circulating immune complexes (IC) by mononuclear phagocyte system is 
defective in SLE, resulting in tissue deposition and inflammation. The tissue deposition of IC 
activates the classical complement system which results in consumption of complement 
proteins reducing the plasma complement levels. Hypocomplementemia is common in SLE 
which contributes to defective complement mediated IC clearance.  
Anti-Ro and anti-La antibody are associated with neonatal lupus. The serious manifestation 
in neonates associated with transplacental passage of anti-Ro /La antibody is congenital heart 
block (CHB) usually detected in the second trimester with absent structural cardiac 
abnormality. The risk of CHB is 2% in an offspring to primigravida lupus pregnancy and the 
recurrence rate of CHB in subsequent pregnancies is 19%(49;50). The mortality with CHB is 
15-30% (fetal and neonatal) and 67% morbidity requiring permanent pacemaker before 
adulthood(51). Neonatal lupus rash is another manifestation associated with maternal anti-
Ro/La and anti-U1RNP antibodies, and is usually apparent by 8 weeks after birth, and clears 
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by 6 to 8 months coinciding with clearance of maternal autoantibodies in the infant. Fetal and 
neonatal lupus is independent of maternal disease and can even occur with asymptomatic 
mothers(51). 
Antiphospholipid antibodies (APLA) which predispose to arterial and venous thrombosis 
include lupus anticoagulant, anticardiolipin antibodies (ACA) of subtype IgG and IgM and 
anti-beta 2 GPI antibodies. Lupus anticoagulant is the most pathogenic followed by IgG ACA 
and then IgM ACA. Antiphospholipid antibodies are present in 30% of lupus patients(46;52) 
and antiphospholipid syndrome (APS) is present in 10%(53), whereas APLA is present in 2-
5% and APS in 2% of the general population(54). The association of APLA with cardiac 
valvular disease as well as PH in SLE has been reported(55;56). Antiphospholipid antibodies 
have been found in up to 83% of SLE patients with PH(57-59) and only rarely these patients 
showed features of thromboembolic pulmonary vascular disease leading to PH. The concept 
of APLA leading to abnormal coagulation and microthrombi in small pulmonary arteries 
resulting in PH has been reported. It has also been shown that APLA are present in patients 
with thromboembolic and non-thromboembolic PH without SLE(60;61).  
1.1.3 Clinical features 
The1982 revised American college of Rheumatology (ACR)classification criteria for 
SLE(62) include 11 clinical, laboratory and pathologic features of lupus [Appendix 1]. The 
presence of 4 or more of the 11 criteria increases the specificity and the sensitivity of lupus 
classification. Though not compulsory, a positive ANA is considered by many an essential 
criterion to improve this specificity, particularly for recruitment to trials and other research 
studies.  
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The cardiac manifestations in SLE are often under recognised as they don’t always cause an 
acutely symptomatic flare. Although pericarditis is the commonest cardiovascular 
manifestation, only 25% of those with pericardial effusion have symptomatic pericarditis 
during the disease course(63) and pericardial tamponade occurs only in 2.5% of SLE 
patients(64). Other forms of cardiac lupus including myocarditis, endocarditis, valvular 
disease and cardiac dysfunction are either rare or subclinical. Cardiac arrhythmias are seen in 
10%, with sinus tachycardia most frequent. Systemic hypertension is present in 50% and 
often associated with lupus nephritis. Pulmonary hypertension is considered rare (see below). 
Accelerated coronary atherosclerosis is increasingly recognised as cause of death in SLE, 
irrespective of age. A 10-fold relative risk of non-fatal MI and 17-fold relative risk of death 
from coronary heart disease even after correcting for Framingham study risk factors was 
reported by Esdaile et al (65). 
The most common respiratory manifestations comprise pleuritis with pleural effusions in 
50% of lupus patients(66;67). Though abnormal pulmonary function tests are often recorded, 
only a few develop interstitial lung disease such as alveolitis and pulmonary fibrosis, or 
shrinking lung syndrome, pulmonary haemorrhage or thromboembolic disease. Indirect lung 
involvement such as pneumonia during immunosuppressive therapy is more often seen in 
SLE patients. 
Raynaud’s phenomenon is seen in 18-46% of patients with SLE. It is prevalent in patients 
with subacute cutaneous lupus, discoid lupus, malar rash, arthritis and photosensitivity(68). 
The presence of high titre ANA, anti-RNP antibody and nucleolar antibodies are predictors of 
LE-associated RP. Raynaud’s phenomenon represents vasculopathy resulting in vasospasm of 
small blood vessels. RP is present in 74% of SLE patients with PH compared to those with 
normal pulmonary artery pressures(69). This raises the possibility of vasospasm involving the 
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pulmonary arteries similar to reports on systemic sclerosis patients(70).  Raynaud’s 
phenomenon carries a poor prognosis in patients with PAH associated with SLE(71). This 
suggests that generalised vasculopathy could be contributing to the pathogenesis of PH in 
SLE, but the degree to which vasospasm plays a role in PH is unknown. 
Thrombosis in SLE is multifactorial and especially associated with nephrotic syndrome and 
antiphospholipid antibodies (APLA). These antibodies are lupus anticoagulant (LA) and 
anticardiolipin antibodies (ACA), and increases arterial and venous thrombotic risk six fold 
and two fold respectively. Antiphospholipid syndrome occurs in the presence of APLA 
resulting in miscarriages, still births, and/or arterial and venous thrombosis(72). The criteria 
for diagnosis of antiphospholipid syndrome (APS) requires at least one clinical and one 
laboratory criterion, which includes detection of one of these antiphospholipid antibodies 
tested positive at moderate to high titres 12 weeks apart (72)(Table 1-1). The clinical criteria 
include either arterial or venous thrombosis, or obstetric criteria including three miscarriages 
before 10 weeks gestation in the absence of an alternate explanation or one miscarriage >10 
weeks gestation or premature delivery before 34 weeks due to preeclampsia, eclampsia or 
intrauterine growth restriction. It is important to note that thrombosis in SLE patients can be 
due to thrombophilic factors other than antiphospholipid antibodies(73).  
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Table 1-1 International consensus statement on revised classification criteria for the 
antiphospholipid syndrome 
Antiphospholipid antibody syndrome (APS) is present if at least one of the clinical criteria 
and one of the laboratory criteria that follow are met* 
Clinical criteria 
1. Vascular thrombosis
†
 
One or more clinical episodes
‡
 of arterial, venous, or small vessel thrombosis
§
, in any tissue 
or organ. Thrombosis must be confirmed by objective validated criteria (i.e. unequivocal 
findings of appropriate imaging studies or histopathology). For histopathologic confirmation, 
thrombosis should be present without significant evidence of inflammation in the vessel wall. 
2. Pregnancy morbidity 
 (a) One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th 
week of gestation, with normal fetal morphology documented by ultrasound or by direct 
examination of the fetus, or 
 (b) One or more premature births of a morphologically normal neonate before the 34th week 
of gestation because of: (i) eclampsia or severe pre-eclampsia defined according to standard 
definitions, or (ii) recognized features of placental insufficiency
¶
, or 
 (c) Three or more unexplained consecutive spontaneous abortions before the 10th week of 
gestation, with maternal anatomic or hormonal abnormalities and paternal and maternal 
chromosomal causes excluded. 
In studies of populations of patients who have more than one type of pregnancy morbidity, 
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investigators are strongly encouraged to stratify groups of subjects according to a, b or c 
above. 
Laboratory criteria** 
1. Lupus anticoagulant (LA) present in plasma, on two or more occasions at least 12 weeks 
apart, detected according to the guidelines of the International Society on Thrombosis and 
Haemostasis (Scientific Subcommittee on LAs/phospholipid-dependent antibodies). 
2. Anticardiolipin (aCL) antibody of IgG and/or IgM isotype in serum or plasma, present in 
medium or high titer (i.e. >40 GPL or MPL, or >the 99th percentile), on two or more 
occasions, at least 12 weeks apart, measured by a standardized ELISA  
3. Anti-β2 glycoprotein-I antibody of IgG and/or IgM isotype in serum or plasma (in titer 
>the 99th percentile), present on two or more occasions, at least 12 weeks apart, measured by 
a standardized ELISA, according to recommended procedures  
*Classification of APS should be avoided if less than 12 weeks or more than 5 years separate 
the positive aPL test and the clinical manifestation. 
†
Coexisting inherited or acquired factors 
for thrombosis are not reasons for excluding patients from APS trials. However, two 
subgroups of APS patients should be recognized, according to: (a) the presence, and (b) the 
absence of additional risk factors for thrombosis. Indicative (but not exhaustive) such cases 
include: age (>55 in men, and >65 in women), and the presence of any of the established risk 
factors for cardiovascular disease (hypertension, diabetes mellitus, elevated LDL or low HDL 
cholesterol, cigarette smoking, family history of premature cardiovascular disease, body mass 
index ≥30 kg m−2, microalbuminuria, estimated GFR <60 mL min−1), inherited 
thrombophilias, oral contraceptives, nephrotic syndrome, malignancy, immobilization, and 
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surgery. Thus, patients who fulfil criteria should be stratified according to contributing causes 
of thrombosis. 
‡
A thrombotic episode in the past could be considered as a clinical criterion, 
provided that thrombosis is proved by appropriate diagnostic means and that no alternative 
diagnosis or cause of thrombosis is found. 
§
Superficial venous thrombosis is not included in 
the clinical criteria. 
¶
Generally accepted features of placental insufficiency include: (i) 
abnormal or non-abnormal or non-reassuring fetal surveillance test(s), e.g. a non-reactive 
non-stress test, suggestive of fetal hypoxemia, (ii) abnormal Doppler flow velocimetry 
waveform analysis suggestive of fetal hypoxemia, e.g. absent end-diastolic flow in the 
umbilical artery, (iii) oligohydramnios, e.g. an amniotic fluid index of 5 cm or less, or (iv) a 
postnatal birth weight less than the 10th percentile for the gestational age. **Investigators are 
strongly advised to classify APS patients in studies into one of the following categories: I, 
more than one laboratory criteria present (any combination); IIa, LA present alone; IIb, aCL 
antibody present alone; IIc, anti-β2 glycoprotein-I antibody present alone. 
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1.1.4 Assessment of disease 
The fluctuating nature and unpredictable course of lupus disease has led to monitoring the 
disease closely as a key management plan to achieve a better outcome. Recurrent activity in 
these organs can lead to cumulative permanent damage resulting in structural and functional 
compromise in these vital organs. Thus it is prudent to monitor the SLE disease activity 
regularly, and promptly control lupus activity with appropriate treatment. Early detection of 
affected organs is important and depends on the sensitivity and specificity of clinical features 
assessed as well as the use of appropriate tests. In almost 50% of lupus patients, changes in 
levels of anti-dsDNA antibodies and complement levels (C3 and C4) can help predict flare as 
well as monitor the response to therapy. Among several validated disease activity monitoring 
indices, the British Isles Lupus Assessment Group (BILAG)(74;75) [Appendix 2] and SLE 
disease activity index (SLEDAI) are commonly used in research setting and increasingly in 
clinical practice(76). Their use in the clinical setting cannot be underestimated despite their 
limitations, with benefits to both patients and physicians. The Systemic Lupus International 
Collaborating Clinics/American College of Rheumatology damage index (SLICC/ACR DI) 
(77;78) [Appendix 3] is used to record the accumulated damage in 12 organ/systems (ocular, 
neuropsychiatric, renal, pulmonary, cardiovascular, peripheral vascular, gastrointestinal, 
musculoskeletal, skin, gonadal failure, diabetes mellitus and malignancy) since the diagnosis 
of SLE. For example, damage recorded in pulmonary system includes pulmonary 
hypertension, pulmonary fibrosis, shrinking lung, pleural fibrosis, pulmonary infarction or 
resection. This damage should be clinically ascertained and present for at least 6 months 
unless otherwise stated in the index such as radiographic evidence. In addition to the damage 
due to disease activity, the damage due to comorbidities and therapies is also recorded such 
as diabetes mellitus, myocardial infarction and malignancy. Stoll et al(79) reported that mean 
pulmonary damage score (DS) at 1 year significantly predicted death within 10 year of 
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diagnosis, and mean renal DS at 1 year after diagnosis was a strong predictor of end stage 
renal failure. Please refer to methods section for more details on BILAG and SLICC/ACR 
damage index. 
1.1.5 Treatment 
The principles of treatment in SLE are directed towards controlling disease activity, 
prevention of damage accumulation and treatment of complications. The prompt and 
adequate treatment of disease flares in a lupus patient reduces long term complications 
related to disease and treatment as well as reduces morbidity and mortality from uncontrolled 
immune-mediated tissue damage to organs. The major determinant of the treatment used in 
lupus management is the level of disease activity which is broadly classified as mild, 
moderate and severe. Severe disease activity in SLE is defined as manifestations that are life 
threatening or cause significant organ dysfunction such as inability to perform daily activities 
due to inflammatory arthritis, nephrotic syndrome or seizures. By comparison, mild disease 
activity is defined as manifestations that only lead to some discomfort such as joint pain 
without interruption to daily activities. Thus, the treatments used in lupus are tailored to each 
patients needs and the treatment categories include: symptomatic treatment, antimalarials, 
thalidomide, dapsone, retinoids, corticosteroids, immunosuppressives/cytotoxics, intravenous 
immunoglobulins (IVIG), plasmapheresis, and biologics such as Rituximab and Belimumab. 
Severe lupus disease activity requires aggressive treatment with high dose corticosteroids 
(more than 20mg/day of prednisolone or equivalent) usually combined with 
immunosuppressive therapy. The efficacy of cyclophosphamide(80), mycophenolate 
mofetil(81) and intravenous methylprednisolone (with cyclophosphamide combination)(82) 
has been shown in the treatment of severe lupus nephritis. It is important to note that the 
clinical trials on lupus patients with severe disease activity predominantly include lupus 
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nephritis and measure renal outcomes for efficacy. Intravenous immunoglobulins(83;84) and 
plasmapheresis(85-88) are used only in those with life threatening complications. Rituximab 
is a chimeric monocolonal antibody against CD20 that causes depletion of B cells is also 
increasingly used in the treatment of severe disease activity in SLE(89-93). Belimumab is a 
fully humanised recombinant IgG1 lambda monoclonal antibody that inhibits B-lymphocyte 
stimulator binding to B cells. Belimumab is the first biologic therapy has been shown to 
achieve disease control, reduce severity of flares, reduce morbidity and improve quality of 
life in SLE patients(94). The immunosuppressants such as azathioprine, methotrexate, 
cyclosporin and mycophenolate mofetil are often the mainstay of maintenance treatment in 
SLE. Cyclophosphamide and Rituximab are used mostly for renal and neuropsychiatric 
lupus. 
Moderate disease activity is usually treated with lower dose steroids (less than 20mg/day of 
prednisolone or equivalent) with or without concomitant immunosuppressive therapy. 
Corticosteroids in different modes of administration (local, oral, intramuscular and 
intravenous) are used in lupus treatment. Intra-articular injections of corticosteroids are used 
to treat inflammatory arthritis while topical corticosteroids are used to treat discoid lupus 
rash. Antimalarials especially hydroxychloroquine have been shown to be effective in 
mucocutaneous manifestations(95) and inflammatory arthritis in SLE and are often used in 
place of immunosuppressive agents. Thalidomide, Dapsone and Retinoids are used for 
refractory lupus rash. Prasterone is an androgen that has been shown to have steroid sparing 
effect(96) as well as efficacy in reducing lupus flares(97) 
 Mild disease activity in SLE requires symptomatic treatment with analgesics and 
nonsteroidal anti-inflammatory drugs.  Topical corticosteroids and antimalarials have also 
been used in resistant mild mucocutaneous manifestations and inflammatory arthritis.  
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Other treatments include calcium channel blockers for Raynaud’s phenomenon, comorbidity 
treatment such as anti-hypertensives, cholesterol lowering agents and anti-resorptive drugs, 
and aspirin, heparin and warfarin for thrombosis prevention. 
The difficulty in designing and conducting clinical trials in SLE has led to failure of several 
drug trials except Belimumab trial(94) in recent years. The non-inferiority randomised 
controlled trials of newer therapies in combination with steroids and standard therapy in SLE 
could have failed due to the complex nature of multisystem involvement making disease 
activity assessment difficult and challenging. The composite SLE Responder Index (SRI) was 
used in the Belimumab trial as the disease activity measure, and SRI incorporates SELENA 
(Safety of Estrogens in Lupus Erythematosus National Assessment) version of SLEDAI, 
BILAG assessment and physician’s global assessment score. It is possible that future drug 
trials in SLE would consider SRI to assess disease activity given the success of Belimumab 
as the only approved treatment in SLE in the last 25 years. 
1.1.6 Prognosis 
The 5 year survival rate was less than 55% prior to the introduction of corticosteroids in lupus 
treatment(98). In recent years, further improvement in treatment approaches of this chronic 
disease and increased detection of milder disease has led to better 10-year survival rate of 
over 90%(1) and 20-year survival of 68%(99). Despite this, the death rate is at least three 
times greater than the general population(2). According to two 24-year studies in 
Holland(100) and Toronto(101) the improved survival was not due to changing 
demographics, age at diagnosis, severity of lupus at presentation, major change in disease 
patterns or new modalities of treatment. 
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The cause of death varied depending on disease duration, such as active lupus if less than 5 
years duration, and vascular events and end organ failure not due to SLE in late deaths(99) 
(Table 1-2). The increased risk of death in SLE patients is associated with  female sex, 
younger age at diagnosis, shorter disease duration and black/African American race(2)  The 
risk of death from active renal disease and infection have decreased whereas it remains the 
same for circulatory disease. 
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Table 1-2 Unadjusted SMR estimates for all-cause mortality and for death by cause* in 
patients with SLE 
Cause of Death  Observed Expected SMR**  
(95% CI) 
1.All deaths 1255 526 2.4 (2.3-2.5) 
2. Disease of the 
circulatory 
system 
All disease 313 184.3 1.7 (1.5-1.9) 
Heart disease 126 73.8 1.7 (1.4-2.0) 
Stroke 21 19.3 1.1 (0.7-1.7) 
3. Malignancy All neoplasms 114 138 0.8 (0.6-1.0) 
All 
haematological 
cancer 
15 7.2 2.1 (1.2-3.4) 
Non-Hodgkin’s 
Lymphoma 
8 2.8 2.8 (1.2-5.6) 
Lung cancer 44 19.4 2.3 (1.6-3.0) 
4. Infections Infections 45 9.0 5.0 (3.7-6.7) 
Pneumonia 19 7.2 2.6 (1.6-4.1) 
5. Other Respiratory 
excluding 
pneumonia 
14 10.4 1.3 (0.8-1.6) 
Renal 34 4.3 7.9 (5.5-11.0) 
*Data shown are for 9,547 patients from 23 participating sites from North America, Europe, 
Asia and Iceland (76,948 person-years) for calendar period 1958-2001.  
**SMR: Standardised mortality ratio is the ratio of observed deaths to expected deaths. This 
table is adapted from the publication on ‘Mortality in SLE ‘by Bernatsky.S et al(2). 
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1.2. Pulmonary arterial hypertension (PAH) 
 
Pulmonary arterial hypertension is a rapidly progressive devastating disease with significant 
morbidity and mortality. PAH is characterised by increased pulmonary vascular resistance 
leading to impending right heart failure and death, unless treated appropriately and early. 
 An epidemic of pulmonary hypertension (PH) following the use of anorexigens in mid-60s 
led to the first World Health Organisation (WHO) conference on PAH in 1973(102). A 
national registry of primary pulmonary hypertension (PPH) patients in USA in early 80’s set 
the platform for initial understanding of PAH such as natural history of disease, clinical 
features and lack of effective therapy and poor survival.  
Over the last two decades, there has been a great improvement in various aspects of PAH 
management. This includes awareness of PAH, early recognition by prompt screening of high 
risk patients, use of right heart catheterisation for accurate measurements of pulmonary artery 
pressures as well as development of modern treatment regimes to improve patient outcomes 
such as survival and quality of life.  
1.2.1 Definition and classification of PH and PAH 
1.2.1.1 Pulmonary Hypertension (PH) 
Pulmonary hypertension (PH) is a haemodynamic and pathophysiological condition which is 
defined by an increase in mean PAP >25mm Hg at rest as assessed by RHC(102-104).  PH 
can be found in many clinical conditions and thus the need to separate them into subgroups 
with PH that share similar pathophysiologic and clinical characteristics. The haemodynamic 
definition of pulmonary hypertension (PH) includes arterial, capillary and/or venous 
hypertension in the pulmonary vasculature. 
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1.2.1.2 Pulmonary arterial hypertension (PAH) 
PAH is a clinical condition characterised by the presence of precapillary PH 
haemodynamically(105). The PAH group excludes other causes of precapillary PH such as 
PH due to lung diseases, chronic thromboembolic PH and other rare disorders such as 
glycogen storage diseases. The various causes of PAH also share similar clinical picture and 
histopathological changes in the lung microcirculation. 
The precapillary PH is defined as an increase in mean PAP >25 mm Hg at rest as assessed by 
RHC, and in addition the presence of normal pulmonary capillary wedge pressure(104) 
(PCWP) <15mmHg. This haemodynamic definition of PAH helps exclude PH due to left 
heart disease. 
1.2.1.3 Classification of PH 
Since the first classification of PH at WHO International symposium on pulmonary 
hypertension (PH) in 1973(102), it has undergone modifications in three further symposiums 
held in Evian in 1998, Venice in 2003(106) and Dana Point in 2008(105). The aim of the PH 
classification was to group together the different manifestations of the disease that share 
similar pathophysiologic mechanisms, clinical features and treatment strategies(107).  
In 1973, pulmonary hypertension (PH) was classified as primary and secondary depending on 
the absence or presence of identifiable cause or risk factor. In 1998, the term secondary PH 
was abandoned. In 2003, the term PPH was replaced by Idiopathic PAH (IPAH) to separate 
familial PAH with presence of family history or associated PAH if another cause such as 
connective tissue diseases (CTD) is present. In 2008, the architecture of classification was 
maintained with minor changes proposed to include schistosomiasis and chronic haemolytic 
anaemia in the PAH subgroup under associated diseases, to make this subgroup more 
homogenous.  
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The clinical classification of PH updated in Venice and Dana Point in 2003 and 2008 are 
shown in Table 1-3 and Table 1-4 respectively. In these classifications, PH is broadly divided 
into 5 main groups: 1. Pulmonary arterial hypertension (PAH); 2. PH with left heart disease; 
3. PH associated with respiratory diseases and/or hypoxia; 4. PH due to chronic 
thromboembolic disease;5. Miscellaneous or PH with unclear multifactorial mechanisms.  
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Table 1-3 Venice clinical classification of Pulmonary Hypertension (2003) 
1. Pulmonary arterial hypertension (PAH) 
1.1. Idiopathic (IPAH) 
1.2. Familial (FPAH) 
1.3. Associated with (APAH) 
1.3.1. Collagen vascular disease 
1.3.2. Congenital systemic-to-pulmonary shunts 
1.3.3. Portal hypertension 
1.3.4. HIV infection 
1.3.5. Drugs and toxins 
1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher disease, 
hereditary hemorrhagic telangiectasia, hemoglobinopathies, 
myeloproliferative disorders, splenectomy) 
1.4. Associated with significant venous or capillary involvement 
1.4.1. Pulmonary veno-occlusive disease (PVOD) 
1.4.2. Pulmonary capillary hemangiomatosis (PCH) 
1.5. Persistent pulmonary hypertension of the newborn 
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2. Pulmonary hypertension with left heart disease 
2.1. Left-sided atrial or ventricular heart disease 
2.2. Left-sided valvular heart disease 
3. Pulmonary hypertension associated with lung diseases and/or hypoxemia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Sleep-disordered breathing 
3.4. Alveolar hypoventilation disorders 
3.5. Chronic exposure to high altitude 
3.6. Developmental abnormalities 
4. Pulmonary hypertension owing to chronic thrombotic and/or embolic disease 
4.1. Thromboembolic obstruction of proximal pulmonary arteries 
4.2. Thromboembolic obstruction of distal pulmonary arteries 
4.3. Nonthrombotic pulmonary embolism (tumour, parasites, foreign material) 
5. Miscellaneous 
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary 
vessels (adenopathy, tumour, fibrosing mediastinitis) 
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Table 1-4 Updated Clinical Classification of Pulmonary Hypertension (Dana Point, 
2008) 
1. Pulmonary arterial hypertension (PAH) 
1.1. Idiopathic PAH 
1.2. Heritable 
1.2.1. BMPR2 
1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia) 
1.2.3. Unknown 
1.3. Drug- and toxin-induced 
1.4. Associated with 
1.4.1. Connective tissue diseases 
1.4.2. HIV infection 
1.4.3. Portal hypertension 
1.4.4. Congenital heart diseases 
1.4.5. Schistosomiasis 
1.4.6. Chronic hemolytic anemia 
1.5 Persistent pulmonary hypertension of the newborn 
1’ Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis  
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2. Pulmonary hypertension owing to left heart disease 
2.1. Systolic dysfunction 
2.2. Diastolic dysfunction 
2.3. Valvular disease 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4. Sleep-disordered breathing 
3.5. Alveolar hypoventilation disorders 
3.6. Chronic exposure to high altitude 
3.7. Developmental abnormalities 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy 
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, 
lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
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5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis 
ALK1: activin receptor-like kinase type 1; BMPR2 :bone morphogenetic protein receptor 
type2; HIV: human immunodeficiency virus 
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1.2.2 Prevalence; incidence; clinical presentation of PH 
Idiopathic PAH (IPAH) is considered to be rare. The NIH registry estimated an annual 
incidence of primary PH of 1-2 per million(104) among general population. The French 
national registry estimated the annual incidence and prevalence of PAH diagnosed by cardiac 
catheterisation at 2.4 and 15 (range 5-25) cases per million population(108). The possibility 
of underestimation was considered due to geographical variation of prevalence in France. The 
prevalence of PAH due to any cause was estimated 30-50 cases per million and the incidence 
of PAH associated with CTD at 1-2 per million. IPAH is common in the third and fourth 
decades of life with a female to male ratio of 1.7:1, and has no racial predilection. IPAH 
accounts for 40% of total PAH cases. 
The rarity of the disease makes it difficult to understand the disease process and to perform 
meaningful experimental and clinical research from small groups of PAH patients. Thus, it 
becomes imperative to have national registries and specialised PAH centres to achieve 
progress in understanding the pathogenesis, improving management strategies to have better 
outcomes and newer treatment modalities.  
The classical symptoms of PH include breathlessness, fatigue, poor exercise tolerance, 
syncope, angina, and palpitations (104). Lupus can manifest with other cardio-pulmonary 
complications which can also result in few or all of the above symptoms. Due to the non 
specific nature of these symptoms, the diagnosis of PH is delayed unless other common 
conditions with similar symptoms are ruled out. Moreover, these symptoms are present at rest 
only in patients with advanced PAH.  
The physical signs of PH include left parasternal lift, accentuation of pulmonary component 
of second heart sound, pansystolic murmur of tricuspid regurgitation, diastolic murmur of 
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pulmonary regurgitation and a right ventricular third heart sound. The physical signs are often 
subtle until the signs of right heart failure develop in advanced stages of PAH. This includes 
elevated jugular venous pressure (JVP), hepatomegaly, peripheral edema, ascites and cool 
extremities. It is also important to look for signs of diseases that can cause PH. The presence 
of calcinosis, sclerodactyly, telangiectasia and skin tightness in systemic sclerosis, malar rash 
or discoid rash in SLE, swollen hands and arthritis in mixed connective tissue disease, spider 
naevi and palmar erythema in liver disease may be present. Though lung sounds are often 
normal, the end inspiratory fine crackles of interstitial lung disease or bi basal crackles of 
cardiac failure may point to the cause of PH. The presence of digital clubbing raises 
possibility of congenital heart disease and pulmonary veno-occlusive disease. 
It is well known that the diagnosis of PH is often delayed for more than 2 years with a 
majority of patients diagnosed in advanced stages(108;109). The prolongation of the time to 
diagnosis of PAH from onset of symptoms has a significant impact on poor survival in these 
patients. The physician awareness of PAH in at risk groups such as those with a strong family 
history of PAH, connective tissue diseases, congenital heart diseases, HIV infection, portal 
hypertension among several others is crucial for earlier diagnosis of PAH. Thus the need to 
improve physician awareness is of paramount importance to reduce delays in diagnosis of 
PAH. 
The severity of dyspnoea and exertional intolerance is quantitated according to World Health 
Organization (WHO) classification of functional status(110) in patients with PH. This is the 
modification adapted from the New York Heart Association (NYHA) functional 
classification. The role of functional assessment in patients with PH was emphasised in the 
pulmonary hypertension working group meeting in Evian, France 1998 and led to the WHO 
functional assessment classification(105) (Table 1-5). The determination of functional class 
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helps to apply the appropriate management options for patients with PAH at multiple levels. 
This could be with initial presentation, coexistent clinical signs, screening for PAH, severity 
of elevated pulmonary artery pressure, treatment choice, quality of life and survival. 
The clinical signs of PH are usually subtle until significant right heart failure has developed. 
It is vital to consider PH in this setting of clinical features, particularly in the absence of other 
cardiac and respiratory conditions presenting with similar clinical features. ECG, Chest x-ray, 
pulmonary function testing and Doppler echocardiography are commonly used initial tests in 
screening for PAH. 
The other categories of pulmonary hypertension such as intrinsic lung disease, hypoxia, left 
heart disease and miscellaneous conditions that can present with similar clinical features have 
to be excluded by relevant tests before making a diagnosis of PAH. 
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Table 1-5 World Health Organisation functional classification for patients with 
pulmonary hypertension 1998* 
Functional 
Class 
Symptomatic profile 
I Patients with pulmonary hypertension but without resulting limitation of 
physical activity. Ordinary physical activity does not cause dyspnoea or 
fatigue, chest pain, or near syncope 
II Patients with pulmonary hypertension resulting in slight limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity causes undue 
dyspnoea or fatigue, chest pain, or near syncope 
III Patients with pulmonary hypertension resulting in marked limitation of 
physical activity. They are comfortable at rest. Less than ordinary activity 
causes undue dyspnoea or fatigue, chest pain, or near syncope 
IV Patients with pulmonary hypertension with inability to carry out any physical 
activity without symptoms. These patients manifest signs of right heart failure. 
Dyspnoea and/or fatigue may even be present at rest. Discomfort is increased 
by any physical activity 
*Functional classification of pulmonary hypertension modified after the New York Heart 
Association functional classification  
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Definition of PH  
The definition of PH adopted from the 1973 World Health Organisation (WHO) conference 
on PH is used in the epidemiological studies to evaluate prevalence of PH as well as clinical 
trials to evaluate PH treatments. PH is defined by RHC measurements of mean PAP >25 mm 
Hg at rest or >30 mmHg at exercise, with pulmonary capillary wedge pressure (PCWP) <15 
mmHg and pulmonary vascular resistance (PVR) >3 Wood units(111). The systolic PAP 
estimated in the presence of tricuspid regurgitation (TR) by Doppler ECHO use a cutoff of 
either >30 mmHg or >35 mmHg for the definition of PH. As most PH patients have systolic 
PAP in the range of 30-40 mmHg in the epidemiological studies, these cut off values play a 
key role in the determination of PH prevalence rates.  
The PH diagnosis by ECHO depends on Doppler evaluation of tricuspid regurgitant signal. 
The tricuspid insufficiency is too weak or insufficient to be measured by Doppler to derive 
the pressure gradient across the tricuspid valve in 10-25% of patients undergoing PH 
screening(112;113). There has been good correlation of systolic PAP (sPAP) measured by 
ECHO and mean PAP measured by RHC. The mean sPAP among 3212 healthy population 
aged 1-89 years with a detectable TR on transthoracic echocardiogram (TTE) was 23+ 4.7 
mmHg assuming right atrial pressure of 5 mmHg(114). The sPAP increases with age and 
body mass index(114). Similarly, the mean sPAP in 134 adults aged 20-85 years was 26.6 
mmHg and had normal cardiac structure and function detected on transthoracic 
echocardiography(115). The calculation of sPAP from ECHO parameters are described in 
detail in the methods section. Mukerjee et al(116) showed that ECHO screening is of value 
only in screening of advanced PH provided high thresholds of sPAP >45mmHg is used to 
define PH. In another large study on SSc patients using sPAP of >35 mmHg and >25mmHg 
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in asymptomatic and dyspnoeic patients respectively , the false positive rate of ECHO 
defined PH was 45% in comparison to RHC measurements(117). 
While the non-invasive ECHO has been a pivotal screening test for PH in those suspected to 
have PH, the gold standard test to confirm PH remains the invasive right heart catheterisation. 
However, there are limitations to RHC measurements. The RHC procedures are associated 
with morbidity of 1.1% and mortality of 0.055%. The measurements are susceptible to 
fluctuation due to respiratory cycle, hyperventilation and Valsalva manoevre. The RHC 
measurements are done at artificial conditions such as rest and overnight fast which might not 
reflect the true pulmonary artery pressures during active daily lives of patients. 
1.2.3 Pathogenesis 
Though the exact mechanisms that initiate the pathological changes seen in PH are unknown, 
a great deal of understanding of pathological and pathophysiological changes as well as 
pathobiology of PH has led to better monitoring and newer treatment strategies in 
management of PH. 
The complex multifactorial process involved in the development of PAH includes 
vasoconstriction, proliferation and obstructive remodelling of pulmonary vessel wall, insitu 
thrombosis and inflammation. Adventitial thickening, medial hypertrophy, intimal 
proliferation and fibrosis, perivascular inflammatory infiltrates, complex plexiform lesions 
and thrombotic lesions are pathological characteristics of PAH(118) 
In PAH, the pathological lesions particularly affect the distal pulmonary arteries 
<500micrometer in diameter. Pulmonary veins are unaffected. The vasoconstriction of 
pulmonary vessels results from endothelial dysfunction as well as potassium channel 
dysfunction in the smooth muscle cells. Endothelial dysfunction (ED) leads to chronic 
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impaired production of vasodilators and antiproliferative agents such as nitric oxide, 
prostacyclin, vasoactive intestinal peptide (VIP) and receptors of bone morphogenetic protein 
(BMPR) pathway. The ED also results in overexpression of vasoconstrictors and proliferative 
substances such as endothelin-I and Thromboxane A2. Endothelial dysfunction promotes 
proliferation of several cell types including smooth muscle cells, endothelial cells and 
fibroblasts which leads to vascular remodelling. The increased production of extracellular 
matrix including collagen, elastin, fibronectin and fibroblast growth factor results in 
thickening and fibrosis of adventitial layer(119). The medial layer undergoes smooth muscle 
cell hypertrophy and hyperplasia resulting in lumen reduction. The migration and 
proliferation of myofibroblasts and fibrosis of both media and intimal layers results in severe 
lumen reduction of distal pulmonary vessels. The morphological changes affecting all layers 
of the vessel wall results in severe reduction of vessel lumen and increasing vascular 
resistance propagating PAH. The severity of each vessel wall layer involvement is variable in 
different forms of PAH, for example adventitial fibrosis is prominent in PAH secondary to 
scleroderma.  
In addition, the increased production of several growth factors such as vascular endothelial 
growth factor (VEGF), platelet derived growth factor (PDGF), insulin like growth factor-I 
and epidermal growth factor have been reported in PAH patients. These growth factors also 
contribute to the vascular remodelling of pulmonary vessels in PH. The hypercoagulable state 
and platelet dysfunction may also contribute to the pathology of PH.  The role of 
inflammation and thrombosis in the pathogenesis of PAH particularly in SLE is discussed 
later. 
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1.2.4 Treatment 
The treatment of PAH includes supportive treatment with oxygen, anticoagulants, diuretics, 
digoxin and calcium channel blockers (CCB).  
As hypoxia is a potent vasoconstrictor of pulmonary circulation, oxygen therapy is 
recommended to maintain oxygen saturation above 90%. The role of anticoagulation in 
supportive therapy of PH has been established with the rationale that thromboembolic 
phenomena play a significant role in the pathogenesis of PH. The presence of vascular 
thrombotic lesions in IPAH patients at post-mortem(120), the demonstration of abnormal 
coagulation(121), fibrinolytic pathways(122) and platelet function in PH(123), and the 
association of antiphospholipid antibodies with SLE-PH which could possibly increase 
thromboembolic risk have all led to support the use of anticoagulation in IPAH as well as 
other forms of severe PAH including SLE associated PH (SLE-PH) and other CTD 
associated PH. The risk to benefit ratio of anticoagulation in CTD-PAH is not well 
understood. The evidence for possible benefits such as improved survival with 
anticoagulation is derived from 1 prospective and 2 retrospective studies(120;124;125) on 
IPAH, hereditary PAH, and anorexigens induced PAH. The 3 year survival improved from 
21% to 49%(120) and 5 year survival from 31% to 62%(124). Anticoagulation should be 
avoided in patients at high risk of bleeding. Patients with indwelling catheters for prostanoid 
infusions are also advised to be anticoagulated to prevent catheter related thrombosis. 
Anticoagulants have not shown to be effective in reducing functional class severity or 
pulmonary haemodynamics. There is a need for randomised controlled studies to evaluate the 
benefits of anticoagulation in PAH and SLE-PH. Calcium channel blockers (CCB) such as 
Nifedipine, Amlodipine and Diltiazem are used in patients with PAH who exhibit an acute 
vasodilator response (a fall in mean PAP > 10 mmHg, to a mean PAP < 40mmHg, with an 
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unchanged or increased cardiac output) to intravenous adenosine or inhaled nitric oxide at 
right heart catheterisation(126;127). This response is most often seen in IPAH patients, while 
other forms of PAH especially CTD-PH rarely show long term response to CCB. In patients 
with high left heart filling pressures and overt right heart failure, CCB is avoided. Rich et al 
reported on a very select group of IPAH patients to have 94% survival rate at 5 years with 
high dose CCB treatment(124). Digoxin is sometimes used in IPAH patients with right heart 
failure, low cardiac output and atrial arrhythmias(128). 
The better understanding various drivers of PAH led to the newer therapies including 
Prostacyclin, Endothelin receptor antagonist (ERA) and phosphodiesterase inhibitors in the 
last decade to improve the survival and quality of life in PAH patients. The outcome 
measures commonly comprise of dyspnoea grade, exercise capacity, hemodynamic measures, 
quality of life and survival. In recent years, the treatment approach in PAH is one of goal 
oriented therapy rather than escalation of treatment only with signs of deterioration(129). 
This incorporates using prognostic indicators of survival as treatment targets, such as WHO 
functional class and various clinical parameters. For example, patients in WHO FC II have 
better survival than those in WHO III/IV. The escalation of treatment from monotherapy to 
sequential combination therapy(105;130) is a recommended step for goal oriented therapy of 
PAH.  
Several Prostacyclin analogues used in PAH treatment for patients in WHO-FC III/IV share 
similar pharmacodynamic properties(131). Prostacyclin induces vasodilatation of all vascular 
beds, inhibits platelet aggregation, and also has cytoprotective and antiproliferative 
properties. Iloprost, Epoprostenol(132-134), and Treprostinil(135) are commonly used 
chemically stable prostacyclin analogues. These are administered by continuous intravenous 
infusion, subcutaneous infusion and aerosol administration depending on individual drug 
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properties.  The continuous intravenous infusion of Epoprostenol has been shown to improve 
symptoms, exercise capacity, haemodynamics, survival(133) and have persistent effect in 
patients with IPAH, CTEPH and CTD-aPAH. Similar efficacy end points were met with 
subcutaneous Treprostinil infusion in a large randomized controlled trial in IPAH 
(135).Inhaled and intravenous Iloprost therapy has shown efficacy as monotherapy as well as 
combination with Bosentan therapy(136) in IPAH.  
The role of high plasma levels of Endothelin-1 in the pathogenesis of PAH led to the 
introduction of ERA in the PAH treatment. Endothelin-1 exerts vasoconstrictor and 
mitogenic effects through endothelin-A receptor activation in smooth muscle cells, and 
causes release of nitric oxide (NO) and prostacyclin through activation of endothelin- B 
receptors in endothelial cells resulting in vasodilatation and antiproliferation effects.  
Bosentan is an oral active dual endothelin receptor antagonist(137-140), and Ambrisentan is 
selective antagonist for endothelin- A receptor(141;142). Both have been shown through 
RCTs to improve exercise capacity, functional class, haemodynamics and time to clinical 
worsening in patients with IPAH and CTD-aPAH. The ERA are effective for PAH patients in 
WHO-FC II as well as those in WHO- FC III/IV. 
The phosphodiesterase type-5 inhibitors (PDE-5i) are the latest addition to the treatment 
armamentarium for PAH, which results in vasodilatation through NO/cGMP pathway in 
pulmonary vessels and also has antiproliferative effects. Sildenafil(143) and Tadalafil have 
shown efficacy both as monotherapy and in combination with epoprostenol(144) and 
Bosentan(145) respectively. 
Few RCTs have been published on the use of combination therapy in PAH(140;144;145). 
These include two or more drugs from prostanoids, ERA and PDE-5i group used either 
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simultaneously or in stepwise fashion particularly in PAH patients in WHO FC III/IV. 
Though the lack of response to monotherapy could be adequate reason to try combination 
therapy, the optimal timing of using combination therapy is still not clear and is variable in 
individual patients. 
At the time of our study period, most of these advanced therapies were at early stages of use 
in PAH therapy. These newer target-specific treatments have offered hope to patients with a 
devastating and progressive disease with poor prognosis by improving symptoms, exercise 
capacity, quality of life, pulmonary haemodynamics as well as extending survival. Over the 
recent years since our study period, there has been increasing evidence through randomised 
controlled trials (RCT) of the advantages of combination therapy over monotherapy of these 
drugs in several subgroups of PAH. These valid reasons make it worthwhile diagnosing PAH 
at early stages and monitoring closely to achieve meaningful outcomes.  
1.2.5 Survival 
The NIH registry from the early 1980’s showed the poor median survival of untreated 
Idiopathic PAH (IPAH) patients to be 2.8 years, with 1, 2 ,3 and 5 year survival rates at 68%, 
57%, 48% and 34% respectively(103).Historically the prognosis of patients with severe PAH 
has been very poor until the introduction of advanced therapies including prostanoids, 
endothelin receptor blockers and phosphodiesterase inhibitors in the treatment algorithm. The 
exercise capacity and WHO functional class are shown to be closely related to survival in 
patients with IPAH(146;147). The predictors of poor prognosis includes advanced functional 
class, reduced exercise capacity as measured by six minute walk test, high right atrial 
pressure, significant right ventricular (RV) dysfunction, evidence of RV failure, low cardiac 
index, elevated brain natriuretic peptide (BNP), and underlying diagnosis of scleroderma 
spectrum of diseases(148). 
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In mid 90’s the introduction of intravenous prostacyclin for IPAH patients with New York 
Heart Association (NYHA) dyspnoea class III and IV improved these survival rates to 88%, 
76% and 63%. A decade later, the introduction of endothelin receptor blocker Bosentan as 
first line therapy in this group improved the survival rates to 97%, 89% and 86% 
respectively(149).  
Since this present study has been undertaken, several PAH registries around the world 
particularly from UK, Europe and USA have published the survival rates of patients 
registered in their cohorts. The 1-year survival observed in the USA registry incident cohort 
with patients with PH of any cause was 91% and 88.4% in the French registry incident cohort 
of PH patients. The UK registry(150) reported 1 and 3 year survival rates of 78% and 74% 
respectively in SLE-PAH compared to 78% and 47% in SSc-PAH (Table 1-6) Among the 
86% of SLE patients who were immunosuppressed, 11% were newly immunosuppressed 
after PAH diagnosis. Seventy five percent underwent advanced therapy for PAH. The 
REVEAL registry(151) reported 1- year survival rate to be significantly worse in SSc-PAH 
compared to SLE-PAH, which were 82% and 94% respectively. This reflects the REVEAL 
registry has predominantly prevalent cases unlike incident cases in UK registry as the risk is 
initially high. Moreover, only 22% of 110 SLE-PAH patients were on immunosuppressive 
therapy. It was also shown that hospitalization rates were high in CTD-PAH and similar 
among all CTD compared to IPAH, and mostly for primary disease flares rather than PAH. In 
contrast, the 1, 2 and 3 year survival rates in IPAH with advanced therapies were reported at 
86%, 70% and 55%(152) compared to 1, 3 and 5 year survival rate of 68%, 48% and 34% 
respectively in pre- advanced treatment era(103).  
The survival in SLE-PAH (median survival 13 months) is poor compared to IPAH (median 
survival 66 months) but appears to be better than SSc-associated PAH.  
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Table 1-6. Survival rates in PAH 
Disease associated 
with PAH 
Source of 
publication, year 
1 year 
survival 
2 year 
survival 
3 year 
survival 
5 year 
survival 
SLE Asherson et 
al(57;153) 
1986, 1990 
 >50  50 
SLE Wilmslow et 
al(154) 
1995 
   86 
SLE Chung et al(155) 
2006 
50  45 17 
SLE UK PH 
centres(150) 
2009 
78  74  
SLE USA PH 
centres(151) 
2010 
 
94    
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SSc Koh et al(156) 
1996 
45 35   
CTD 
(includes 8 SLE  
out of 64  CTD 
patients) 
Denton et al(157) 
2006 
86 73   
SSc UK PH 
centres(150) 
2009 
78  47  
SSc USA PH 
centres(151) 
2010 
82    
Idiopathic PAH Chung et al(155) 
2006 
77  73 68 
SLE: Systemic lupus erythematosus; SSc: Systemic sclerosis; CTD: Connective tissue 
disease; PAH: Pulmonary arterial hypertension 
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1.3. PAH and CTD 
 
Pulmonary arterial hypertension is an increasingly recognised complication of several 
connective diseases, in particular systemic sclerosis (SSc), systemic lupus erythematosus 
(SLE) and mixed connective tissue disease (MCTD). PAH associated with CTD contributes 
to 8% of all cause severe PAH.  The national PAH registries from France, Scotland and UK 
have estimated the prevalence and incidence of PAH associated with CTD to be 2.3 and 0.4, 
10 and 2.8, 4.3 and 1.55 cases per million respectively. The prevalence is highly variable 
depending on the definition of PAH, diagnostic method used, study population number and 
characteristics. Patients with PAH and CTD are mostly women (4:1), diagnosed at older age 
(mean 66years), have concomitant disorders such as interstitial lung disease and left heart 
disease, and have shorter survival rates in comparison to IPAH patients(158).  
Systemic sclerosis is the most common CTD associated with PAH and thus most data on 
clinical features and treatment strategies are derived from SSc patients. The prevalence of 
PAH in SSc  is 10-15%(158) and it is more frequent in limited SSc compared to diffuse SSc. 
Though isolated PAH is common in SSc, the presence of interstitial lung disease particularly 
in diffuse SSc could contribute to development of PH. It is recognised that PH associated 
with hypoxic lung disease have relatively mild elevation of pulmonary pressures without 
compromise in cardiac output(159). This was also reflected from the UK study(150) that SSc 
patients with PAH and interstitial lung disease had similar pulmonary haemodynamics to 
those with isolated PAH and disproportionate to the severity of lung disease. In the 90’s it 
was reported that the median survival of patients with PAH in SSc was 12 months 
irrespective of the disease type of SSc. The same study on 17 SSc patients with PAH also 
showed patients with PAH and restrictive lung disease lived longer than isolated PAH (156). 
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Chang et al(160) also reported no difference in survival between PAH patients with (n=112) 
and without (n=119) restrictive lung disease. Though this study had a larger cohort, 
significant limitations were low sPAP threshold of 35 mmHg for PAH diagnosis and the lack 
of RHC data. In 2009, the UK PH centres reported on a large cohort of 315 unselected 
incident SSc cases with PAH diagnosed by RHC. The survival rate in SSc patients with PAH 
and interstitial lung disease(n=56) was found to be  significantly worse compared to those 
with isolated PAH(n=259) (150). A recent study(161) has retrospectively analysed 70 SSc 
patients with PH and ILD who received advanced targeted therapy including prostanoids, 
ERA and/or PDE-5i. No benefits of therapy were found and the 1, 2 and 3-year survival rates 
in this subgroup were 71%, 39% and 21% respectively. The risk of death from PAH related 
to SSc  is three to fourfold higher than for IPAH(162;163).The 1 year survival rate was 55 % 
in SSc-PH compared to 84% in IPAH patients who were treated with prostanoids and other 
supportive therapy such as anticoagulation, digoxin and diuretics(162). 
Despite the similar histopathological features in IPAH and CTD-associated PAH, the poor 
prognosis in PAH with CTD suggests that the pathophysiological processes are different, 
complex and not yet clearly understood. The initiating and propagating pathways are not 
known though several hypothesis exist involving the vasoconstriction, vascular proliferation 
and remodelling, and endothelial dysfunction. The drivers of PAH can be different at various 
stages of this disease. It is vital to target these drivers at the most appropriate time in order to 
achieve better outcome. Vasospasm plays a role in the early stages of PAH development 
while proliferation and fibrosis of vessels in later stages of severity.   
Though the pulmonary vascular lesions in PAH associated with CTD are similar to IPAH, the 
prognosis and response to therapy are distinctly poor in comparison to IPAH. The prognosis 
of PAH patients associated with CTD is very poor with 1, 2 and 3 year survival rates of 45%, 
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35% and 28%(156). The median survival with CTD associated PAH was only 1 year in 
comparison to 2.8 years with IPAH prior to introduction of prostacyclin treatment in mid-90s. 
Though the advent of advanced therapies in PAH have improved survival rates, the long term 
outcome is still poor in patients with PAH associated with CTD than in IPAH (refer to 
section 1.2.5) 
1.3.1 Why PAH in SLE is important 
Both these conditions independently can contribute to poor morbidity and mortality. The 
association of these conditions together can reduce the quality of life and survival 
considerably. The cardiac and respiratory functional compromise could be catastrophic if 
PAH develops in the background of active SLE affecting major organs. Moreover, 
pathogenesis such as thrombosis and vasculitis are common to both these conditions 
favouring the association as well as poor survival in this association. 
In SLE, the possible reasons for PAH development includes thrombosis, vasculopathy, active 
lupus disease, valvular heart disease, and interstitial lung disease. Vasospasm is another 
mechanism that may be important and Raynaud’s has been increasingly recognised as an 
association in SLE patients with PAH. Raynaud’s phenomenon is seen in 75% of patients 
with PAH compared to 25% of patients  without PAH in SLE (71;153;164;165) suggesting 
vasculopathy as a cause. This raises suspicion that antiphospholipid antibodies, Raynaud’s 
phenomenon, vasculitis and autoantibodies, interstitial and thromboembolic lung disease, and 
left heart disease causing pulmonary venous hypertension could be potential risk factors for 
development of PAH in SLE. 
To date SLE patients have been poorly studied to assess the true prevalence of PAH in non 
tertiary centre SLE patients. Most studies until now from tertiary centres are likely to 
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represent patients with severe SLE disease activity and do not necessarily reflect the general 
SLE population. Depending on the definition of PAH and diagnostic methods used, the 
prevalence of PAH in SLE patients range from 0.5-43%(69;154;166-170). The highly 
variable prevalence of PAH in the few epidemiological studies of SLE patients reflects the 
inconsistent epidemiological data. In addition, the retrospective nature of these studies with 
fewer SLE patients are also sources of error such as confounding and bias. These studies 
predominantly used ECHO as the screening tool. Only few patients have severe PAH, both 
symptomatic and haemodynamic. It is not known who progresses and how soon do they 
progress. What is known is that prognosis is poor in this group of secondary PAH compared 
to IPAH (see section 1.2.5)  
1.3.2 Variable data on prevalence of PAH in SLE 
Pulmonary arterial hypertension is considered to be uncommon in SLE unlike other CTD 
such as systemic sclerosis and mixed connective tissue disease (MCTD). Overall, the range 
of prevalence of PH in SSc diagnosed by echocardiogram (ECHO) is 16-59%(171-176) and 
by right heart catheterisation (RHC) is 7-29%(117;158;172;177-179), with majority of these 
studies reporting at lower end of the range mentioned above except older studies. In 2003, an 
UK study on 794 patients with SSc reported the prevalence of PH by ECHO was 18% and 
RHC 12%(158). Excluding interstitial lung disease related  PH, the prevalence of PAH in SSc 
patients by RHC is 7.85%(117).In a population based approach from UK, the prevalence of 
PH in SSc was 2.93 per million(150). The prevalence rate of PH in MCTD is 23-53%(180-
182). It is also known that a significant number of CTD patients may have undiagnosed PAH 
(UNCOVER study)(175). Undiagnosed PAH was found in 13.3% in a community cohort of 
669 patients with systemic sclerosis or MCTD with an overall prevalence of 26.7%(175) 
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The lack of robustness in the prevalence studies in PH in SLE stems from studies reported 
retrospectively or only in a small group of SLE patients. The wide variability depends on the 
definition of PH, diagnostic methods used, awareness of PH in SLE, study centres, number of 
study patients and retrospective nature of most studies. The prevalence rates are lower with 
studies using the gold standard right heart catheterisation (RHC) to diagnose PAH, but these 
studies are very few with SLE-associated PH (SLE-PH). PAH is also of mild degree in 
patients with lupus. The inconsistent epidemiological data in PAH associated with SLE 
influence the prevalence rates to a great degree. The following studies on lupus patients 
describe the wide variation in prevalence rates of PH in SLE (Table 1-7). 
- 1954: Harvey et al(183) reported that none of the 138 SLE patients had PAH. 
- 1981: Perez and Kramer(167) found a 9% prevalence of PAH in 43 SLE 
patients seen over 3 year follow up. 
- 1984: Quismorio et al(69) reported a prevalence of 0.5% of PAH in 400 SLE 
patients followed up over 10 years. They also reported the clinical and 
haemodynamic characteristics of the 20 PAH cases reported until then, 
concluding that the disease course is variable but small numbers of patients 
and short duration of follow up could bias these findings. 
- 1985: Badui et al(166) identified a prevalence of 9% for PAH in 100 SLE 
patients with Doppler ECHO measurements 
- 1989: Simonson et al(168) found that 5 out of 36 SLE patients representing 
60% of their tertiary care cohort to have PAH. This prevalence rate of 14% 
was evaluated by Doppler Echocardiography in this case control study. Only 
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one of the 5 patients had systolic PAP > 40 mm Hg and had past history of 
PAH prior to this study. In 1995, Winslow et al(154) reported the 5 year 
follow up data of these patients with a prevalence rate of 43% for PAH in 28 
SLE patients. Among the 5 PAH patients from initial study, 2 had died, 2 had 
normal systolic PAP and only 1 had persistent PAH.  The maximum systolic 
PAP was 38 mm Hg suggesting only mild elevation of PAP in all patients. 
- 1990: Asherson et al(57) reported 5% prevalence for PAH in 500 SLE patients 
over 5 years. 
- 1999: Among the 419 SLE patients from Hong Kong, 176 patients underwent 
Doppler echo in this retrospective analysis over 12 years. This study by Li et 
al(170) showed a prevalence of 4.3% for PAH in SLE. 
- 2000: Pan et al(169) reported PAH prevalence of 5.8% in a retrospective study 
of 786 SLE patients diagnosed over last 20 years from Singapore. Twenty four 
of the total 46 PAH patients had a secondary cause for PAH with valvular 
heart disease, interstitial lung disease, pulmonary embolism or combination at 
50%, 8%, 13%, and 29% respectively.  
- 2002: Tanaka et al(184) studied 194 SLE patients retrospectively and reported 
a prevalence of 6.2% for PAH. A third of these PAH patients had overlapping 
SSc features, predominantly limited SSc. 
- 2004: Johnson et al(185) reported a retrospective survey of 117 SLE patients 
who underwent Echocardiography over previous 7 years, from the cohort of 
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1100 patients from Canada. The prevalence rate of 5.4% for PAH was 
calculated, with systolic PAP >40 in a quarter of PAH patients. 
Most of these studies were retrospective analyses of SLE cohorts worldwide. These patients 
underwent ECHO Doppler studies to investigate cardiac and respiratory symptoms, abnormal 
chest X-ray or ECG, suspicion of valvular heart disease and rarely clinical signs of right heart 
failure. Thus, ECHO was neither done nor performed early in the asymptomatic or mild PAH 
patients with subtle clinical features. The possibility of underestimation of PAH is highly 
likely because the studies were not prospective and only a fraction of the cohort underwent 
Doppler ECHO. The few prospective studies were of small size which could significantly 
influence the reported prevalence rates. The tertiary care cohorts are likely to represent 
patients with severe disease activity and unlikely to reflect the true prevalence in the general 
SLE population. Except a very few, Doppler ECHO has been the screening method of choice 
in above studies due to the invasive nature or cost of the right heart catheterization (RHC).  
Except for a very few PAH patients, the systolic PAP were of mild and moderate degree less 
than 45 mmHg. The progress of PAH is variable depending on the presence of any secondary 
cause for PH in these patients. The advantages of management of severe and symptomatic 
PAH patient of any cause to improve symptoms, exercise capacity or haemodynamic 
measures has been clearly shown with newer targeted and combination therapies. The 
evidence for the benefits of treatment in mild and moderate PAH especially when 
asymptomatic is not known and needs further evaluation in future. The PH registries from 
UK, France and USA and few other research groups including Chung et al(155), Condliffe et 
al(150), Fois et al(186), Cefle et al(55) and Ruiz-Irastorza et al(187) have published on the 
epidemiological data on PH in CTD since the present study has been undertaken and will be 
detailed in chapter 3 (section 3.4). 
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Table 1-7 Epidemiologic studies of the prevalence of pulmonary hypertension (PH) in 
SLE 
First 
author of 
study 
(n= No. of 
patients in 
cohort) 
No. 
under
-gone 
test 
Prevalence 
rate of PH 
 (%) 
PH  
defi-
nition 
(mmHg) 
Country 
where 
study was 
conduc-
ted 
Type 
of 
SLE 
coh-
ort 
PH 
diagn-
osed 
by 
ECHO 
or 
RHC 
Durat-
ion  
of 
study 
(years) 
Nature 
of 
study  
(R/P)# 
Year 
of 
stu-
dy 
Harvey 
(n=138) 
138 0 n/a USA n/a n/a n/a n/a 1954 
Perez 
(n=43) 
43 9.3 n/a USA T RHC 3.5  R 1981 
Quismor-
io 
(n=400) 
20 0.5 >40 USA T RHC 10  R 1984 
Badui 100 9 n/a n/a n/a ECHO n/a P 1985 
Simonson 
(n=36) 
 
36 14 > 30 USA T ECHO 1 P 1989 
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Asherson 
(n=500) 
n/a 5 n/a UK T n/a 5  R 1990 
Ong 
(n=40) 
40 10 >55 Malaysia T ECHO 1  P 1992 
Winslow 
(n=28) 
28 43 >30 USA T ECHO 5  P 1995 
Li 
(n=419) 
176 4.3 >30 Hong 
Kong 
T ECHO 12 R 1999 
Shen 
(n=84) 
84 11 >30 China T ECHO 1 P 1999 
Pan 
(n=786) 
 
n/a 5.8 (2.8% 
had PAH) 
>30 Singapore T ECHO 20 R 2000 
Tanaka 
(n=194) 
194 6.2  
 
> 40*  Tokyo T ECHO 8 R 2002 
Johnson 
(n=1100) 
117 1.3 
 
5.4 
> 40 
 
> 30 
Toronto T ECHO 8 R 2004 
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Chung 
(N-725) 
181 2.8 >45* 
 
South 
Korea 
T ECHO 9 R 2006 
Chung 
(n=725) 
10 1.4 >30 South 
Korea 
T RHC 9 R 2006 
Fois 
(n=93) 
93 13  
(9.6 % had 
PAH) 
>35 France T ECHO 11 R 2010 
* Includes right atrial pressure of 10mm Hg; # Nature of study: R- retrospective, P-prospective; T: 
Tertiary centre; RHC-Right heart catheterisation; ECHO-Echocardiogram; Data unknown from 
original publications are entered n/a (not available). 
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1.3.3 ECHO as a screening tool for PAH 
The modern Doppler ECHO techniques have been the screening tool of choice for PAH in 
most studies on SLE patients. Doppler echocardiography is an indirect and observer 
dependent measure of systolic pulmonary artery pressure using tricuspid gradient (TG) 
estimation. Only a few retrospective studies reported on the right heart catheterization (RHC) 
measurements in patients that met PAH criteria on Doppler ECHO.  The correlation of mean 
PAP measured by RHC has shown good correlation with estimated systolic PAP measured by 
Doppler ECHO(112;188-190). There are other echocardiographic variables suggestive of PH 
including increased velocity of pulmonary valve regurgitation and a short acceleration time of 
right ventricular (RV) ejection into pulmonary artery (PA), increased dimensions of right 
atrium and ventricle, abnormal shape and function of interventricular septum, increased RV 
wall thickness, and dilated main PA. In 2009, the European Society of Cardiology (ESC) 
published guidelines to estimate the presence of PH using these ECHO variables in addition 
to the estimated sPAP(105). 
Mukerjee et al(116)  prospectively studied 137 patients with SSc to compare Doppler 
echocardiography and RHC in differentiating patients with and without PAH. It was noted 
that resting echocardiography performs adequately as a screening tool only in the diagnosis 
of advanced PAH, provided high thresholds of TG >45mmHg for PAH diagnosis is used. 
There were several limitations to this study including inter-observer variability and also, 
echocardiographic parameters studied were useful in advanced rather than early PAH. It was 
concluded that echocardiography as an adjunct to clinical evaluation was the optimal 
screening approach to identify patients with PAH. 
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1.3.4 Valvular diseases and other cardiac manifestations in SLE 
Cardiac involvement in SLE can present with anatomical as well as functional abnormalities. 
It affects all layers of cardiac wall including endocardium, myocardium and pericardium. 
SLE can manifest as pericarditis or pericardial effusion, myocarditis, valvular heart disease, 
endocarditis, arrhythmias, systemic hypertension and ischemic heart disease. These 
manifestations can present at any stage of disease and could worsen during active lupus 
disease.  
Initially when cardiovascular disease (CVD) in SLE was increasingly recognised in 70’s, 
autopsy studies in SLE confirmed the presence of anatomical cardiac abnormalities in the 
range of 15-75%(63;191). Later on, transthoracic echocardiography (TTE) based studies 
reported the prevalence of similar CVD in SLE was 40-50% (192)and the transoesophageal 
echocardiography (TOE) studies reported morphological cardiac abnormalities in 50-60% 
(192;193)of SLE patients. To begin with it was considered that cardiovascular manifestations 
were predominantly a feature of SLE in later stages resulting in severe life threatening 
complications.  The increasing use of non invasive screening with TTE brought to light the 
commoner manifestations of pericardial involvement as well as valvular abnormalities. 
Moreover, these were present in early stages of SLE onset with less disease duration and 
rarely caused cardiac functional impairment. This change in pattern recognition of cardiac 
involvement led researchers to identify risk factors and associations in lupus patients with 
cardiac valvular abnormalities. In particular antiphospholipid antibodies and antiphospholipid 
syndrome were significantly associated with cardiac valvular abnormalities.  
In 1924, Libman and Sacks(194) reported on verrucous non-bacterial endocarditis 
predominantly affecting mitral valve and in 1940, Gross (195)associated these lesions with 
SLE. The Libman-Sacks endocarditis lesions were found in 7 out of 74 SLE patients in a 
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study by Galve et al(196). Though earlier studies predominantly reported from autopsy 
findings, the introduction of 2 dimensional and M-mode transthoracic echocardiogram, 
Doppler studies and transoesophageal echocardiogram led to non-autopsy larger series 
studies reporting 11-72% of lupus patients with valvular heart disease(197). The valvular 
heart disease in SLE is predominantly asymptomatic, but if symptomatic can lead to 
substantial morbidity and mortality(197). The common echocardiographic abnormalities of 
valves include mild to moderate thickening of valve cusps and valvular vegetations, and these 
are often accompanied by valvular regurgitation and rarely lead to stenosis. Valvular 
replacement may be needed in 22% with valvular stenosis and/or regurgitation(196;197). The 
association of antiphospholipid antibodies such as anticardiolipin antibodies and lupus 
anticoagulant with cardiac valve abnormalities in SLE has been well documented(198-203), 
though a few studies did not find this association(204;205). It has also been shown that 
patients with primary antiphospholipid syndrome have higher prevalence of valvular lesions 
in 32-60% of patients(206;207). It was found that 50% of lupus patients with a history of 
cardiovascular and/or cerebrovascular disease had valvular abnormalities(208).  The aortic 
and mitral valve lesions resulting in significant cardiac dysfunction can lead to secondary PH 
in SLE.  
Myocardial involvement is seen in 8-81% of patients with SLE (209-212)and can result in 
systolic and diastolic cardiac dysfunction. Predominantly myocardial involvement is 
asymptomatic and noted in autopsy findings. The clinical manifestations due to myocardial 
involvement are reported less frequently(196;211;213). The increase in left ventricular 
systolic dimensions and decrease in ejection fraction indicates systolic dysfunction and the 
increased mitral valve A:E ratio indicates diastolic dysfunction on echocardiographic 
evaluation.  
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The cardiovascular disease is considered among the leading causes of increasing mortality 
and morbidity in SLE. Coronary arterial disease (CAD) is also common in SLE. This is due 
to accelerated atherosclerosis from increasing number of traditional risk factors in SLE 
patients, inflammatory risk factors related to lupus as well as treatment such as 
corticosteroids. It is well known that the number of traditional cardiovascular risk factors is 
higher in lupus patients in comparison to age and sex matched controls(214-216). Petri et 
al(217) reported 3 or more known risk factors for CAD in 53% of their cohort.Systemic 
hypertension, hyperlipidemia and increasing age are predictors of cardiovascular disease in 
lupus. The accelerated coronary atherosclerosis and systemic hypertension seen in SLE can 
also contribute to left heart systolic and diastolic dysfunction. It is well known that left heart 
disease can cause pulmonary hypertension, which is a separate entity in itself in the WHO 
classification of pulmonary hypertension. In particular, the systolic and diastolic dysfunction, 
and left heart valvular disease can lead to secondary PH. Echocardiogram and Doppler 
studies are used to assess cardiac systolic and diastolic function and valvular diseases as part 
of screening for PH in order to discriminate PAH from secondary PH due to left heart disease 
in SLE. 
1.3.5 Inflammation in PAH with SLE 
 PAH is considered to have an inflammatory pathogenesis in CTD, HIV and IPAH. Tuder et 
al (218)identified perivascular inflammatory infiltrates such as T cells, B cells and 
macrophages suggesting the role of cytokines and growth factors in plexiform lesions found 
in lungs of patients displaying severe IPAH. Cool et al(219) reported the perivascular 
mononuclear cells were present only in the plexiform lesions and absent in extravascular and 
uninvolved vessels of the lungs of scleroderma patients with PAH. Patients with IPAH have 
detectable levels of ANA(220) and elevated proinflammatory cytokines IL-1 and IL-6(221) 
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in the absence of systemic autoimmune disease. 40% of IPAH patients had positive ANA 
without any features of CTD. It is possible that some of these patients had subtle ANA 
related CTD symptoms which could have been missed at the diagnosis of PAH.  Balabanian 
et al(222) showed patients with severe IPAH have increased plasma levels of various 
inflammatory markers compared to normal controls. 
The presence of IgG and complement fraction immune deposits(223) similar to the renal 
glomeruli deposits were found in pulmonary vascular endothelium of PAH secondary to 
CTD. On the other hand, disseminated immune deposits have been found in lungs of lupus 
patients without PAH(224). 
As SLE is an autoimmune inflammatory disease that can cause vasculitis, the concept of 
pulmonary vasculitis causing PAH is plausible. The inflammatory pathogenesis supports the 
fact that active lupus disease could predispose to pulmonary vasculitis causing PAH that can 
respond to immunosuppressive therapy. The response to immunosuppressive therapy and 
corticosteroids have been shown to improve PAH in CTD patients particularly SLE(225-
227). The lack of similar response in other CTDs especially scleroderma, suggests that 
different mechanisms could play a role in the pathogenesis of PAH in different CTDs. Most 
of this evidence is derived from small series and case reports, and the lack of placebo 
controlled studies makes it difficult to assess the true efficiency of immunosuppressant 
therapy in PAH. Moreover, the frequent use of vasodilators in addition in these patients could 
also bias the outcome. 
Lupus nephritis and Raynaud’s phenomenon have been shown to be associated with PAH in 
SLE. However disease activity of other organ manifestations as well as damage scores in 
lupus has not been studied and it is not known if they are associated with PAH or not. 
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A meta-analysis of antiphospholipid antibodies (APLA) including 1000 SLE patients 
reported an average frequency of  34% for lupus anticoagulant and 44% for anticardiolipin 
antibodies in lupus patients (46)..A review by Petri et al(52) reported a frequency range of  7-
65% for lupus anticoagulant and 17-86% anticardiolipin antibodies in SLE. However, 
definite secondary APS occurs only in 10% of SLE patients(53). The prevalence of secondary 
APS in SLE in the same cohort of 667 SLE patients increased to 15% when follow up was 
extended from 7.5 months to 3 years(228) and further increased to 23% with a follow up of 
18 years. APLA have been shown to be associated with PAH in SLE. None of these patients 
had thromboembolic pulmonary vascular disease leading to PH; however the concept of 
APLA and microthrombi in small pulmonary vessels resulting in PH is possible. 
The presence of inflammatory cells in the PAH lesions, the association of autoantibodies and 
inflammatory markers and cytokines with PAH, a few lupus manifestations known to have 
predictive value for PAH, and significant response of PAH to immunosuppressive therapy all 
do suggest the possibility of inflammatory pathogenesis for PAH in SLE.  
1.3.6 Assessment of pulmonary involvement in SLE 
Pleurisy, pleural effusion, interstitial lung disease (ILD), pulmonary embolism, shrinking 
lung syndrome (SLS) are the most important lung manifestations in SLE.  The symptoms of 
lung disease include chest pain, dyspnoea, poor exercise tolerance, and cough. These non 
specific symptoms are not uncommon in renal or cardiac involvement including PAH in SLE. 
It is important to be aware of lung diseases that cause secondary PH such as interstitial lung 
disease, pulmonary embolism and emphysema. The assessment of lung diseases, whether it is 
serosal, interstitial, airways or vascular disease is vital to ascertain the cause of PH, degree of 
lung involvement and the impact of cardiorespiratory symptoms in SLE patients. High 
resolution CT (HRCT) scanning of lungs and CT pulmonary angiography (CTPA) are very 
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useful imaging investigations in diagnosing interstitial lung disease and pulmonary 
thromboembolic disease respectively. 
1.3.6.1 Pulmonary function tests 
The pulmonary function testing includes spirometry, lung volumes and transfer factor 
measurement. The PFT parameters help to determine the restrictive or obstructive nature of 
lung disease. The decline in lung function is used as a guide to monitor closely with repeated 
lung function tests as well as assess the need for imaging and invasive testing modalities for 
cardiac or lung involvement.  
It has been shown that abnormal PFT is common in patients with SLE, particularly low 
transfer factor (TLCO) and low forced vital capacity (FVC)(229;230) often in the presence of 
normal chest x ray. Most patients with SLE and abnormal PFT were asymptomatic and did 
not have a history of lung disease. It is possible that chronic ILD can lead to secondary PH in 
SLE. The prevalence of clinically significant chronic ILD is 3-13%. The restrictive lung 
pattern with reduced FVC <80% predicted is seen in patients with chronic ILD. A reduced 
FVC without evidence of ILD on HRCT lungs is seen in patients with SLS(231) and with 
imaging evidence in pleural fibrosis. The PFT abnormalities if detected in patients with SLE 
associated PH would help to ascertain the secondary cause of PH in these patients and guide 
further investigations necessary such as HRCT scan of chest and CTPA lungs. 
 It has been shown that reduced TLCO is a valuable screening test for PAH associated with 
systemic sclerosis (SSc)(116;179) and less often in Idiopathic PAH (IPAH)(232). The UK 
PH registry reported that TLCO was low in SSc patients with PH especially those with ILD 
compared to SLE related PAH. 
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1.3.6.2 Respiratory muscle strength 
The respiratory muscle predominantly involved in quiet breathing is the diaphragm. During 
exercise, the inspiratory muscles include external intercostals, scalene and sternomastoids and 
the expiratory muscles include abdominal wall muscles and internal intercostals. Respiratory 
muscle dysfunction involving both inspiratory and expiratory muscles have been reported in 
patients with SLE(233-235), scleroderma, RA(236) as well as IPAH(237). Shrinking lung 
syndrome seen in SLE has been attributed to diaphragm malfunction or weakness. The 
severity of inspiratory and/or expiratory muscle weakness has been different in patients with 
IPAH compared to those with chronic obstructive airways disease (COPD) and congestive 
cardiac failure (CCF). There has been good correlation between maximal inspiratory pressure 
(MIP) and maximal expiratory pressure (MEP) in patients with IPAH, and the pressure 
changes are independent of NYHA functional class and haemodynamic parameters such as 
mean PAP. A similar correlation of MIP and MEP are seen in COPD. In patients with CCF 
the reduction in MIP is greater than MEP(237;238) and is associated with NYHA functional 
classes(238). Isolated diaphragm weakness is associated with normal MEP and low MIP. The 
normal values of MIP and MEP vary widely depending on sex, and the mouthpiece type used 
for measuring pressures. The normal values vary widely for MIP and MEP and range 70-73 
cmH2O and 89-94 cmH2O in females, and 105-113 cmH2O and 140-154 cmH2O in males 
respectively(239-242). In this study, values lower than 40 cmH2O for both MIP and MEP 
were used as evidence for respiratory muscle weakness. 
1.3.6.3. Respiratory symptom questionnaires 
There are several validated respiratory questionnaires which reliably relate respiratory 
symptoms and lung function. Their role in determining the risk of PAH development in 
patients with respiratory symptoms has not been proven. Among several respiratory 
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questionnaires, Modified medical research council (MRC)dyspnoea scale, Baseline dyspnoea 
index (BDI) and St.George’s respiratory questionnaire (SGRQ) are often used, These 
questionnaires are easy to complete in a short duration. They are valid, reliable and rates 
dyspnoea during different tasks and levels of activity. 
1.3.6.4. Six minute walking test (6MWT) 
There are several clinical exercise tests to evaluate objective functional exercise capacity. 
The most popular exercise tests include stair climbing, 6MWT, shuttle walk test and cardiac 
stress test (eg. Bruce protocol)(243).6MWT is a practical simple self-paced test to assess 
submaximal level of functional exercise capacity.  As the patients choose their own intensity 
of walking, and are allowed to stop and rest during the test they do not achieve maximal 
exercise capacity. The daily activities are most often performed at submaximal levels of 
exertion and thus, the six minute walking distance reflects the functional exercise level for 
daily activities better than other exercise tests such as shuttle walk test.  
6MWT has been used to measure the response to medical interventions in patients with 
moderate or severe heart or lung disease. 6MWT also helps predict mortality and morbidity 
in heart failure, COPD and PAH(244;245). The 6MWT does not measure peak oxygen 
uptake, diagnose the causes of dyspnoea or exercise limitation. Though 6MWT does not 
provide all the objective information that a formal cardiopulmonary test provides, a 
significant correlation between six minute walking distance (6MWD) and peak oxygen flow 
uptake in end stage lung diseases such as PAH has been reported(245;246). 6MWT also 
correlates better with quality of life measures, and in contrast questionnaire indices of 
functional status have larger short term variability. 
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1.3.7 Biomarkers 
Biomarkers can a useful tool to provide prognostic, diagnostic or therapeutic response value 
in a disease process. The National Institute of Health (NIH),USA biomarkers definition 
working group defines ‘The  biomarker is a characteristic that is objectively measured and 
evaluated as an indicator of normal biologic processes, pathogenic processes or 
pharmacologic response to therapeutic intervention(247). It is essential that these biomarkers 
are validated in a large longitudinal cohort study. 
Several biomarkers have been researched in the area of pulmonary hypertension, particularly 
in patients with systemic sclerosis. These include brain natriuretic peptide (BNP), vascular 
endothelial growth factor (VEGF), Fractalkine, endothelin (ET) and soluble CD40ligand. 
1.3.7.1 BNP and NT-proBNP 
B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are released from 
both cardiac ventricles in response to volume or pressure overload. The increase in 
pulmonary vascular resistance in PAH leads to right ventricular systolic dysfunction (RVSD) 
and death. It has been shown that RVSD at presentation can predict early death in PAH 
patients. The gold standard for detecting RVSD is by cardiac magnetic resonance imaging 
(MRI) which is expensive and not readily available. The right ventricular ejection fraction 
(RVEF) can be indirectly estimated by transthoracic echocardiography. This estimation 
called the Tei Index is detectable easily in the presence of overt right heart failure but 
otherwise an experienced competent echocardiographer is essential to detect this. B-type 
natriuretic peptide and NT-proBNP correlates well with RVEF measured by ECHO(248), 
invasive pulmonary haemodynamics(249) and survival(250-252) in PAH patients. The 
threshold levels of BNP and NT-proBNP indicating RVSD has also been determined, and 
thus are an ideal alternative to identify early RVSD by expensive and invasive methods(248). 
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Both in IPAH and secondary PAH particularly systemic sclerosis, it has been shown that 
plasma levels of BNP and NT-proBNP correlate well with mean PAP(249). It is important to 
understand that the levels of BNP and NT-proBNP could be elevated in other conditions such 
as left ventricular (LV) dysfunction, ischaemic heart disease, renal failure, LV hypertrophy, 
hypertrophic cardiomyopathy, aortic stenosis, pregnancy induced hypertension, pulmonary 
embolism, hypoxia and subarachnoid haemorrhage.  
NT-proBNP is more stable than BNP both in vivo and in vitro. Thus, it is considered an ideal 
biomarker to measure cardiac dysfunction in PAH. The baseline levels would identify RVSD 
at presentation. The follow up levels would help monitor response to therapy or can be an 
indicator for further haemodynamic testing such as cardiac catheterisation and need for 
change of therapy for PAH. 
Since the completion of my study, Chung et al(253) in 2008 reported that SLE patients have 
elevated NT-proBNP levels compared to healthy controls. NT-proBNP levels correlated well 
with disease duration, damage index but not with disease activity or markers of vascular 
disease such as augmentation index in patients with SLE.  
Blyth at al(248) showed a threshold of NT-proBNP levels at 1684 pg/ml specific for 
detecting RVSD in PAH. Mukerjee et al ascertained that NT-proBNP cut off value of 395 
pg/ml had a sensitivity of 69%, specificity of 100% and high negative predictive value of 
91% in predicting PAH in systemic sclerosis as determined by mean PAP value >25mmHg 
by RHC (249). 
1.3.7.2 Fractalkine (FKN) 
Fractalkine is a chemokine that has been implicated in the pathogenesis of several 
inflammatory diseases such as rheumatoid arthritis, atherosclerosis, HIV, crescentic 
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glomerulonephritis and psoriasis. The presence of circulating ANA, inflammatory cell 
infiltrates in plexiform lesions, elevated levels of proinflammatory cytokines IL-1 and IL-6, 
and increased expression of chemokines including RANTES and FKN supports the role of 
inflammation in the pathogenesis of PAH including IPAH and connective tissue disease 
related PH. 
Fractalkine is expressed as membrane bound (mFKN) protein on endothelial cells activated 
by proinflammatory cytokines such as tumour necrosis factor-alpha and interferon-gamma. 
The soluble forms (sFKN) are released by proteolytic cleavage of mFKN. Fractalkine 
receptor CX3CR1 expressed on T cells, mast cells and natural killer cells rapidly and firmly 
adhere to membrane bound FKN on EC. The upregulation of CX3CR1 in circulating T 
lymphocytes and elevated sFKN levels has been shown in patients with PAH(222). The lung 
biopsies from patients with PH have confirmed the presence of mononuclear inflammatory 
cell infiltrate in the perivascular areas surrounding plexiform lesions in CTD related PH(219)  
and IPAH(218).  The detection of sFkn mRNA in the lung biopsies of PAH and the 
significantly increased sFkn mRNA expression in PAH patients compared to controls further 
supports the role of sFkn in PAH(222). Animal studies(222;254) have shown that sFkn is 
possibly a growth factor for pulmonary artery smooth muscle cells resulting in vascular 
remodeling in PAH.  
Soluble FKN has also been shown to be elevated in active neuropsychiatric SLE(255;256). 
The sFKN levels in serum and cerebrospinal fluid of SLE patients correlated with SLEDAI, 
SLICC/ACR Damage index, anti- double stranded DNA and anti-Sm antibody titres and 
serum complement CH50 levels. The serum and CSF levels of sFKN reduced with treatment 
for active NPSLE.  Fractalkine has been described as a mediator with anti-apoptotic 
properties supporting the survival of multiple cell types during inflammation(257). SLE being 
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a disease of defective apoptosis would support the increased expression of chemokine such as 
Fractalkine. Patients with PAH associated with SLE have shown improvement with 
immunosuppressive therapy(227) raising the possibility of inflammation playing a role in the 
pathogenesis of PAH. Fractalkine being associated with PAH as well as SLE activity 
separately made us explore the possibility of raised sFkn levels in PAH associated with SLE. 
1.3.7.3 Vascular endothelial growth factor (VEGF) 
VEGF is a selective endothelial cell growth factor, potent enhancer of microvascular 
permeability and angiogenic peptide which is secreted by a variety of cell types including 
endothelial cells, macrophages, fibroblasts and smooth muscle cells. VEGF interacts with two 
specific tyrosine kinase receptors VEGFR-1 and VEGFR-2 found in endothelial cells. 
Endothelial cell proliferation is associated with several physiological and pathological 
processes and VEGF has been implicated in these processes. VEGF has been measured in 
several kinds of biological fluids and cells of the lung parenchyma. The most common 
origins used for its measurements are blood (serum or plasma), bronchoalveolar lavage 
(BAL) fluid, sputum, bronchial epithelial cells, alveolar type II cells, alveolar macrophages, 
neutrophils, endothelial cells of the alveolar capillaries, and airway or vascular smooth 
muscle cells. Serum VEGF levels are 2 -7 fold higher than plasma due to ex vivo platelet and 
leucocyte release of VEGF during blood clotting(258). 
Elevated serum levels of VEGF have been shown to be associated with RA(259), 
scleroderma and SLE (260;261). Dysregulated VEGF expression has been shown in primary 
APS(262), glomerular disease, diabetic retinopathy and in metastases. Basic fibroblast 
growth factor associated with angiogenesis has been detected in serum of SLE and 
dermatomyositis patients(263). In SLE, the serum VEGF levels have been shown to be higher 
than the controls. Serum VEGF levels were found to be higher in active SLE compared to 
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inactive SLE(264;265), and lupus nephritis was associated with strong expression of VEGF 
in renal tissues and high serum VEGF levels(266). It has been reported that VEGF plays a 
significant role in the pathogenesis of PH(267) as the serum VEGF levels  were markedly 
raised in idiopathic and secondary pulmonary hypertension. It has also been shown that 
continuous prostacyclin infusion increases circulating VEGF levels thus raising an important 
question as to whether VEGF has deleterious or protective effects. VEGF has been shown to 
be strongly expressed in the normal pulmonary circulation as well as plexiform lesions of 
primary pulmonary hypertension(268). Elevated levels of serum VEGF has been reported in 
SLE patients with pulmonary hypertension (PH) compared to those without PH and 
controls(269). 
1.3.8 Pregnancy in SLE 
It is well documented that PAH in pregnancy carries a poor prognosis, with maternal 
mortality of 56% with secondary PAH compared to 30% with IPAH(270). As SLE 
commonly affects women in childbearing age group, it is important to identify those with 
PAH or at risk of developing PAH. This would help plan multidisciplinary care from early 
pregnancy onwards or prevent pregnancy, and achieve a favourable maternal and fetal 
outcome. The timing of diagnosis of PAH and admission to hospital with individualised care 
are predictors of good prognosis.  
Antiphospholipid antibodies (APLA) and antiphospholipid syndrome (APS) have also been 
shown to be associated with PAH in SLE patients. Though antiphospholipid antibodies is 
present in 30% of SLE patients, only a third have antiphospholipid syndrome(53). However, 
there is lack of evidence for thromboembolic phenomenon causing PAH associated with 
APLA. The risk of miscarriages and fetal deaths is high in the presence of APS, and the 
added burden of PAH in SLE is likely to increase this risk significantly. In the absence of 
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predictors to point who will deteriorate in pregnancy with SLE, we have to be vigilant of high 
risk groups such as those with suspected cardiorespiratory symptoms, interstitial lung disease 
and pulmonary embolism. 
1.3.8.1. Pregnancy, PAH and SLE 
Pulmonary arterial hypertension shortens survival and when it coincides with pregnancy, this 
risk considerably increases during labour and immediate postpartum period. The 
cardiovascular demands during pregnancy help to adapt to the fetal development and 
placental circulatory changes. During pregnancy, the increase in heart rate, circulatory blood 
volume and cardiac output is tolerated with dilatation in the systemic and pulmonary 
vasculature resulting in only minimal change to PAP. There are further haemodynamic 
changes that can occur rapidly during labour, delivery and puerperium.  However, in the first 
72 hours postpartum, the cardiac output further increases secondary to maternal auto 
transfusion and increased venous return to right heart. These physiological demands during 
pregnancy can significantly compromise the cardiopulmonary status and result in poor 
tolerance leading to complications and mortality soon after delivery. In PAH, there is 
increased pulmonary vascular resistance such that this high cardiac output status results in 
right heart failure that can cause death.  
A systematic overview in pregnancy from 1978 through 1996 showed  that among 27 patients 
with primary and 25 with secondary PH had maternal mortality of 30% and 56%, and 
neonatal survival of 89% and 88% respectively(270) . The secondary PH patients with SLE 
and scleroderma had the worst prognosis with 100% maternal mortality. The independent 
predictive risk factors of maternal mortality were diagnosis of pulmonary vascular disease 
during or after pregnancy (odds ratio 5.4) and late hospital admissions (odds ratio 1.1 per 
week of pregnancy). 
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The rapid deterioration of PAH occurs when pulmonary thromboembolic disease complicates 
PAH(271). The risk is highest in those with a prothrombotic tendency such as 
antiphospholipid syndrome during pregnancy.   
McMillan et al(271) reported a case series of 3 SLE patients with PAH from our cohort, who 
declined termination of pregnancy and had high mortality rate of 66%. Both the patients who 
died were diagnosed with PAH during pregnancy and deteriorated rapidly, while the survivor 
had mild PAH and diagnosed very early in pregnancy and managed with close monitoring of 
multidisciplinary team as well as invasive monitoring in intensive care following delivery. 
This report by McMillan et al(271) suggests the importance of diagnosing PAH prior to 
pregnancy planning in high risk groups such as SLE. We can advise appropriately regarding 
pregnancy prevention and early interruption of pregnancy to improve the survival of lupus 
patients with PAH. An individually tailored treatment during pregnancy with particular 
attention to medical care postpartum is vital in patients with early diagnosis and preferably 
mild PAH. As there are no clear pointers to who will deteriorate and how rapidly they would 
do so during pregnancy in this subgroup, we are in need of further detailed study to address 
this. Until then, we have to be vigilant of high risk groups such as those with suspected 
cardiorespiratory symptoms, interstitial lung disease and pulmonary embolism. 
 
 
 
 
 
 
 
 68 
1.4. Aims and Objectives of the study 
 
Aims:  
To estimate the point prevalence of PAH, identify risk factors and evaluate screening tests for 
PAH in a large cohort of SLE patients.  
Objectives: 
1. To estimate the point prevalence of PAH in patients with SLE using transthoracic 
echocardiogram (TTE). 
2. To evaluate risk factors for patients with PAH in SLE 
a. To estimate the prevalence of left heart structural and functional abnormalities using 
TTE in patients with PAH and SLE  
b. To evaluate the role of autoantibodies, BILAG disease activity scores and 
SLICC/ACR damage scores as predictors for PAH in patients with SLE.  
c. To evaluate respiratory muscle strength (RMS) abnormalities in SLE patients and 
compare RMS abnormalities in those with and without PAH. 
d. To evaluate serum NT-proBNP, plasma sFkn, and plasma VEGF concentration in 
patients with SLE and compare between patients with and without PAH. 
e. To assess relationship of serum NT-proBNP, plasma sFkn, and VEGF levels with 
lupus disease activity measures such as monitoring tests especially anti-dsDNA 
antibody titre and complement C3 and C4 levels and autoantibodies associated with 
SLE,.BILAG disease activity scores and SLICC/ACR organ damage scores 
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3. To evaluate the role of other screening tests in patients with PAH in SLE 
a) To evaluate pulmonary function test (PFT) abnormalities in patients with SLE, and 
assess relationship with lupus related autoantibodies and BILAG disease activity 
scores 
b) To compare PFT abnormalities in lupus patients with and without PAH, and in 
patients with and without known restrictive lung diseases  
c) To evaluate dyspnoea in patients with SLE using respiratory symptom questionnaires, 
and compare dyspnoea scores between patients with and without PAH in SLE. 
d) To determine distance walked in six minutes (6MWD) in SLE patients and compare 
6MWD by patients with and without PAH 
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CHAPTER 2   METHODS 
 
2.1 Patient Recruitment 
 
This prospective cross-sectional study was conducted in the Wellcome Trust Clinical 
Research Facility (WTCRF) at the Queen Elizabeth Hospital (QEH), Birmingham UK 
between January 2004 and December 2005. This study was carried out in accordance with 
Helsinki declaration and received ethical approval from multicentre research ethics 
committee, UK (MREC 03/9/067). The study protocol synopsis submitted to ethics 
committee is shown in Appendix 4. Three hundred and ninety-two patients in the cohort with 
SLE who attend the Lupus UK centre of excellence clinics at QEH and City Hospital (CH), 
Birmingham were invited to take part in this study. Pregnancy and/or age below 18 years 
were the exclusion criteria for this study. Two hundred and eighty-eight (73%) patients gave 
informed written consent to participate. Two hundred and eighty-five (99%) patients fulfilled 
4 criteria for SLE diagnosis defined by 1982 revised American college of Rheumatology 
(ACR) criteria(62) while the remaining patients fulfilled 3 criteria and a clinical diagnosis of 
SLE by the Consultant Rheumatologist responsible for patient’s care (CG or RDS). The 
patients attended no more than twice at WTCRF for this study.  
At the initial visit, a detailed clinical evaluation including history of smoking and Raynaud’s 
phenomenon  plus, ECG, assessment of SLE disease activity using BILAG index(74;75) and 
of accumulated damage using the SLICC/ACR damage index(77;78) was undertaken. 
Echocardiography and the screening tests and assessments of risk factors for PAH were 
performed either at the same visit or within 4 weeks of this assessment. Echocardiography 
was done on a separate day to the other assessment in 19.8% (57/288) of patients.  
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2.2 Demographics 
 
The demographic details of patients were collected and includes their full name, hospital 
where recruited, hospital identification (ID) number, study ID, age, sex, disease duration, race 
(Caucasian, Asian, Afro-Caribbean, Oriental and other), the date of onset of 1
st
 criteria for 
SLE and the date when SLE was diagnosed and if fulfilling ACR criteria for SLE (Appendix 
1). The presence of Raynaud’s phenomenon, history of antiphospholipid syndrome and 
presence of overlap syndrome features of systemic sclerosis and/or mixed connective disease 
were also recorded. The written copies of the patient confidential data as well as the study 
results data were stored at the WTCRF and the electronic copies in an access database at 
WTCRF. 
2.3 Electrocardiography (ECG)  
 
During the initial visit, all patients had 12 lead ECG performed. The ECG was analysed to 
identify heart rate, axis deviation, ventricular hypertrophy and bundle branch block. The 
following definitions were used to record the ECG abnormalities relevant to this study. 
Left ventricular hypertrophy (LVH)(272): ‘probable’ if the sum of S wave amplitude in V1 
and R wave amplitude in V5 or V6 is > 35mm, and ‘definite’ if features of left ventricular 
strain pattern such as T wave inversion or ST segment depression in lateral leads were 
present in addition. 
Right ventricular hypertrophy (RVH): R/S ratio is >1 in V1 or <1 in V6, or sum of R in V1 
and S in V5/6 is >10.5mm. In addition, the presence of right axis deviation and/or RV strain 
pattern such as ST segment depression or T wave inversion in anterior or inferior leads makes 
RVH highly likely.   
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Right bundle branch: QRS >120ms and terminal R wave in V1 and a slurred S in lead I.  
 Left bundle branch block: QRS >120m and QS or rS complex in leadV1 and a monophasic R 
wave in lead I. 
Right axis deviation if axis <-30 degrees 
Left axis deviation if axis > +90 degrees 
2.4 Echocardiography (ECHO) 
 
All patients had transthoracic echocardiographic examinations performed at rest using a 
Sonos 7500 echocardiogram (Philips Medical systems) by experienced echocardiographers, 
who were unaware of the patient’s previous clinical characteristics and cardiovascular 
diagnosis. The scan was performed by a consultant cardiologist (KP) in 75% of patients, and 
the remainder by 2 senior echo cardiographers. All scan results were reviewed by consultant 
cardiologists (KP and JT). 2D, M-mode and colour Doppler echocardiography were obtained 
from parasternal long- axis and short-axis, apical four chamber and subcostal four-chamber 
views. These were used to evaluate valvular anatomy and function, flow abnormalities, 
cardiac morphology including left and right sided chamber sizes, and cardiac functional 
status including ejection fraction (EF).   Tricuspid regurgitant flow was identified by colour 
flow Doppler techniques, and the maximum jet velocity was measured by continuous wave 
Doppler. 
The data recorded were:  
1. Right ventricular systolic pressure (RVSP) - This was estimated in all patients in whom 
tricuspid regurgitation was detected by colour flow Doppler technique. This maximum 
velocity of the tricuspid valve regurgitant (TR) jet was measured by the continuous wave 
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Doppler. RVSP was calculated by using the modified Bernoulli equation. This was 
considered to be equal to the systolic PAP in the absence of right ventricular outflow tract 
obstruction  
2. Systolic PAP – This was estimated by adding RVSP and right atrial pressure (RAP), in the 
absence of any right ventricular outflow tract obstruction such as pulmonary stenosis. RAP 
was estimated using standard criteria.  Those patients without tricuspid regurgitation had a 
very low probability of having elevated sPAP and thus, were considered to have ‘normal’ 
sPAP.  
3. Grade of valvular regurgitation and stenosis as mild, moderate and severe in keeping with 
guidance from British Society of Echocardiography and American College of 
Echocardiography(273-275) 
4. Presence of anterior and/or posterior mitral valve thickness, and to assess for focal valve 
abnormalities differentiating from age related diffuse nonspecific thickness. 
5. Grade of systolic and diastolic dysfunction in left and right ventricle as mild, moderate and 
severe.  
6. Calculation of left ventricular ejection fraction (EF).  
7. Right and left ventricular systolic and diastolic measurements.  
8. Any other cardiac findings such as septal wall thickness or motion abnormality, and 
limitations of the study were also recorded. 
The World Health Organisation (WHO) defines PAH as a mean PAP>25 mm Hg at rest and 
>30mmHg with exercise measured by RHC, in the presence of normal pulmonary capillary 
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wedge pressure. We have defined PAH as systolic pulmonary artery pressure (sPAP) > 30 
mm Hg at rest estimated by ECHO, as in other studies using Echo as a screening tool for 
PAH(169;170;276;277).  
2.5 Right heart catheterisation (RHC) 
 
Right heart catheterisation is an invasive test which is performed using femoral approach 
under local anaesthesia. RHC is the gold standard test to confirm PAH by measuring the 
mean PAP. The pulmonary capillary wedge pressure (PCWP) is also measured to assess the 
pulmonary vascular resistance and influence of left heart disease on PAP. If the resting mean 
PAP was < 25 mm Hg, then   a 2 minute benchfly exercise is performed to measure post-
exercise mean PAP to confirm PAH. 
 All patients who were found to have severe PAH with sPAP>40mmHg on ECHO, with 
World Health Organisation (WHO) class III or IV dyspnoea were offered referral to a 
cardiologist (JT and KP) for consideration of right heart catheterisation. Patients with PAH 
that did not meet these criteria were not offered this invasive test  at the request of the ethics 
committee as they felt that the risks outweighed the benefits(278) . Patients were explained 
about RHC during consent at recruitment and if they were found eligible for RHC, additional 
consent would be taken from patients by the cardiologist (JT or KP). 
2.6 Assessment of Risk factors for PAH 
 
2.6.1 Autoantibodies  
The autoantibodies were measured as part of routine care using kits from The Binding Site, 
UK at The Department of Clinical Immunology, University of Birmingham, UK. Anti-
nuclear antibody (ANA) was assessed by indirect immunofluorescence on Hep2 cells 
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(FK001.2), anti- double-stranded DNA (dsDNA) antibody  done by indirect 
immunofluorescence on Crithidia Luciliae (FK002.2) and enzyme-linked immunosorbent 
assay (ELISA) (MK017), and Complements C3 and C4 done by turbidimetry (Roche 
Diagnostics TinaQuant kits). Antibodies to extractable nuclear antigens (ENA) were assayed 
using an ELISA screen kit (MK201) and if positive serum was assayed on separate ELISAs 
for RNP (MK306), Sm (MK305), Ro (MK303), La (MK304), Jo-1 (MK308) and Scl-70 
(MK307) antibodies. Anti-IgG and anti-IgM anticardiolipin antibodies (aCL) were done by 
ELISA (MK027, MK029). Lupus anticoagulant (LAC), as determined by dilute Russel viper 
venom test (DRVV), was recorded if it was ever positive. Antiphospholipid antibodies were 
considered positive only if tested positive on 2 occasions at least 3 months apart(72). 
ANA, anti dsDNA and complements C3 and C4 were recorded if tested within the previous 
month of study assessment. ANA titre >1:40, anti dsDNA levels > 75ku/l, and Complement 
C3 <0.75g/l and complement C4 <0.14g/l were considered abnormal. Antibodies to ENA and 
LAC were reported positive if ever done and present. For anticardiolipin antibodies, an aCL 
IgG titre >15IU/ml and aCL IgM titre >10IU/ml were reported as positive if present at these 
titres at least twice anytime in the past but with a minimum of 3 months between both results.  
2.6.2 BILAG index and SLICC/ACR damage index 
The BILAG index(74;75) is a valid, reliable and comprehensive clinical measure of lupus 
disease activity (Appendix 2). This index reports disease activity in eight organ/systems 
separately and is based on the scores calculated for each system depending on the presence of 
clinical features and relevant investigations. The eight organ/systems assessed include 
general features, mucocutaneous, neurological, musculoskeletal, cardiovascular and 
respiratory, vasculitis, renal and haematology. The scores were determined using the BLIPS 
(British Lupus Integrated Prospective System) software programme. The scores are graded A 
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through to E. Grade A refers to the most active score in each organ or system indicating 
disease activity that is usually treated with high dose steroids or immunosuppressive therapy. 
Grade B applies to those patients with disease activity usually requiring lower dose steroids, 
antimalarials or non-steroidal anti-inflammatory drugs (NSAIDs). Grade C refers to patients 
with mild features only needing symptomatic therapy. Grade D refers to a previously 
involved system but no current activity and grade E applies to systems that have never been 
involved. The SLICC/ACR damage index(77;78;279) describes the accumulated damage in 
12 organ/systems since the diagnosis of SLE (Appendix 3). The 12 organ/systems assessed 
include ocular, neuropsychiatric, renal, pulmonary, cardiovascular, peripheral vascular, 
gastrointestinal, musculoskeletal, skin, premature gonadal failure, diabetes mellitus and 
malignancy. The damage score ranges from 0 (no damage) to a possible maximum of 47 that 
accumulates over time. 
2.6.2 Respiratory muscle strength 
The respiratory muscle strength was assessed by measuring maximum static expiratory and 
inspiratory mouth pressures, and sniff nasal inspiratory pressure (SNIP). These pressures do 
vary with the point in lung volume that they are performed at. So, the maximum expiratory 
mouth pressure (MEP) is assessed at total lung capacity, maximum inspiratory pressure 
(MIP) at residual volume, and the SNIP at functional residual capacity.  
The inspiratory and expiratory muscle strength measurements were performed using a 
portable, non invasive, handheld respiratory pressure meter (MicroRPM, Micro medical Ltd). 
The device is fitted with expiratory and inspiratory valve assembly to help perform the 
manoeuvre without much difficulty as well as controlled leak through the meter during 
manoeuvres to prevent high false positive values. The flanged mouthpiece attached to the 
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valve assembly enables the patient to perform the mouth pressure measurements easily. The 
appropriate sizes of nasal probes were used to avoid incorrect SNIP measurements. 
The MIP and MEP were measured using a forceful inspiratory and expiratory manoeuvre 
respectively with nostrils closed, leading to a sustained maximal effort lasting for at least 2 
seconds followed by natural release upon fatigue. The SNIP was measured through one 
plugged nostril with the nasal probe while the other remained open. A forceful inspiratory 
sniff manoeuvre performed and the peak pressure value achieved to measure SNIP. There 
was at least 1 minute recovery between all the respiratory efforts, to avoid any effects from 
muscle fatigue. 
MIP measurement: The flange of mouth piece is positioned over the gums and inside the lips, 
and the ‘bite blocks’ between teeth. The patient was instructed to exhale fully to residual 
volume and then inhale with maximal effort possible for at least 2 seconds with the nostrils 
closed. The MIP measured was the maximal average inspiratory pressure in 1 second. 
MEP measurement: With the flanged mouthpiece in place, the patient was instructed to inhale 
fully to total lung capacity, and then exhale to maximum effort possible for at least 2 seconds. 
The MEP measured was the maximal average expiratory pressure over 1 second. 
SNIP test: The SNIP test was performed by plugging one nostril with a nasal probe so that a 
good seal was made. The patient was instructed to exhale normally to functional residual 
capacity, and then to inhale with maximal effort possible through the open nostril with mouth 
closed. The SNIP measured was the peak inspiratory nasal pressure. 
The normal values of MIP, MEP and SNIP vary widely depending on sex, and the 
mouthpiece type used for measuring pressures. The normal values vary widely for MIP and 
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MEP and range 70-73 cmH2O, 89-94 cmH2O and 82-182 cmH2O in females, and 105-113 
cmH2O,140-154 cmH2O and 112-204 cmH2O in males respectively(239-242). The MIP, 
MEP and SNIP were determined from the best of five consecutive manoeuvres, in units of 
cmH2O gauge pressure. As there is a wide variability in the published reference values(242) 
for these parameters, we have considered values  >40 cmH2O to be normal. 
2.6.3 Pre-existing lung disease 
In patients with SLE, the lung diseases can be a manifestation of lupus activity, a 
complication (damage) or comorbidity (for example, infection). The non specific nature of 
respiratory symptoms and the risk of secondary pulmonary hypertension in patients with lung 
disease are important points to remember during assessment. 
 The presence of SLE related lung diseases in these patients were obtained from clinical 
examination and medical records, pulmonary function tests, chest X-ray and high-resolution 
CT chest. The restrictive lung diseases recorded were pulmonary fibrosis, shrinking lung 
syndrome, pleural fibrosis, and pulmonary infarction. Patients with shrinking lung syndrome 
(SLS) have unexplained dyspnoea with restrictive pattern and small lung volumes on lung 
function testing and absence of parenchymal disease with elevated diaphragm on CT chest 
(280;281). The obstructive lung diseases were asthma and chronic obstructive pulmonary 
disease (COPD). The presence of other lung diseases such as TB lung, lung malignancy, and 
bronchiectasis were obtained also. 
Smoking history status was recorded as non smoker, ex-smoker and current smoker. The 
relevant chest X-ray and HRCT results were obtained from patient records if ever done. 
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2.7 Screening tests for PAH 
 
2.7.1 Six minute walking test (6MWT) 
The six minute walking test was performed according to international guidelines(282). This 
test is easy to administer with good reproducibility(283;284), well tolerated by patients with 
respiratory symptoms and also reflects the patient’s daily living activities better than shuttle 
walk test(285).  
The 6MWT was performed indoors in a corridor, with a 15m walking course marked with 
bright coloured tapes at 0 and 15 m as turnaround points and white tape marking at every 5m. 
There was provision of chairs alongside the corridor for patient to rest if necessary.  
The patient was advised to use appropriate clothing and footwear, and walking aids if any. 
The pulsoximeter and heart rate monitor were attached. The Borg scale(286) (Appendix 4) 
for scoring dyspnoea and fatigue were explained to patient and baseline scores recorded. The 
instructions were made clear to the patient such as the objective of the test is to walk as far as 
possible for 6 minutes, and that they are allowed to slow down, stop and rest if necessary, and 
resume when able to. Patients who were on bronchodilators were advised to use them as they 
would have normally used in daily routine. A demonstration lap was performed by the nurse 
and clarified any queries from the patient. The countdown timer was set to 6 minutes and 
started with the patient commencing the test. The patient was informed the remaining time at 
every minute, and 15 seconds before end of test. The completed laps and additional distance 
measured at final partial lap if any, were entered and calculated on worksheet. The modified 
Borg Dyspnoea and fatigue scores were recorded post exercise and it was made sure that the 
patient was comfortable at end of test. The modified Borg scale is a descriptive 10 point scale 
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and the adjectives used in this scale assist patients to determine intensity of dyspnoea and 
fatigue. 
The data recorded include: 
Total distance walked (meters) in 6 minutes, baseline and post-exercise Borg dyspnoea and 
fatigue scores (Grades 0-10 with 0 being asymptomatic and 10 being severe symptoms) 
(Appendix 4), heart rate (rate/min) and oxygen saturation (%) were recorded (Pulsox-3i, 
Konica Minolta, Japan). 
2.7.2 Respiratory symptom questionnaires 
 The respiratory symptom questionnaires used in this study were modified Medical Research 
Council (MRC) dyspnoea scale(287), Baseline dyspnoea index (BDI)(288;289) and 
St.George’s respiratory symptom questionnaire (SGRQ)(290;291). 
Modified MRC dyspnoea [Appendix 5] is an easy to administer 5 point scale. It grades 
dyspnoea between 0-4 according to different levels of activity, 0 being dyspnoea with 
strenuous exercise and 4 being dyspnoea with minimal activity. 
Baseline dyspnoea index (BDI) (Appendix 7) measures the functional impairment due to 
dyspnoea, magnitude of task and effort required to produce dyspnoea and they are graded 0-
4, 0 being severe impairment and 4 being no impairment. The total score is the sum of all 
three categories with a maximum score of 12. This scale also includes grade W for amount 
uncertain, X for unknown and Y for reasons other than dyspnoea causing impairment. 
SGRQ is a standardised self-completed questionnaire (Appendix 5) for measuring quality of 
life in patients with dyspnoea. This contains 76 items divided into three sections: 1. 
‘Symptoms’ – the frequency and severity of respiratory symptoms. 2. ‘Activity’- the 
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activities that cause or are limited by dyspnoea.  3. ‘Impact’- the social functioning and 
psychological disturbances resulting from airways disease. The SGRQ score calculator is a 
software programme based on the calculation algorithms and missing data imputation (if total 
number of missing items < 10). The scores ranging from 0 (no impairment) to 100 (maximum 
impairment) is calculated for each section and for the overall score. Each item in the 
questionnaire has an empirically derived weight.  
2.7.3 Pulmonary function testing (PFT) 
The results of pulmonary function tests performed in the respective referring hospitals within 
12 months of the study were recorded. Spirometric measurements were performed using a 
wedge bellows
 
spirometer (Model S; Vitalograph, Jaeger Compact system, Viasys 
Healthcare, UK) and included assessment
 
of vital capacity (VC), forced vital capacity (FVC) 
and forced
 
expiratory volume in 1 second (FEV1). Functional residual capacity
 
was estimated 
via the steady-state helium dilution method (Benchmark;
 
Morgan Medical, Gillingham, UK) 
from which residual volume and
 
total lung capacity (TLC) was calculated. All tests were 
performed
 
according to national guidelines(292) and the results compared
 
with standard 
reference values(293). Transfer factor (TLCO)
 
was measured using the single-breath method 
(Benchmark; Morgan
 
Medical; Jaegar Compact system) according to the Association for 
Respiratory Technology and Physiology (ARTP)/ British Thoracic Society (BTS) 
guidelines(292).  
The measurements of FEV1, FVC, FEV1/FVC , TLC, TLCO and transfer coefficient for 
carbon monoxide (KCO) were expressed as percentages of predicted values and any 
percentage less than 80% predicted was considered potentially abnormal(231). KCO is 
derived from DLCO divided by alveolar volume. 
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2.7.4 Biomarkers 
 
2.7.4.1 N-terminal pro brain natriuretic peptide (NT-proBNP) 
The electrochemiluminescence immunoassay for in vitro quantitative determination of NT-
proBNP (Elecsys Systems E170 proBNP assay 03121658122, Roche) in human serum was 
performed by Joanne Heynes at the Department of Clinical Biochemistry and Immunology, 
Birmingham Heartlands Hospital, UK (BHH). An aliquot of serum sample collected and 
stored in gel separator tubes at initial visit was sent to BHH. These samples were collected on 
the same day as the patient had their echocardiogram and six minute walk test. The test was 
performed on serum samples (0.2-0.5ml) from 12 patients with PAH, 16 patients with 
systolic PAP 26-30mmHg, and also on 56 patients with systolic PAP < 25 mmHg who were 
age and sex matched. As the sample of one patient with systolic PAP 26-30 mmHg was lost, 
the 2 matched patients with systolic PAP < 25mmHg were removed from analysis. Thus, 81 
samples in total were included in the analysis.  The assay calculated the NT-proBNP 
concentration of each sample in values of pg/ml on automated analysers.  
The analytical range for NT-proBNP assay is 5 pg/ml to 35,000 pg/ml. According to the 
manufacturer of the assay, NT-proBNP levels above 125pg/ml may indicate cardiac 
dysfunction. The values below 144pg/ml in women and 93pg/ml in men reliably exclude 
cardiac failure in symptomatic patients with a negative predictive value (NPV) of 97%(294). 
The expected NT-proBNP values (95
th
 percentile) for women at age <50 was 125pg/ml, 50-
59 years were 186 pg/ml, > 60 years was 204 pg/ml, for men at age <50 years was 64 pg/ml, 
50-59 years were 125 pg/ml and > 60 years was 194 pg/ml.  These expected normal NT-
proBNP values were used to classify our study patients with and without high NT-proBNP 
concentration for their age and sex. 
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2.7.4.2 Fractalkine (CX3CL1)  
Soluble CX3CL1 was measured in human plasma using a sandwich ELISA method according 
to the protocol supplied by R & D systems. The tests were performed by Dr Gemma White at 
the Greaves Lab in Sir William Dunn School of Pathology at University of Oxford. The 96 
well Maxisorp ELISA plates were coated overnight at RT with 100 µl capture antibody 
diluted to 8 µg/ml in D-PBS. Unbound antibody was removed by washing three times with 
200 µl ELISA wash buffer (PBS, 0.05% Tween-20). Non-specific binding was blocked with 
200 µl ELISA blocking buffer (1% BSA, 5% sucrose, 0.05% NaN3, D-PBS) for 2 hours at 
RT, before a second wash step. Samples/standards (50-100 µl) were added and incubated for 
2 hours at RT. Recombinant chemokine domain CX3CL1 was used as a standard and was 
diluted in ELISA dilution buffer (1% BSA, D-PBS). Unbound antigen was again removed by 
washing. Biotinylated detection antibody was diluted in ELISA dilution buffer (250 ng/ml) 
and 100 µl added to each well before incubation for 2 hours at RT. Plates were washed again 
before the addition of 100 µl of poly-HRP Streptavidin diluted 1:5000 in endogen buffer for 
45 minutes at RT. Unbound reagent was removed by washing for a final time. OPD substrate 
tablets were reconstituted in water (1 tablet in 3 ml dH2O + 1.25 µl hydrogen peroxide 30% 
solution) and 100 µl added per well. Colour was allowed to develop to give a suitable 
detection range before the reaction was stopped with 50 µl 3 M H2SO4. Plates were read at 
492 nm using a 96 well spectrophotometer (BioTek) and Gen5 software. 
The cut off value was defined for each individual ELISA plate as determined by the mean 
background optical density (OD) + 3 standard deviations (SD). The OD 490nm values were 
converted to ng/ml using nonlinear regression. The original assay was performed across 8 
plates and the range of cut off values was 0.49 - 0.62 ng/ml, with a mean of 0.57ng/ml. All 
samples which were below the mean cut off point cannot have a concentration assigned 
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because they cannot be distinguished from the background absorbance with buffer alone. 
Fractalkine assay was performed in all 283 patients in this study. 
2.7.4.3 Human Vascular endothelial growth factor (VEGF) 
Human VEGF concentration in plasma was quantitatively measured on undiluted samples of 
all 81 patients who had underwent NT pro-BNP assay. Plasma VEGF was measured using a 
sandwich ELISA kit and manufacturer’s instructions were followed (R&D systems, 
Abingdon, UK). This assay measures biologically active VEGF121 and VEGF165. A 
monoclonal antibody specific for VEGF was coated onto a microplate. Standards and 
samples were pipetted into the wells and any VEGF present was bound by the immobilized 
antibody. After washing away any unbound substances, an enzyme linked polyclonal 
antibody specific for VEGF was added to the wells. Following a wash to remove any 
unbound antibody-enzyme reagent, a substrate solution is added to the wells and colour 
developed in proportion to the amount of VEGF bound in the initial step. The intensity of the 
colour was measured spectro-photometrically in a plate reader. The lower limit of detection 
of VEGF was 5 pg/ml. This in vitro quantitative immunoassay for VEGF was performed by 
Anne Garfield at the Department of Rheumatology and Immunology, University of 
Birmingham, Birmingham, UK. According to assay manufacturer, the mean detectable VEGF 
level was 61 pg/ml and range 0-115 pg/ml for EDTA plasma from 37 healthy volunteers. 
Plasma VEGF assay was performed in the 81 SLE patients who underwent NT-proBNP assay 
in this study. Among the 81 patients with SLE, 12 had PAH, 15 had sPAP 26-30mmHg and 
54 patients who were age and sex matched had sPAP <25mmHg. 
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2.8 Statistical methods 
 
SPSS 13.0 software was used for statistical analysis. Data were analysed with the SPSS 13.0 
statistics package. Variables are summarised as counts and/or percentages or as medians and 
ranges. Comparisons between groups were made using the Mann Whitney U test, two-sided 
Fisher's exact test or Pearson’s chi-square tests. . Association between variables were 
assessed with Spearman rank correlation. The p value<0.05 was considered significant. The p 
values quoted have not been adjusted for multiple comparisons as this is an exploratory study 
aiming to identify possible risk factors. A Bonferroni correction would not be appropriate as 
the risk factors are not independent of each other. 
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CHAPTER 3   PREVALENCE OF PAH 
 
3.1 Abstract 
Objectives: 
1. To estimate the point prevalence of PAH in patients with SLE using transthoracic 
echocardiogram. 
2. To evaluate the role of electrocardiogram (ECG) in screening for PAH in patients with 
SLE 
3. To evaluate the role of autoantibodies, BILAG disease activity scores and SLICC/ACR 
damage scores as predictors for PAH in patients with SLE. 
Methods: A prospective cross-sectional study of 288 patients with SLE were recruited from 
lupus clinics in Birmingham, UK. Resting transthoracic echocardiography was performed to 
estimate the pulmonary artery pressures and to assess cardiac morphology and function. PAH 
was defined as systolic pulmonary artery pressure (sPAP) >30 mm Hg. We assessed potential 
risk factors such as autoantibodies, Raynaud’s phenomenon, anti-phospholipid syndrome, 
prior drug therapy, BILAG disease activity scores and SLICC/ACR damage index in 
predicting PAH in patients with SLE. 
Results: Of 288 patients who consented for participation, 283 patients were suitable for 
analysis. 12 patients were found to have PAH with systolic pulmonary artery pressure (sPAP) 
>30 mm Hg. The range of sPAP in our PAH patients was 31-59 mmHg and 3 patients had 
sPAP >40 mm Hg. The only significant risk factor for PAH was lupus anticoagulant (Fisher’s 
exact test, p=0.005).  
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Conclusion: The point prevalence of PAH was 4.2% in our cohort of patients with SLE. 
Most of the PAH cases were found to be of mild severity (<40mm Hg). The significant 
association of lupus anticoagulant and presence of antiphospholipid syndrome in PAH cases 
suggests that thrombosis may play an important role in PAH with SLE. This is important, as 
it is treatable. 
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3.2 Introduction and Methods  
 
 The prevalence of PAH in SLE is widely variable depending on the nature of study. The 
wide variability depends on the definition of PH, diagnostic methods used, awareness of PH 
in SLE, study centres, number of study patients and retrospective nature of most studies. 
Transthoracic echocardiogram has predominantly been the screening test in the studies for 
estimating PAH in SLE, and a few studies using RHC to screen for PAH in SLE reported a 
low prevalence rate compared to echo estimated PAH prevalence in SLE. Please refer to 
methods chapter for full details on methods used to estimate the prevalence and assess risk 
factors for PAH in SLE.  
3.3 Results  
 
3.3.1 Demographics 
Two hundred and eighty three patients with SLE were studied, and 266 patients (94%) were 
females. The median age was 41 years (range18-82) and median disease duration was 8.7 
years (range 0-32). Raynaud’s phenomenon occurred in 66.4%, and 63.6% were non-
smokers. Antiphospholipid syndrome (APS)(295) was known to be present in 12.4%.  The 
racial distributions were Afro-Caribbean 18.7%, Asian (Indian Subcontinent) 19.8%, 
Caucasian 56.2%, Oriental 0.7% and others 4.6%.  
3.3.2 Prevalence of PAH 
Among the 288 patients with SLE that took part in the study, 5 patients were excluded from 
analysis as their echocardiographic views were very limited and thus the echocardiographer 
was unable to estimate the pulmonary artery pressure. Of the remaining 283 patients, 
tricuspid regurgitation (TR) was absent in 114 (40.3%) patients by ECHO assessment. In all 
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cases with absent TR, there were no other echocardiographic features (right ventricular 
dilation or hypertrophy) to suggest PAH. There was only one patient each with right 
ventricular dilatation and hypertrophy in the remainder of cases but their estimated sPAP was 
normal at 25 and 9 respectively. Of those with absent TR, 85 patients had residual volume 
(RV) measured in their pulmonary function testing (PFT) and their %predicted RV was more 
than 120 and 150 in only 4 and 2 patients respectively. The difficulty with TR estimation was 
not statistically relevant to high residual volume noted in hyperinflated lungs. The reason for 
inability to estimate TR was poor and/or limited echocardiographic views and patient’s body 
habitus making right heart assessment technically difficult, which was noted in 24 patients 
with absent TR. 
Among the 169 patients in whom TR was present, 12 were estimated to have sPAP>30 
mmHg at rest. According to the definition of PAH used in this study which was performed 
between January 2004 and December 2005, the point prevalence rate of PAH in patients with 
SLE was 4.2% (CI 2.2%-7.3%). Excluding patients with no TR, the prevalence of PAH in our 
study group would be 7.1% (CI 3.7%-12.1%).  
The distribution of PAP among the 169 patients in the latter group is shown in Figure 3-1.  
Only 1 patient was previously known to have PH diagnosed by echocardiography and was 
recorded in their SLICC/ACR damage index scores.  There were 4 other patients with a 
previous history of PH by echocardiogram who did not meet the criteria for PAH by 
echocardiogram in this study. These 4 patients did not have persistent PH as they all had a 
secondary treatable cause for PH such as PE, left heart valvular disease and/or borderline PH 
and thus were not recorded in SLICC/damage scores. The characteristics of these patients 
with previous PAH diagnosed by echocardiography are shown in Table 3-1. Among the 
remaining 109 patients in the cohort (104 who refused to participate in this study and 5 whose 
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echo assessment was not suitable for analysis), three patients (2.7%) had PAH diagnosed by 
echocardiography in the past.  
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Figure 3-1 Distribution of systolic pulmonary artery pressure (sPAP) in SLE cohort 
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3.3.3 Risk factors for PAH in SLE 
 
3.3.3.1. Raynaud’s and APS 
The comparison of the demographic variables between lupus patients with and without PAH 
is shown in Table 3-1 and 3-2. The association of PAH with history of APS in patients with 
SLE was statistically significant but weak (Fisher’s exact test p value 0.043). 
3.3.3.2 BILAG index 
At the time of this study, only 29.3% had active SLE in one or more of the eight 
organ/systems scoring A or B using assessment by BILAG index (Appendix 1). Two-thirds 
of these patients had evidence of activity either in the musculoskeletal or haematological 
system. None had scored A, one had scored B and 15 had scored C in cardiorespiratory 
system. There was no statistical difference in the number of patients with and without active 
disease in any systems according to BILAG scores between the subgroups of lupus patients 
with and without PAH (Table 3-3). 
3.3.3.3. SLICC/ACR damage index 
Assessment of patients with SLICC/ACR damage index (Appendix 2) revealed that 57.2% 
did not have any organ damage. It was noted that 5.6% of patients had pulmonary damage 
and 4.9% of patients had cardiovascular damage secondary to SLE. In this cohort, the highest 
damage score for both cardiovascular and pulmonary systems was 2, which was noted in 3 
(1%) patients for cardiovascular damage and 3 (1%) patients for pulmonary damage. The 
maximum damage score that can be accumulated for cardiovascular system is 6 and 
respiratory system is 5. Eleven patients had pleural fibrosis, 2 had pulmonary fibrosis, 2 had 
shrinking lung syndrome, 1 had pulmonary hypertension and 1 had pulmonary infarction. The 
cardiovascular damage score included 8 patients with valvular disease, 7 with angina, 1 with 
cardiomyopathy and 1 with pericarditis. The total score by SLICC/ACR damage index was 
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significantly different between patients with PAH (median 0, range 0-5) and without PAH 
(median 0, range 0-8) (Mann Whitney U test, p value 0.03). The number of lupus patients 
with SLICC/ACR damage score (total) >2 was 7/12 (58.3%) in PAH subgroup and 56/271 
(20.6%) in those without PAH, and this difference between groups with and without PAH 
were statistically significant (Fisher’s exact test 2 sided, p value 0.006). Left heart valvular 
disease, pulmonary embolism interstitial lung disease and/or shrinking lung syndrome were 
present in all 5 patients with previous history of pulmonary hypertension in the study cohort 
(Table 3-4). Patients with shrinking lung syndrome (SLS) have unexplained dyspnoea with 
restrictive pattern and small lung volumes on lung function testing and absence of 
parenchymal disease with elevated diaphragm on CT chest (280;281).   
3.3.3.4. Autoantibodies 
The presence of ANA, dsDNA, ENA, low complements C3/C4, anticardiolipin antibody and 
lupus anticoagulant were compared between PAH cases and non-PAH patients. Lupus 
anticoagulant (p=0.005) was significantly associated with PAH while other antibodies did not 
show any difference between both groups (Table 3-5).  Anti-La antibody might be considered 
borderline (p=0.03).  Some results were not available for ENA (6/283) and lupus 
anticoagulant analysis (67/283) due to either technical reasons (no result from the laboratory) 
or to patients being on warfarin therapy and not suitable for testing of lupus anticoagulant 
(Table 5). 
3.3.3.5. Prior drug therapy 
The distribution of drug therapy in the study cohort is shown in Table 3-6. The prior use of 
warfarin (Fisher’s exact test 2 sided, p value 0.005) and calcium channel blockers (Fisher’s 
exact test 2 sided, p value 0.031) were found more frequently with PAH in SLE. None of the 
patients were on Bosentan or Sildenafil prior to this study. 
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Table 3-1 Characteristics of SLE patients with and without PAH. 
 SLE 
 
SLE without 
PAH  
SLE-PAH 
 
p value* 
No. of SLE patients  283 271 12 - 
Age (years) 41 (18-82) 41 (18-82) 45.5 (30-72) 0.22 
Sex (M:F) 266:17 255:16 11:1 0.53 
Disease duration (years) 8.7 (0-32) 8.6 (0-32) 9.6 (1.9-22.1) 0.95 
Afro-Caribbean (%) 18.7 18.8 16.7 1.0 
Asian (%) 19.8 20.3 8.3 1.0 
Caucasian (%) 56.2 55.7 66.7 1.0 
Oriental (%) 0.7 0.4 8.3 1.0 
Other race (%) 4.6 4.8 0 - 
Variables expressed in median and range and unless specified. *p value calculated by Mann 
Whitney U test for comparison between groups of SLE patients with and without PAH.  
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Table 3-2 Frequency of clinical parameters between PAH and non-PAH patients with 
SLE. 
Risk factors non-PAH 
patients 
 
n 
PAH 
patients  
 
n 
Positive in  
non-PAH 
patients  
n       (%) 
Positive in  
PAH 
patients 
n      (%) 
p 
value** 
 
APS 271 12 30     (11) 4      (33) 0.043

 
History of 
Raynaud’s 
271 12 180   (66) 8      (67) 1.000 
Ever smoked 271 12 97     (36)   6      (50) 0.364 
Current smokers 271 12 44     (16) 4       (33) 0.127 
APS: antiphospholipid syndrome. 

p<0.05. APS = antiphospholipid syndrome.  
**Fisher’s exact test 2 sided, p value 
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Table 3-3 Comparison of SLE disease activity scores assessed by BILAG index in lupus 
patients with and without PAH 
Systems involved SLE without 
PAH 
(no. of 
patients) 
SLE with 
PAH 
(no. of 
patients) 
p value comparing SLE groups 
with and without PAH 
(Mann Whitney U test) 
General, active/inactive 2/265 0/12 1.0 
Mucocutaneous, 
active/inactive 
13/254 0/12 1.0 
Neurological, 
active/inactive 
1/266 0/12 1.0 
Musculoskeletal, 
active/inactive 
29/238 1/12 1.0 
Cardiorespiratory, 
active/inactive 
1/266 0/12 1.0 
Vasculitis, active/inactive 4/263 0/12 1.0 
Renal , active/inactive 11/256 2/10 0.102 
Haematological, 
active/inactive 
28/239 1/11 1.0 
* p value <0.05. Active SLE- BILAG score A or B, Inactive SLE- BILAG score C, D or E 
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Table 3-4 Characteristics of five SLE patients in our study with prior diagnosis of PAH 
(all causes) by Echocardiography that were reassessed during this study. 
Patient 
study 
no. 
Year of 
SLE 
diagnosis 
Year of 
PAH 
Diagnosis 
Associated 
conditions 
sPAP 
when 
diagnosed 
(mmHg) 
Treatment sPAP in 
this study  
(mmHg) 
058 2003 2003 Previous PE 
and ILD 
44 Amlodipine, 
Perindopril, 
Warfarin 
10.7 
060 1994 1994 Previous PE 
and pericarditis 
55 Warfarin, 
Nifedipine 
46 
064 1995 2000 Mitral 
regurgitation, 
MV 
replacement. 
Previous PE. 
60 Amlodipine, 
Doxazosin, 
Perindopril, 
Warfarin 
11.8 
065 1986 1997 Aortic and 
mitral valve 
disease 
44 Amlodipine, 
Perindopril 
TR 
absent 
216 2000 2003 Shrinking lung 
syndrome 
31 Amlodipine, 
Warfarin 
25 
PE = pulmonary embolism; ILD = interstitial lung disease; MV = mitral valve; TR = 
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tricuspid regurgitation; PAH = pulmonary arterial hypertension; sPAP = systolic pulmonary 
arterial pressure 
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Table 3-5 Frequency of serological risk factor variables and results of Fisher’s exact test 
between PAH and non-PAH patients with SLE. 
Risk factors non-PAH 
patients 
n 
 
 PAH 
patients 
 n 
 
Positive in  
non-PAH 
group  
n      (%) 
Positive in  
PAH patients 
n      (%) 
p value 
 
ANA (Titre>1:40)
††
 271 12 225  (83) 12   (100) 0.226 
Anti-dsDNA
††
 271 12 112  (41) 7      (58) 0.371 
ENA
†
 265 12 148  (56) 10    (83) 0.076 
Anti-Ro
†
 265 12 98    (37) 4      (33) 1.000 
Anti-La
†
 265 12 56    (21) 6      (50) 0.030

 
Anti-Sm
†
 265 12 29    (11) 1      (8) 1.000 
Anti-Jo
†
 265 12 1      (0) 0      (0) 1.000 
Anti-scl70
†
 265 12 6      (2) 0      (0) 1.000 
Anti-RNP
†
 265 12 67    (25) 3      (25) 1.000 
Low C3 (<0.75)
 ††
 271 12 29    (11) 0      (0) 0.619 
Low C4 (< 0.14)
 ††
 271 12 64    (24) 5      (42) 0.173 
LA
†
 205 11 32    (16) 6      (55) 0.005

 
 100 
aCL
†
 
(IgG/IgM)
 #
 
271 12 63    (23)  
(44/38) 
5      (42) 
(3/3) 
0.168 
†
Test results if ever done 
††
Test results at or within previous month of study assessment 
#
aCL IgG titre>15 IU/ml and aCL IgM titre >10 IU/ml were considered positive according to 
local laboratory reference criteria  

p<0.05, 

p<0.01. aCL = anticardiolipin antibody; LA = 
lupus anticoagulant. 
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Table 3-6 Frequency of prior drug therapy among SLE patients with and without PAH. 
Drug therapy Prior use in SLE 
patients without PAH     
(n=271) 
(n)              (%) 
Prior use in SLE 
patients with PAH    
(n=12) 
(n)           (%) 
p value 
(Fisher’s Exact test- 2 
sided) 
Warfarin  26               9.6 5              41.7 0.005

 
Aspirin  107             39.5          4              33.3           0.770 
CCB  58               22.9 6              50 0.031

 
ACE inhibitors  61               22.5 1              8.3 0.474 

p<0.05, 

p<0.01. CCB = Calcium channel blockers; ACE inhibitors =angiotensin 
converting enzyme inhibitors. 
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3.3.4 Screening with ECG for PAH in SLE  
One of the 7 patients with resting tachycardia had PAH. Only one of 14 patients with right 
axis deviation (RAD), and 2 of 8 patients with left axis deviation (LAD) had PAH. The 
statistical significance for association of LAD with non-PAH is weak (p=0.041). Right 
ventricular hypertrophy (RVH) was absent in all 278 patients. Left ventricular hypertrophy 
(LVH) was present in 54 patients in non-PAH group, with 47 probable and 7 definite LVH. 
Both patients with LVH in PAH group had definite LVH.  In the study cohort, RBBB and 
LBBB were also not associated with PAH. None of the ECG parameters especially right heart 
parameters such as axis deviation and right ventricular hypertrophy were associated with 
PAH in patients with SLE (Table 3-7) 
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Table 3-7 ECG abnormalities in SLE patients with and without PAH 
 SLE patients without 
PAH (Group I) 
SLE patients with 
PAH (Group II)  
p value comparing 
Group I and II 
(Fisher’s exact test 2 
sided) 
Number of patients, 
 n (%) 
266 (94) 12 (4)  
Resting HR<60, n 
(%) 
46 (17) 0 (0) 0.228 
Resting HR>100, n 
(%) 
6 (2) 1 (8) 0.268 
Right axis deviation, 
 n (%) 
13 (5) 1 (8) 0.469 
Left axis deviation*, 
 n (%)  
6 (2) 2(17) 0.041* 
RBBB, n (%) 10 (4) 2 (17) 0.089 
LBBB, n (%) 3 (1) 0 (0) 1.0 
RVH, n (%) 0 (0) 0 (0) - 
LVH, n (%) 54 (20) 2 (17) 1.0 
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HR: heart rate, RBBB: right bundle branch block, LBBB: left bundle branch block, RVH: 
right ventricular hypertrophy, LVH: left ventricular hypertrophy. *p value <0.05 
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3.3.5 Right heart catheterisation  
Only 1 of 3 patients with sPAP>40 mmHg had WHO grade III dyspnoea and was eligible for 
right heart catheterisation (RHC) according to study protocol approved by by research ethics 
committee. However, this patient refused to undergo this invasive test. Thus none of our 
study patients underwent RHC during the study period for estimation of pulmonary artery 
pressures. 
3.4 Discussion 
 
In this study, we found that the prevalence rate of PAH in patients with SLE was 4.2%. If 
patients with no TR jet on echocardiography were excluded from the analysis, the prevalence 
rate was 7.1%. These rates are at the lower end of the range of prevalence rates reported from 
previous studies (69;154;168;210). This prospective cross-sectional cohort study is likely to 
reflect the prevalence rate better than the previous retrospective and smaller studies. The 
majority (80.4%) of this cohort have Birmingham postcodes suggesting that the majority are 
from local community rather than a patient cohort mainly referred from other centres for 
tertiary care. The SLICC/ACR damage index scores recorded as part of this study were low 
suggesting that only few patients had severe disease.  It has been suggested that studies with 
predominantly a tertiary care based cohort(168) and/or patients with severe SLE(154) are 
likely to overestimate the true prevalence of PAH. We believe that our cohort has minimal 
bias from these factors resulting in a more accurate estimation and lower prevalence rate of 
PAH in SLE patients. Those patients who refused to participate (n= 104; 27%) could have 
done so for various reasons including active disease, lack of interest  in participating in 
research studies, inconvenience due to distance required to travel to the centre, and work 
commitments. We are not aware of any main reason for non-participation.   
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In this study, TR velocity was measurable in one hundred and sixty nine patients (59.7%). 
This is in keeping with previously reported frequencies of identifying measurable TR in the 
range of 39% to 86% of patients (172;296). This frequency increases to almost 100% in 
patients with signs of right heart failure and in those with sPAP >50mmHg (190). The 
interobserver variability in the measurement of maximal TR velocity has been found to be 
less than 3% (112). Arcasoy et al (297) reported that the estimation of sPAP in patients was 
achieved less frequently in patients with obstructive airways disease compared with 
interstitial lung disease, and in those with residual volume (RV) exceeding more than 150% 
of predicted compared with RV <150% predicted. Only 2 patients in our cohort had RV 
>150% predicted and 27 patients had obstructive airways disease. Neither the presence of 
obstructive airways disease nor the predicted RV >150% were statistically significant 
between patients with and without detectable TR (data not shown). Several studies have 
shown significant correlation between RVSP measured by Doppler echocardiography and 
mean PAP measured by RHC (172;276;277;298).  
Of 12 patients with PAH, 9 had sPAP <40 mmHg and 10 had WHO Grade II dyspnoea or 
less. This suggests PAH in this SLE cohort was predominantly mild with minimal or no 
symptoms. In the PAH group, only 1 patient each had restrictive lung disease, known 
valvular heart disease and previously recorded PAH. This supports the mild nature of cardio-
respiratory manifestations and lack of significant dyspnoea in our PAH cases. The role of left 
heart disease (discussed in Chapter IV in detail) is negligible in our patients with PAH as 
none of them had significant left ventricular dysfunction with or without valve disease 
evaluated by ECHO. 
The ECG may demonstrate signs of right ventricular hypertrophy and/or right atrial 
enlargement in pulmonary hypertension. Thus, the ECG findings may include right axis 
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deviation, P-pulmonale, right bundle branch block, and R/S ratio >1 in lead V1. The higher 
the pulmonary artery pressure, the more sensitive is the ECG. As most patients in our PAH 
cohort have mild PAH, this could explain the lack of significant ECG findings of PAH in our 
study. A recent study by Goncalvesova et al(299) showed the ECG signs of RVH/overload 
may help distinguish PAH from LV dysfunction related secondary PH in SLE patients. 
Though the RHC measurement of mean PAP is the gold standard to confirm PAH, only one 
patient with PAH fulfilled criteria of systolic PAP >40 mmHg with dyspnoea Grade III or 
more required to undergo RHC according to the protocol approved by the research ethics 
committee. But this patient refused to undergo RHC measurements due to the invasive nature 
of intervention. It is thus possible that our ECHO prevalence rate of PAH in SLE might have 
been an overestimation as they have not been confirmed by RHC mean PAP measurements. 
Since our study was completed, several epidemiological studies on the prevalence of PH in 
SLE have been published including the reports by PH registries from UK, USA and France. 
In 2006, Chung et al(155) reported a retrospective analysis and found that 181 out of 725 
SLE patients who underwent either ECHO or RHC over 9 year period .The prevalence of 
PAH was 11%, using sPAP >45 mmHg including 10 mmHg as right atrial pressure (RAP). 
This study reported on 20 patients with PAH and SLE with an average sPAP 65.3mmHg by 
ECHO, including 10 patients with mean (+S.D) PAP 50+13.5mmHg and RAP 7+4mmHg by 
RHC. They published the prevalence, as 2.8% (20 out of 725) while in fact it should be 11% 
(20 out of 181) as the others were not assessed. In 2010, Fois et al(186) reported on 93 lupus 
patients in a tertiary centre in France over 10 year retrospective analysis and found 13% 
prevalence using a cut off >35mmHg by ECHO. In 2011, Cefle et al(55) reported a 
prevalence of 1.8% from a retrospective analysis of 544 patients with SLE of which 104 
underwent echocardiography. In 2012, Ruiz-Irastorza et al(187) prospectively studied 245 
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patients with lupus and reported 50% of patients had sPAP > 30 mmHg and 13.5% had sPAP 
> 40mmHg but only 5% (12 patients) had definite PH with persistent sPAP > 40mmHg 
which was confirmed on a repeat echo 6-12 months later. They also concluded that all lupus 
patients with PH diagnosis had secondary PH (cardiomyopathy or valvulopathy in 8 patients, 
severe COPD in 2, SLS in 1 and LV dysfunction in 1 patient) and none had PAH which is 
considerably different from most previous studies published. The definitions of PH and 
secondary PH in the study by Ruiz- Irastorza et al if applied to our cohort would result in 
5.3% having sPAP> 30mmHg, 1% having sPAP > 40mmHg and two-thirds of our reported 
PAH patients would have secondary PH  due to valve regurgitation, though all those patients 
had EF> 50% and none had LVSD. But the limitation of these results is that repeat 
echocardiogram was not performed on all our patients. 
The PH registries from UK, Scotland, France and USA have provided vast information on 
epidemiology of PH in various subgroups which otherwise would have been difficult to 
ascertain. The trend towards older age at diagnosis is reported from all registries compared to 
National Institute of Health (NIH) registry. The US and UK registries report a female 
predominance in SLE -PAH of 94.5-96% compared to 79-82% with IPAH. Table 3-8 and 3-9 
represent the recent epidemiology data published from registries worldwide. 
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Table 3-8 Prevalence of pulmonary hypertension published by PH registries 
Registry 
(Year reported) 
PAH  
 
(cases/million) 
CTD-PAH 
 
(cases/million) 
PAH 
No. of 
patients 
SLE-PAH 
No. of patients 
France (2006) 15 2.3 674 15 
Scotland (2007) 52 15 n/a n/a 
Scottish PVU* (2007) 26 10 n/a n/a 
UK (2008) 24.9  4.23 484 35 
USA-REVEAL** 
(2011) 
12.4 n/a 2967 110 
* PVU: pulmonary vascular unit;  n/a: Not available 
**REVEAL: Registry to Evaluate Early And Long-term PAH management 
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Table 3-9 Incidence of pulmonary hypertension published by PH registries 
Registry 
(Year reported) 
PAH 
(cases/million) 
CTD-PAH 
(cases/million) 
SLE-PAH  
(cases/million) 
France (2006) 2.4 0.4 n/a 
Scotland (2007) 7.1 2.1 n/a 
Scottish PVU* (2007) 7.6 2.8 n/a 
UK (2008) n/a 1.55 35 
USA-REVEAL** 2.3 n/a n/a 
* PVU: pulmonary vascular unit 
**REVEAL: Registry to Evaluate Early And Long-term PAH management 
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In 2006, the French registry(108) reported on a one-year study commencing in October 2002 
including 121 incident and 553 prevalent cases of PAH. The prevalent cases differed from 
incident cases with higher mean pulmonary artery pressure (mPAP) and female 
predominance. The CTD-PAH was present in 103 patients (15.3% of all PAH) with 22 
incident and 81 prevalent cases. This included 76% systemic sclerosis and 15 % SLE-PAH. 
Most patients were of NYHA III or IV functional class at diagnosis. 
In 2007, the Scottish study(300) investigated Scottish Morbidity Records (SMR) from 1986-
2001 of 16-65 year old ever-hospitalised patients with a diagnosis of pulmonary 
hypertension. Among 374 cases of PH, 111 patients had CTD-PAH with annual incidence of 
1 and 2.2 cases per million in males and females respectively. The female incidence was 
twice that previously reported. The estimated incidence of CTD-PAH for whole adult 
population was 7 and 2 cases per million in females and males respectively. A comparison 
with the records from tertiary Scottish Pulmonary vascular unit (SPVU) from 1997-2005 was 
also reported in this study. An annual incidence of 2.8 cases per million and a prevalence of 
10 cases per million in patients with CTD-PAH was reported from SPVU records, compared 
to 2.1 and 15 cases per million from SMR data respectively. 
In 2008, the UK consensus statement from PH centres(301) reported a prevalence of 24.9 
patients with PAH treated per million in mid-2005. In 2009, Condliffe et al(150) reported on 
484 patients with CTD-PAH collected from unselected incident cases from UK PH centres 
over a 5.5year period from January 2001 with follow up ranging from 3.3 to 6 years. The 
PAH diagnosis was made by right heart catherisation. The incidence of CTD-PAH increased 
from 0.68 to 1.55 cases per million over the 5 years and the prevalence was 4.23 per million. 
Among the 35 patients with SLE and PH (8% of 429 CTD-associated PAH diagnosed at rest), 
80% had isolated PAH. The SLE-PAH patients were of mean age 42 years and statistically 
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differed from SSc-PAH with more females (96% vs. 82%), non-Caucasians (30% vs. 4%), 
and less TLCO% reduction (59.2% vs. 41.5%).  
The US registry to evaluate early and long- term PAH disease management (REVEAL) 
includes 2967 patients from 54 centres(151). Among the 641 with associated CTD, 110 had 
SLE. Approximately 15% of patients in CTD and SLE group were newly diagnosed with 
PAH during the 19 month study until September 2007. SLE-PAH patients were younger 
compared to SSc and CTD associated PAH patients (mean 45 vs 62 and 57 respectively) and 
had a female to male ratio of 10:1. The REVEAL study characteristically had more female 
predominance overall at a ratio 4.3:1 compared to 1.7:1 in NIH registry and 1.9:1 from 
French registry. All above reports confirm the wide variability published on the prevalence of 
PAH in SLE. 
It is well recognized that patients with SLE can develop PH at anytime during the course of 
their illness, most often in the first 5 years (mean delay 4.9 +3.7 years) or as an initial 
manifestation(302). In the present study, the PAH subgroup as well as the whole SLE cohort 
had a long disease duration with median more than 8 years. The increased prevalence of 
Raynaud’s phenomenon (62-80%) in lupus patients with PAH(57;69;167) suggests the role of 
pulmonary arterial vasospasm in pathogenesis of PAH in addition to other factors. However, 
we did not find the association of RP with PAH in SLE as there was a high prevalence of RP 
in both groups with and without PAH (66% vs 67%). The under-reporting of Raynaud’s 
phenomenon in lupus patients (16%) recruited in the PH registry cohort in USA has also been 
noted.  
Most of our patients with systemic hypertension or Raynaud’s phenomenon were on 
treatment with vasodilators such as calcium channel blockers (CCB) and angiotensin 
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converting enzyme (ACE) inhibitors. 31/283 patients with previous thromboembolic disease 
and/or antiphospholipid syndrome (APS) were on anticoagulant therapy. The significant 
association of prior use of warfarin and calcium channel blockers (Table 3-6) suggests the 
possible role of these drugs in either lowering the sPAP or preventing the sPAP from rising to 
significantly higher values indicative of PAH, as well as supporting the hypothesis that there 
may be a thrombotic mechanism underlying the pathogenesis of PAH in these SLE patients. 
In our SLE study cohort, there were no association between PAH and activity in any system 
scored by BILAG index. None of the patients in PAH group had BILAG score A or B in the 
cardiorespiratory system, and 8 out of 12 (75%) patients in the PAH group did not have 
BILAG score A or B in any system. It has been previously reported that the development of 
PH and its severity do not correlate with SLE disease activity in non-pulmonary disease or 
duration of SLE(303). Active SLE in pulmonary or non-pulmonary disease(185) is not 
associated with PH in a cohort of 129 patients with SLE. There have been several anecdotal 
reports(184;304) as well as small retrospective series suggesting immunosuppressive therapy 
(IST) such as intravenous cyclophosphamide (IVCYC) and steroids are an effective treatment 
in the early stages of PAH in SLE. A randomised controlled study(305) in 36 SLE associated 
PAH patients comparing IVCYC therapy to oral enalapril reported the benefits of IVCYC in 
reducing sPAP in mild and moderate PH. This report also reported higher SLE disease 
activity index (SLEDAI) scores in patients with PH who responded to treatment. Jais et 
al(306) showed that high SLEDAI scores greater than 3 in PAH associated with SLE was not 
a predictive factor for response to immunosuppressive therapy and concluded the reason for 
response in a subset of lupus patients is unclear. Another recent study(307) showed intensive 
IST in combination with specific vasodilator therapy improved haemodynamics and 
prognosis in 6 out of 7 SLE patients, especially when used in early phase of PAH.  Sanchez et 
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al(308) showed disease duration from PAH diagnosis in SLE patients does not predict 
response to IST. Interestingly, the UK PH registry data(150) from unselected incident cases 
of SLE shows 86% were on immunosuppressive agents, and 11% of those were newly 
commenced on IST after PH diagnosis. This compared with only 22% in the PH registry 
(REVEAL) from USA(151). The UK consensus statement(301) recommends 
immunosuppressive therapy (IST) for active CTD in addition to other advanced vasodilator 
treatment for PH, and points to lack of published data on combination therapy with IST in 
PAH associated with CTD. Though this present study did not find any association between 
disease activity and PAH in SLE, the concept of subclinical disease activity in relation to PH 
associated with SLE in early stages is possible given the response to IST reported in several 
publications discussed above. 
We have shown that PAH in SLE is strongly associated with SLICC/ACR damage index 
score >2. This reflects the long disease duration of the study cohort and the PAH subgroup 
resulting in damage accumulation due to recurrent active disease, comorbidities, drug therapy 
and overall inflammatory burden. Another recent echo screening study(187) for PH in a 
series of 245 patients with SLE reported a lack of association of SLICC/ACR damage index 
score with PAH. Another study(55) on patients with SLE reported that high SLICC/ACR 
damage scores in patients with PH compared to those without PH reached statistical 
significance. It is important to be aware of the risk of PH in those lupus patients with high 
SLICC/ACR damage index scores but low or normal scores should not preclude suspicion of 
PAH. 
In this study, lupus anticoagulant was the only significant risk factor for PAH in SLE. Several 
researchers have reported the increased frequency of lupus anticoagulant(58) and 
anticardiolipin antibodies(53;57;59;309) in association with PH in SLE. The presence of 
 115 
antiphospholipid antibodies in SLE patients with PAH is most often not accompanied with 
pulmonary thromboembolism(309). The antiphospholipid antibodies are also detected in 
patients with and without thromboembolic PH without SLE(60;61). The frequency of 
antiphospholipid antibodies is 30-40% in SLE and usually is present in low titre, while the 
frequency can be as high as 80% in patients with PH in SLE(55). Some studies have also 
reported that the anticardiolipin antibodies is neither frequently seen(170) nor associated with 
PAH(185;310) in patients with SLE. The significant association of lupus anticoagulant in 
addition to the borderline significance of clinical APS, suggests the role of thrombosis as a 
mechanism in the pathogenesis of PAH in our SLE patients. However, a recent study by 
Farzaneh-Far et al on 200 patients from a tertiary care lupus cohort with a PAH prevalence of 
17.5% did not find any association with antiphospholipid antibodies, defined as IgG or IgM 
anticardiolipin antibody titre >40 IU/ml and/or positive lupus anticoagulant. When we 
increased the sPAP threshold to >35mm Hg for PAH we found a statistically significant 
association between antiphospholipid antibodies (anticardiolipin antibodies and/or lupus 
anticoagulant) and PAH (p=0.005, data not shown) though numbers were small. The 
association of autoantibodies such as anti-RNP antibodies and rheumatoid factor with PAH in 
SLE has been previously reported but we did not find any similar association in the present 
study. The weak association of anti-La antibodies to PAH in SLE in the study is unlikely to 
be of clinical significance. The absence of any association of low complements C3/C4 or 
dsDNA positivity with PAH in SLE is keeping with the minimal disease activity scores 
evaluated by BILAG index in the study cohort. We have published the prevalence and risk 
factors for PAH in SLE study results in a peer reviewed journal (Appendix 8) 
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3.5 Conclusion 
The point prevalence of PAH in SLE is 4.2% in our cohort of SLE patients. Most of the PAH 
cases (75%) were found to be of mild severity (sPAP <40mmHg) and were asymptomatic 
and such would not meet criteria for guideline-based treatment(301). It is currently unclear 
whether establishing the diagnosis of PAH in the pre-symptomatic phase improves outcome 
in SLE patients. A strong association of PAH in SLE to those with SLICC/ACR damage 
scores >2 and presence of lupus anticoagulant is evident from this study.  
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CHAPTER 4    CARDIOVASCULAR DISEASE IN LUPUS 
 
4.1 Abstract 
 
Background: The cardiovascular manifestations in systemic lupus erythematosus 
(SLE) may involve the pericardium, myocardium and endocardium. These include 
pericarditis, valvular diseases, ischaemic heart disease, impaired cardiac function and 
conduction defects. Left heart disease leading to secondary PH is a recognised 
complication in patients with SLE.  
Objectives: To determine the prevalence of cardiac morphological and functional 
abnormalities as assessed by electrocardiogram (ECG) and transthoracic 
echocardiography (TTE) in patients with SLE, and compare between patients with 
and without PH in SLE. 
Methods: A prospective cross-sectional study of 283 patients with SLE was recruited 
from lupus clinics in Birmingham, UK. They underwent a 12-lead ECG and resting 
transthoracic echocardiography (TTE) to assess cardiac morphology and function. 
The systolic pulmonary artery pressure was estimated using Doppler echocardiogram. 
PH was defined as systolic pulmonary artery pressure (sPAP) >30 mm Hg. We 
assessed the role of autoantibodies, the BILAG disease activity scores and the 
SLICC/ACR damage index in predicting cardiac abnormalities detected on TTE in 
patients with SLE. 
Results: The median age was 41 years (range 18-82) and disease duration was 8.7 
years (range 0-32). 94% were female and 98.2% fulfilled 4 of the 1982 ACR 
classification criteria for SLE.14/283 (4.9%) were known to have SLICC/ACR 
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damage index cardiovascular score of 1 (3.8%) or 2 (1.1%), including 8 patients with 
valvular heart disease, 6 with ischaemic heart disease, 1 with cardiomyopathy and 1 
with pericarditis. Mitral valve thickening, valvular regurgitation, left ventricular 
systolic dysfunction (LVSD) and concentric left ventricular hypertrophy (LVH) were 
the commonest abnormalities detected on TTE (Table 4-2). 41/283 (14%) had mitral 
valve thickening, commonly involving the anterior leaflet. Other abnormalities 
included left ventricular and left atrial dilatation, and segmental wall motion 
abnormality. We were able to calculate the ejection fraction (EF) in 256/283 patients 
and 10 patients had an EF <50%. None of the patients had pericardial effusion or 
thickening at the time of assessment. Mitral regurgitation was significantly associated 
with the combined positive anticardiolipin IgG titre >40IU/l, positive anticardiolipin 
IgM titre >40 IU/l and positive lupus anticoagulant. There was no significant 
difference in the frequency of cardiac valvular and functional abnormalities between 
lupus patients with and without PAH. None of the patients with PAH had right and/or 
left ventricular systolic/diastolic dysfunction. 
Conclusion: Thickening of the anterior mitral valve was the most common cardiac 
morphological abnormality in our SLE cohort. The majority of valvular abnormalities 
are mild without compromise in cardiac function. Left heart morphological and 
functional compromise was not associated with PAH in this cohort. In contrast to 
previous studies, pericardial disease was absent in our cohort at the time of 
assessment. A strong association between MR and combined positive LAC and high 
titre aCL IgG and aCL IgM was present. 
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4.2 Introduction and Methods 
 
Cardiac involvement in systemic lupus erythematosus (SLE) may involve the 
pericardium, myocardium and endocardium. The cardiovascular (CV) manifestations 
include pericarditis, myocarditis, endocarditis, valvular diseases, ischaemic heart 
disease, impaired cardiac function and conduction defects(311). Coronary artery 
disease (CAD) secondary to accelerated atherosclerosis is due to traditional CV risk 
factors as well as other factors such as elevated homocysteine level, and combination 
of oxidative stress, inflammation and presence of antiphospholipid antibodies(312-
314). The leading causes of death in SLE patients with disease duration greater than 5 
years are CAD, infection and malignancy. Females aged 35-44 years with SLE are 52 
times increased risk of myocardial infarction compared to healthy age matched 
women(315). The evaluation of CAD in SLE patients is not within the remit of this 
present study. Predominantly the valvular diseases noted in SLE is subclinical being 
asymptomatic and of mild degree in severity. Though left heart disease causing 
secondary PH is not often reported in the prevalence studies in SLE, a recent study by 
Ruiz-Irastorza reported PH in 5% of their lupus cohort and all had secondary PH(187) 
which is considerably different from most previous studies published. The association 
of antiphospholipid antibodies with valvular diseases and PAH in SLE is well 
recognised(56).  
Please refer to section 1.3.4 in the introduction chapter for details on CV disease in 
SLE, and refer to methods section 2.2 for patient demographics, 2.3 for ECG, 2.4 for 
echocardiogram, 2.6.1 for autoantibodies and 2.6.2 for BILAG and SLICC/ACR 
damage index. 
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4.3 Results 
 
4.3.1 BILAG disease activity index and SLICC/ACR damage index 
in SLE patients  
 Only 1 patient had activity in cardiorespiratory system with BILAG score B in this 
cohort. None had severe activity with BILAG score A in cardiorespiratory system 
(Appendix 1). 
 Fourteen out of 283 (4.9%) SLE patients were known to have SLICC/ACR damage 
index (Appendix 2) cardiovascular score of 1 (3.8% of patients) or 2 (1.1% of 
patients), including 8 patients with valvular heart disease, 7 with ischaemic heart 
disease, 1 with cardiomyopathy and 1 with chronic pericarditis.  
4.3.2 ECG abnormalities in patients with SLE 
 Twelve lead ECG was performed in 278/283 patients. Five patients did not have 
ECG due to technical difficulties. The majority of patients (204, 73%) had normal 
rate, rhythm, and axis. 
Forty six (17%) patients had a resting heart rate <60/min and 7 (2.5%) had a resting 
rate >100 beats/min. Right axis deviation was present in14 (4.9%) patients and left 
axis deviation in 8 (2.8%) patients. Three (1.1%) patients had left bundle branch 
block and 12 (4.3%) patients had right bundle branch block. No other conduction 
defects were detected. Left ventricular hypertrophy present was present in 56 (20%) 
patients. None had right ventricular hypertrophy.  
None of the SLE patients with tachycardia or bradycardia had activity with BILAG 
index score A or B for cardiovascular system (CVS). The cardiovascular damage 
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score (SLICC/ACR DI) was 2 in 1/46 patients and 1 in 3/46 patients with bradycardia. 
None of the patients with tachycardia had damage score in CVS. There were no 
statistical association between any ECG abnormality recorded and BILAG disease 
activity or SLICC/ACR damage index scores (Table 4-1). 
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Table 4-1  Disease activity and damage indices in the cardiovascular system in 
278 SLE patients with ECG abnormalities 
 SLE active 
 
(BILAG 
disease activity 
score A or B in 
CVS) 
SLE inactive 
 
(BILAG 
disease activity 
score C,D or E 
in CVS) 
Damage in 
CVS 
 
(SLICC/ACR 
DI score 1 or 2 
in CVS) 
No damage in 
CVS                                  
 
(SLICC/ACR 
DI score 0 in 
CVS) 
Bradycardia 
No. of patients 
(%) 
0 (0) 46 (17) 4 (1) 42 (15)  
Tachycardia 
 No. of patients 
(%) 
0 (0) 7 (3)  0 (0) 7 (3) 
Right axis 
deviation 
 No. of patients 
(%) 
0(0) 14 (5) 0 (0) 14 (5) 
Left axis 
deviation 
 No. of patients 
(%) 
0(0) 8 (3) 1 (0) 1 (0) 
Right bundle 
branch block 
 No. of patients 
(%) 
0(0) 11 (4) 1 (0) 10 (4) 
Left bundle 
branch block 
 No. of patients 
(%) 
 
0(0) 3 (1) 0 (0) 3 (1) 
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Right 
ventricular 
hypertrophy 
No. of patients 
(%) 
0(0) 0 (0) 0 (0) 0 (0) 
Left 
ventricular 
hypertrophy  
No. of patients 
(%) 
0 56 3 (2 OF 1, 
AND 1 OF 2) 
53 
BILAG: British Isles lupus activity group; SLICC/ACR DI: Systemic lupus 
international collaboration committee/American College of Rheumatology damage 
index 
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4.3.3 Echocardiographic evaluation of cardiac 
morphology/function 
 Transthoracic Echocardiography (TTE) was performed in all 283 patients with lupus. 
Mitral valve thickening, valvular regurgitation, left ventricular systolic dysfunction 
(LVSD) and concentric left ventricular hypertrophy (LVH) were the commonest 
abnormalities detected on TTE (Table 4-2).  
The mitral valve (MV) thickening was present in 41(14%) patients. It involved the 
anterior and posterior MV leaflet in 39 and 8 patients respectively, while 6 patients 
had both leaflets affected. The valvular regurgitation involved mitral valve in 
95(34%) patients, tricuspid valve (TCV) in 128(45%) patients and aortic valve (AV) 
in 26 (9%) patients. A trace or mild pulmonary incompetence was present in 17 (6%) 
patients. Seven out of 9 patients who had MV, TCV and AV regurgitation together 
were only of mild degree. 
Three (1%) patients had aortic sclerosis. Three (1%) patients had aortic stenosis (AS), 
with 2 being mild and one moderate degree AS. None of the patients had mitral 
stenosis. 
Three patients had valve replacements, with 2 patients having mitral valve and 1 
having aortic valve replacement. The dilated cardiac chambers were all of mild degree 
with involvement of left atrium in 7 (2%), left ventricle in 10 (4%), right atrium in 
5(2%), and bi-atrial in 2 (1%) patients. The segmental wall motion abnormality and 
thickening of septal wall were noted in 4 patients each. Mild right ventricular 
hypertrophy was seen in one patient, who did not have PAH. 
Left ventricular systolic dysfunction (LVSD) was mild in 15 (5.4%) and moderate in 
6 (2.1%) patients. None had severe LVSD. Left ventricular hypertrophy (LVH) was 
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mild in 35 out of 38 patients (13.4%). We were able to calculate ejection fraction (EF) 
in 256/283 (90%) patients and 10 (4%) patients had an EF <50%. The EF% was 
>50% in 246 patients, >60% in 126, >70% in 24, >80% in 3 patients. 
No patients had pericardial effusion or pericardial thickening at the time of 
assessment. 
The number of patients with left heart valvular abnormalities, LVSD and LVH were 
not different between SLE patients with and without PAH (Table 4-3). 
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Table 4-2 Frequency of cardiac abnormalities detected by TTE in patients with 
SLE 
 
 
 
 
 
 
 
 
Cardiac abnormality detected 
on TTE 
Mild  
No. of patients 
(%) 
Moderate 
No. of patients 
(%) 
Severe  
No. of patients 
(%) 
Tricuspid regurgitation  122 (43.1) 4 (1.4) 2 (0.7) 
Mitral regurgitation  83 (29.6)  11 (3.9) 1 (0.4) 
Aortic regurgitation  24 (8.6) 2 (0.7) 0 (0) 
LV systolic dysfunction  15(5.4) 6 (2.1) 0 (0) 
LV hypertrophy 35 (12.3) 2 (0.7) 1 (0.4) 
TTE: Transthoracic echocardiogram; LV: Left ventricular 
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Table 4-3 Left heart abnormalities detected by TTE in patients with and without 
PAH 
Left heart 
abnormality detected 
on TTE 
SLE without 
PAH (n=272) 
No. of patients 
(%) 
 
SLE with 
PAH(n=12) 
No. of patients 
(%) 
 
p value comparing SLE 
patients with and without 
PAH 
(Fisher’s exact 2 sided 
test) 
AMVLT 36 (13) 3 (25) 0.227 
PMVLT 7 (3) 1 (8) 0.303 
MR  88 (32)  7 (58) 0.115 
AR  24 (9) 2 (17) 0.310 
MS 0 0 - 
AS 6 0 1.0 
LVSD  21 (8) 0 0.609 
LVH 35 (13)  3 (25) 0.215 
MR: mitral regurgitation; AR: aortic regurgitation; LVSD: left ventricular systolic 
dysfunction; LVH: left ventricular hypertrophy; AMVLT: anterior mitral valve 
thickening; PMVLT: posterior mitral valve thickening 
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4.3.4 Autoantibody associations with cardiac valvular 
abnormalities 
All the autoantibodies listed in the serological risk factors for PAH study (section 
2.6.1, Table 3-5) was compared between patients with and without cardiac valvular 
abnormalities (regurgitation, stenosis or thickening). The association of positive 
autoantibodies and presence of cardiac valvular defects did not reach statistical 
significance. In particular, positive anticardiolipin IgG with a titre >15 IU/ml and 
>40IU/ml, positive anticardiolipin IgM with a titre >10 IU/ml and >40IU/ml, and 
positive lupus anticoagulant were not associated with cardiac valve defects in this 
cohort of SLE patients. 24/70 patients with MR and 25/ 150 patients without MR had 
combined high titre positivity of anticardiolipin IgG >40IU/ml, anticardiolipin 
IgM>40 IU/ml and positive lupus anticoagulant. The number of patients with (n=49) 
and without (n=171) combined high titre positivity of anticardiolipin IgG >40IU/ml, 
anticardiolipin IgM>40 IU/ml and positive lupus anticoagulant were significantly 
different between patients with and without MR (p=0.005 Fisher’s exact test 2 sided).  
The history of APS was noted in 34/283 patients. There was no difference in the 
frequency of valvular thickening, stenosis or regurgitation between patients with and 
without history of APS. 
4.4 Discussion 
 
The majority (99%) of the SLE cohort had inactive disease in cardiovascular system 
(CVS) according to BILAG disease activity scores and similarly 95% patients had no 
damage in cardiorespiratory system measured by SLICC/ACR damage index.  Only 8 
(3%) patients had valvular disease with audible murmur recorded as cardiovascular 
damage. This is similar to previous studies reporting that majority of SLE patients 
have subclinical valvular disease. In another study of 217 SLE patients(316), the 
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mean SLEDAI score was 4.1 and the mean SLICC score was 1 with only 2.3% 
patients having CAD..  
The ECG was predominantly normal in the study cohort and those who had abnormal 
rate, rhythm, axis or ventricular hypertrophy abnormalities did not show any 
association with the disease activity or damage in CV system. This is possibly 
because of very small number of patients who had active disease and/or damage in 
CVS (see above). An increasing tendency towards tachycardia in SLE patients was 
reported previously(317). The ECG abnormalities detected in our cohort could 
possibly reflect subclinical coronary vascular disease often reported in SLE patients.  
The objectives of this study did not include ischemic heart disease assessment in SLE 
and thus unable to confirm the reason for ECG abnormalities in this study cohort. 
The main aim was to estimate the prevalence of structural and functional cardiac 
abnormalities by TTE in this large lupus study cohort. Our study confirmed that 
thickening of the anterior mitral valve was the most common cardiac morphological 
abnormality (14%), similar to reports published before and after our study period. 
Mitral valve thickening was found to be focal thickening consistent with nodules in 
anterior and posterior leaflets and distinct from the normally observed age related 
diffuse thickening. It has been postulated that MV thickening could be the hallmark of 
early valve disease preceding valvular damage and insufficiency. However, the 
clinical significance of MV thickening has remained uncertain for many years now.  
The majority of valvular abnormalities in the cohort were mild regurgitation without 
compromise in cardiac function. Tricuspid and mitral regurgitation were frequently 
noted. No patients had mitral stenosis and only 2% had aortic stenosis or sclerosis. 
The valvular defects seen in our study were similar to previous studies confirming 
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mild valvular disease and focal thickening of mitral valve leaflets being most frequent 
in SLE. The anatomical lesions were reported in 40-50% of cases with TTE and 50-
60% of cases with TOE evaluation in SLE patients (192). The benefits of TOE are 
better sensitivity, specificity and negative predictive value than TTE evaluation(193). 
It is important to consider TOE evaluation in SLE patients with non-diagnostic TTE, 
particularly in those with cardiac thrombo-embolism and suspected endocarditis. The 
combined incidence of IE, heart failure, stroke, peripheral embolism and valve 
replacement was 22% in those with valvular heart disease (VHD) compared to 8% in 
those without VHD(197). There were no significant associations of left heart 
anatomical defects with PH in suggesting that secondary PH due to valvular disease is 
unlikely in this SLE cohort (Table 4-3). 
Left ventricular hypertrophy was present in 13% and is likely to be due to systemic 
hypertension (24%) in SLE patients. The LVSD seen in 7%  in this cohort is similar 
to a previous report using TOE in SLE patients(197) and not associated with PAH. 
The LVH and LVSD in this present study were predominantly mild and not 
associated with PH. It is possible that LVSD could be due to subclinical ischemic 
heart disease but the objectives of this study did not include evaluation of IHD and 
traditional CV risk factors. 
A retrospective study(318) of 275 SLE patients reported on the prevalence of 
infective endocarditis (IE) associated with valvular disease secondary to SLE. This 
report from American dental association found 18.5% with clinically detectable 
cardiac murmur and only 4.4% with clinically significant valvular abnormality 
potentially required antibiotic prophylaxis before certain dental procedures, but no 
cases of IE were found related to SLE. Roldan et al(197) reported IE as a 
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complication in 3/45 (7%) patients with SLE related valvular disease evaluated by 
repeated transoesophageal echocardiogram with an interval of 29+13 months and 
followed up for 57 months. The antibiotic prophylaxis for bacteremia producing 
dental procedures such as dento-gingival manipulations is advisable for SLE patients 
with clinically significant valvular abnormalities confirmed by TTE or TOE 
(193;197;318;319). 
In contrast to previous studies, acute pericardial disease was absent in our cohort at 
the time of assessment. None of our patients had pericardial abnormalities recorded. 
This could be attributed to average disease duration of 9.7 years, the cross sectional 
nature of study, and minimal cardiovascular damage recorded with only one patient 
scoring for chronic pericarditis in SLICC/ACR damage index in our cohort. 
Pericarditis is common and characteristic of SLE. Though this is a manifestation seen 
at any stage of SLE, it is often noted at disease onset or during active SLE relapse. It 
is not uncommon for pericarditis to be recurrent. The echocardiographic diagnosis of 
pericardial abnormalities was found in 16-54% of patients(320) and the variability 
depends on symptoms, definitions and diagnostic tools. Often asymptomatic 
pericardial effusion is only elicited by ECHO, and can be associated with active 
disease in other organs. 
The association of antiphospholipid antibodies(56) and other autoantibodies such as 
anti-Ro and anti-La(321) with cardiac valvular abnormalities in SLE has been 
reported by several research groups. The combined positive lupus anticoagulant and 
high titre anticardiolipin IgG and IgM> 40 IU/ml was strongly associated with mitral 
regurgitation. However, other valvular defects were not found to be associated with 
autoantibodies including antiphospholipid antibodies. 
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4.5 Conclusion 
 
The thickening of the anterior mitral valve and the mild valvular regurgitation without 
compromise in cardiac function were the most common cardiac anatomical 
abnormality detected by TTE in our SLE cohort. Left heart morphological and 
functional compromise was not associated with PAH in this cohort. In contrast to 
previous studies, acute pericardial disease was absent in our cohort at the time of 
assessment. A strong association between MR and combined positive LA and high 
titre aCL IgG and aCL IgM was present. 
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CHAPTER 5   RESPIRATORY ABNORMALITIES IN SLE 
AND PAH 
 
5.1 Abstract 
 
Hypothesis: Pulmonary hypertension associated with SLE can be secondary to lung 
diseases. Dyspnoea can predict severity of PH in SLE. 
Aims:  
1. To assess  respiratory muscle strength abnormalities, pre-existing lung diseases 
and smoking status as the risk factors for PAH in SLE 
2. To assess the role of pulmonary function tests, respiratory symptom 
questionnaires and six minute walk test as the screening tests for PAH in SLE. 
Objectives: 
1. To determine the presence of underlying lung diseases and history of smoking 
in our SLE cohort based on history, clinical records and/or SLICC/ACR 
damage scores, and compare between patients with and without PAH in SLE. 
2. To evaluate respiratory muscle strength (RMS) abnormalities in SLE patients 
and compare RMS abnormalities in those with and without PAH. 
3. To evaluate dyspnoea in patients with SLE using respiratory symptom 
questionnaires, and compare dyspnoea scores between patients with and 
without PAH in SLE. 
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4. To evaluate pulmonary function test (PFT) abnormalities in patients with SLE, 
and assess the relationship with lupus related autoantibodies and BILAG 
disease activity scores 
5. To compare PFT abnormalities in lupus patients with and without PAH, 
determined by Echocardiogram in this study. 
6. To compare PFT abnormalities in lupus patients with and without known 
restrictive lung diseases  
7. To determine distance walked in six minutes (6MWD) in SLE patients and 
compare 6MWD by patients with and without PAH 
Methods: 
A detailed clinical history and examination, clinical records evaluation including 
SLICC/ACR damage index were performed in all 283 patients with lupus in this 
study. Respiratory muscle strength measurements, pulmonary function testing, 
and six minute walk test were performed according to international guidelines. 
The modified MRC scale, baseline dyspnoea index (BDI), and St. George’s 
respiratory questionnaire were also self completed by study patients. 
Results: 
In this SLE cohort, 15% of patients had known lung disease and 17% were current 
smokers. The presence of SLE related restrictive lung diseases or smoking status 
between patients with and without PAH in SLE did not reach statistical significance 
(Table 5-1). Respiratory muscle weakness was present in 55% with PAH and 31% 
without PAH with no significant difference between the groups. A strong correlation 
was found between inspiratory and expiratory muscle pressures in the whole cohort. 
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The screening tests including all respiratory questionnaires, 6MWT and PFT 
parameters were not able to distinguish patients with PAH from those without in this 
cohort. 
Conclusion: 
The prevalence of pre-existing restrictive lung disease in lupus was 5%. Two-third 
never smoked, and predominantly was in NYHA functional class I (85%). Respiratory 
muscle weakness was present in one-third and a strong correlation existed between 
inspiratory and expiratory muscle pressures in SLE. There were no respiratory risk 
factors identified for PAH in SLE in this study. Pulmonary function tests in patients 
with SLE revealed low TLCO in 55% and isolated low TLCO in 33%, and significant 
difference in all parameters noted between patients with and without dyspnoea or pre-
existing lung disease. Pulmonary function test parameters, 6MWT distance, and 
respiratory questionnaires did not have screening potential for identifying PAH in 
SLE in this cohort. 
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5.2 Introduction and Methods 
 
Pleurisy, pleural effusion, interstitial lung disease (ILD), pulmonary embolism, 
shrinking lung syndrome (SLS) are the most important lung manifestations in SLE. 
Patients with shrinking lung syndrome (SLS) have unexplained dyspnoea with 
restrictive pattern and small lung volumes on lung function testing and absence of 
parenchymal disease with elevated diaphragm on CT chest(280). The prevalence of 
SLS is 0.6- 0.9% in large multiethnic lupus cohorts(322) while a higher prevalence of 
SLS of 6% was reported in patients with refractory SLE requiring haematopoietic 
stem cell transplantation (323).  The assessment of lung diseases, whether it is serosal, 
interstitial, airways or vascular disease is vital to ascertain the cause of PH, degree of 
lung involvement and the impact of cardiorespiratory symptoms in SLE patients.  
A detailed clinical history and examination, clinical records evaluation including 
SLICC/ACR damage index were performed in all 283 patients with lupus in this 
study. The results of pulmonary function tests, chest X-ray and high resolution CT 
scan of chest were noted only from those patients who underwent these tests 
previously. Respiratory muscle strength measurements were performed using 
handheld respiratory pressure meter (MicroRPM, Micro medical Ltd). Pulmonary 
function testing (PFT) including spirometry, lung volumes and diffusion factor were 
measured as per standardized guidelines(292). Six minute walk test (6MWT) was 
performed according to international guidelines(282). The modified MRC scale, 
baseline dyspnoea index (BDI), and St. George’s respiratory questionnaire were also 
self completed by all study patients. Please refer to section 1.3.6 for introduction and 
sections 2.6 and 2.7 for methods in detail. 
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Statistical analysis: The distribution of variables was not normally distributed and 
thus non-parametric tests were used for comparison between groups. The continuous 
variables were expressed in median and range, or counts and percentages. Mann 
Whitney U test was used to compare continuous variables between groups. Fisher’s 
exact (2 sided) test and Pearson’s test when appropriate were used to analyse 
categorical variables between groups. Spearman Rank test was used for bivariate 
correlation analysis between two continues variables.  A p value of <0.05 was 
considered significant. 
5.3 Results: Respiratory risk factors for PAH 
5.3.1 Presence of underlying lung disease in SLE 
The presence of underlying lung diseases  in our lupus patient cohort were obtained 
from clinical examination and medical records including previous pulmonary function 
tests, chest X-ray and high-resolution CT chest results. The pulmonary function tests 
performed in our current study were not used to confirm the presence or absence of 
the nature of lung diseases already known in our patients.  
Among the 283 SLE patients, 14 (5%) had known lupus related restrictive lung 
diseases (RLD) and 27 (10%) had obstructive airways disease (OAD). In the RLD 
subgroup, 7 had pulmonary fibrosis, 5 had pleural thickening and 2 had shrinking 
lung syndrome. Of the 27 with OAD, 25 had asthma and 2 had chronic obstructive 
airways disease (COPD). Among other lung diseases, two patients with PAH had 
previous history of pulmonary embolism. In the non-PAH group, 7 had previous 
history of TB, 1 had pleural effusion and 4 had pulmonary embolism. None in our 
SLE cohort had history of bronchiectasis or lung malignancy.  
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Among the 12 patients with PAH, only one had asthma and another had shrinking 
lung syndrome and pleural fibrosis. In other words, 8% had RLD and 8% had OAD in 
PAH group compared to 5% with RLD and 9.5% with OAD in non-PAH group. 
There was no statistical significance in the difference in the number of patients with 
RLD and/or OAD between patients with and without PAH. (Table 5-1) 
5.3.2. History of smoking 
In the whole SLE cohort, the number of patients who ever smoked was 103 (36%), 
who currently smoked were 48 (17%) and who never smoked were 180 (64%). In 
PAH subgroup, 33% were current smokers and 50% had never smoked. In the non-
PAH group, 16% were current smokers and 64% have never smoked (Table 5-1). 
There were no significant difference between current smokers and the rest of cohort, 
as well as between ever smoked and never smoked status with the risk of PAH in 
SLE. 
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Table 5-1 Risk of smoking and previous lung disease in SLE patients with and 
without PAH 
 SLE 
 
 
 
SLE without 
PAH 
(Group I) 
SLE with PAH 
 
(Group II) 
p value 
(Fisher’s test,   
2 sided)* 
( Group I and II 
comparison) 
No. of patients  283 271 12  
Any lung disease,  
No. of patients (%) 
41 (14.5) 39 (14) 2 (17) 0.687 
Restrictive lung 
diseases 
No. of patients (%) 
14 (5) 13 (5) 1 (8)  0.463 
Obstructive lung 
diseases 
No. of patients (%) 
27 (9.5) 26 (9.5) 1 (8) 1.0 
Ever smoked 
No. of patients (%) 
103 (36) 97 (36) 6 (50) 0.364 
Current smokers 
No. of patients (%) 
48 (17) 44 (16) 4 (33) 0.127 
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5.3.3 Respiratory muscle strength 
The inspiratory and expiratory muscle pressure measurements were performed in 11 
patients with PAH and 254 patients without PAH. The median maximal inspiratory 
pressure (MIP) was 53.5 cmH20 and maximal expiratory pressure (MEP) was 62 
cmH20 in non-PAH group, while these were 42 cmH20 and 46 cmH20 respectively in 
PAH group. The difference in MIP and MEP between patients with and without PAH 
was not significant (Mann Whitney U test). 
In the PAH group, 5 patients had inspiratory muscle weakness and 3 had expiratory 
muscle weakness. In the non-PAH group, 70 patients had inspiratory muscle 
weakness and 38 had expiratory muscle weakness. Both inspiratory and expiratory 
muscle weakness were found in 2 patients with PAH and 29 patients without PAH in 
SLE. The sniff nasal inspiratory pressure was abnormal in 7 out of 11 patients with 
PAH and 96 out of 240 patients without PAH (Table 5-2). 
All measurements of respiratory muscle strength including MIP, MEP and SNIP were 
not statistically significant as a risk factor for PAH in SLE. There was a significant 
correlation between MIP and MEP (Spearman Rho test p value 0.00) in the whole 
lupus cohort (Figure 5-1). The correlation between BMI and MIP was strong 
(Spearman Rho test p=0.005) (Figure 5-2) and that between BMI and MEP was weak 
correlation (p=0.045).  
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Table 5-2 Respiratory pressure measurements (RPM) in SLE patients with and 
without PAH. 
Respiratory pressure 
measurements (RPM) 
PAH (n=11) Non PAH 
(n=254) 
Fishers t test 
(2-sided) p value 
MIP <=40 cm H20,  
No. of patients (%) 
5 (45) 70 (28) 0.302 
MEP <=40 cm H20,  
No. of patients (%) 
3 (27) 38 (15) 0.384 
MIP and MEP <40 cm H20, 
No. of patients (%) 
2 (18) 29 (11) 0.623 
MIP and/or MEP <40 cm 
H20, No. of patients (%) 
6 (55) 79 (31) 0.183 
MIP: Maximal inspiratory pressure; MEP: Maximal expiratory pressure 
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Figure 5-1 Scatter plot to show the correlation between maximal inspiratory 
pressure and maximal expiratory pressure. 
 
Spearman Rho test p value 0.00 
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Figure 5-2 Scatter plot to show the correlation between maximal inspiratory 
pressure and body mass index (BMI). 
 
Spearman Rho test p value 0.007. 
 
 
 
 
 
 
 144 
5.4 Results: Pulmonary screening tests for PAH in SLE 
 
5.4.1 Respiratory symptom questionnaires 
5.4.1.1. Modified MRC dyspnoea score  
Two hundred and seventy nine patients completed modified MRC questionnaire 
(Appendix 5). There were 67% patients with dyspnoea score 1-4 in the whole lupus 
cohort, including 83% in the PAH group and 66% in the non-PAH group (Table 5-3). 
There was no significant difference in the dyspnoea status between patients with and 
without PAH in our cohort. 
5.4.1.2. Baseline dyspnoea index (BDI)  
Two hundred and fifty eight patients including 11 patients with PAH completed BDI 
questionnaire (Appendix 6) and there were no significant difference in the dyspnoea 
scores in all 3 categories between patients with and without PAH (Table 5-4). The 
BDI total score (range 0-12) is the sum of scores from all three categories in this 
index. The median BDI total score was 9 for the whole cohort as well as for patients 
with and without PAH subgroups. This suggests that most patients in this study had 
mild dyspnoea only, as the maximum total score of 12 is indicative of no dyspnoea 
with ordinary tasks. 
5.4.1.3. St. George’s respiratory questionnaire score  
Among the 279 lupus patients who completed the symptom category of SGRQ 
questionnaire (Appendix 7), 264 completed the activity category and 265 completed 
the impacts category of the questionnaire. Thus the total score could be calculated in 
258 patients. The scores ranges from 0-100 in each of the category, and none of the 
scoring categories differentiated SLE patients with and without PAH as the statistical 
significance were not reached (Table 5-5). 
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Table 5-3 Modified Medical Research Council (MRC) dyspnoea score in SLE 
patients 
MRC dyspnoea 
score 
SLE, no. of patients (%) 
PAH absent  
(n=267) 
No. of patients (%) 
PAH present 
(n=12) 
No. of patients (%) 
0 91 (34) 2 (17) 
1 103 (38) 7 (59) 
2 58 (22) 1 (8) 
3 10 (4)  2 (16) 
4 5 (2) 0 (0) 
n: Total number of patients in each group; Score 0: No dyspnoea; Score 4 : severe 
dyspnoea 
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Table 5-4 Baseline dyspnoea index (BDI) in patients with and with PAH in SLE. 
  BDI dyspnoea scores 
SLE patients BDI dyspnoea 
categories 
0 1 2 3 4 
PAH absent 
(n=247) 
No. of patients (%) 
Functional impairment 6 
(2) 
13 
(5) 
29 
(12) 
76 
(31) 
119 
(48) 
Magnitude of task 4 
(1) 
19 
(8) 
78 
(32) 
72 
(29) 
74  
(30) 
Magnitude of effort 2 
(1) 
24 
(10) 
85 
(34) 
66 
(27) 
67  
(27) 
PAH present 
(n=11) 
No. of patients (%) 
Functional impairment 0 
(0) 
0  
(0) 
1  
(9) 
4  
(36) 
4  
(36) 
Magnitude of task 0 
(0) 
1  
(9) 
1  
(9) 
6  
(55) 
3  
(27) 
Magnitude of effort 0 
(0) 
0  
(0) 
5  
(45) 
2  
(18) 
3  
(27) 
Score 0: very severe impairment; 1: severe impairment; 2: moderate impairment; 3: 
Mild impairment; 4: No impairment.  n: Total number of patients in each group 
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Table 5-5 St. George’s respiratory questionnaire scores in patients with and 
without PAH. 
 SLE SLE without 
PAH 
SLE with PAH 
(n=12) 
p value (Mann 
Whitney test)* 
Total score 
(n=258) 
19 (0-82) 19 (0-82) 24 (3-78) 0.50 
Symptoms 
score (n=279) 
17 (0-100) 17 (0-100) 19 (7-82) 0.32 
Activity score 
(n=264) 
35 (0-100) 35 (0-100) 38 (6-100) 0.83 
Impacts score 
(n=265) 
9 (0-87) 9 (0-87) 11 (0-64) 0.54 
Variables are expressed in median and range in brackets. n= Number of SLE patients. 
*Mann Whitney U test p value comparing median scores between SLE patients with 
and without PAH.  n: Number of patients in each group 
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5.4.2. Pulmonary function tests (PFT) 
Pulmonary function tests were performed in 222 patients with lupus in this cohort, 
and 207 had all the parameters including spirometry, lung volumes and diffusion 
factor measured. The remaining 15 patients were unable to complete the tests due to 
respiratory symptoms limiting their performance of the test. The spirometry 
parameters included forced expiratory volume in 1 second (FEV1) and forced vital 
capacity (FVC), lung volumes included total lung capacity (TLC), and diffusion 
capacity included total diffusion capacity adjusted for haemoglobin (TLCO) and 
TLCO adjusted for alveolar volume (KCO). 
Pulmonary function test parameters less than 80% predicted values were considered 
low. Restrictive pulmonary defect was defined by low predicted FVC <80% and low 
predicted TLC <80%.Obstructive defect was defined by decreased FEV1predicted 
<80% and ratio of FEV1/FVC less than 0.8(231). 
5.4.2.1. PFT in SLE cohort  
The median age of the patients who underwent PFT was 41.5 years (range 18-82 
years) and the median disease duration was 8.7 years (range 0-32 years). The only 
median PFT parameter that was below 80% predicted value was TLCO (median 74%, 
range 16-127%) and low TLCO was found in 130 (59%) patients in this SLE cohort. 
An isolated reduction of TLCO <80% predicted was found in 73 (33%) patients with 
SLE (Table 5-8). Reduction of TLCO and FVC less than 80% was present in 30 
(13%) patients. The obstructive defect was found in 5 (2%) patients and restrictive 
defect was found in 24 patients (11%). All PFT parameters were normal in 70 patients 
(32%). The majority (85%) had no dyspnoea on performing ordinary tasks. Patients 
with low TLCO were dyspnoeic (19%) more than those with normal TLCO (9%) but 
the difference was not significant (Fisher’s exact test p=0.053). The only association 
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of low TLCO with BILAG disease activity score was found for haematologic activity 
(Pearson chi square p=0.001). The weak association of low TLCO with anti-Sm 
antibody was also evident (Fishers exact test p=0.047) 
Association with dyspnoea: All SLE patients in this study were graded by NYHA 
functional class according to their symptoms limiting physical activity. We compared 
patients with dyspnoea (classes II, III, IV) and those without dyspnoea (Class I) in 
this cohort and found that all parameters except KCO were significantly lower in 
those with dyspnoea. However, TLCO was the only parameter that was below 80% in 
both groups, with 63% in those with dyspnoea compared to 77% in those without 
dyspnoea (Table 5-6). 
Association with lung disease: All PFT parameter except KCO predicted were 
significantly lower in patients with SLE related lung diseases compared to those 
without lung diseases (Table 5-7). 
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Table 5-6 Pulmonary function test parameters in SLE patients with and without 
dyspnoea.  
 SLE 
 
 
SLE without 
dyspnoea 
(Group I) 
 
SLE with 
dyspnoea 
(Group II)* 
 
p value 
(Mann 
Whitney test 
comparing 
Group I and II) 
No. of patients 
who had PFT 
222 189 33  
FEV1, % 
predicted 
96 (21-143) 98 (30-143) 83 (21-127) 0.00 
FVC, % 
predicted 
103 (20-157) 104.5 (45-157) 89 (20-129) 0.001 
TLC, % 
predicted 
94 (36-156) 96 (52-156) 88 (36-127) 0.005 
TLCO, % 
predicted 
74 (16-127) 77 (32-127) 63 (16-96) 0.00 
KCO, % 
predicted 
85.5 (43-130) 86 (46-130) 82 (43-128) 0.319 
FEV1: Forced expiratory volume in 1 second. FVC: Forced vital capacity. TLC: Total 
lung capacity. TLCO: Total diffusion capacity. KCO: Transfer coefficient.  
*Group II had NYHA dyspnoea classes’ II-IV. 
Values are expressed as median and range in brackets, unless otherwise specified. 
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Table 5-7 Pulmonary function test parameters in SLE patients with and without 
related lung diseases*  
 SLE without lung 
disease 
 
(Group I) 
SLE with related  
lung diseases 
 
(Group II) 
p value 
(Mann Whitney test 
comparing Group I 
and II) 
No. of patients who 
had PFT 
210 12  
FEV1, % predicted 97 (31-143) 66 (21-116) 0.00 
FVC, % predicted 104 (47-157) 66.5 (20-111) 0.00 
TLC, % predicted 95 (56-156) 87 (36-98) 0.001 
TLCO, % predicted 76(35-127) 47 (16-72) 0.00 
KCO, % predicted 86 (46-130) 75 (43-117) 0.207 
FEV1: Forced expiratory volume in 1 second. FVC: Forced vital capacity. TLC: Total 
lung capacity. TLCO: Total diffusion capacity. KCO: Transfer coefficient. 
Values are expressed as median and range in brackets. 
*SLE related lung diseases such as pleural disease including effusion, fibrosis and 
thickening, interstitial lung disease and shrinking lung syndrome. 
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5.4.2.2. PFT in SLE patients with and without PAH 
All twelve patients with PAH and 210 patients without PAH had undergone lung 
function testing. None of the parameters were significantly different between patients 
with and without PAH. The median values of PFT parameters are shown in Table 5-8. 
The box plot analysis of PFT parameters for patients with and without PAH is shown 
in Figure 5-3. Though the median predicted TLCO % was below 80% in both groups, 
the low TLCO values between patients with and without PAH were not statistically 
significant.  
The numbers of patients with isolated reduction of predicted TLCO less than 80% 
was found in 73 (35%) patients without PAH and 3 (25%) patients with PAH in SLE 
(Table 5-9). All PFT parameters were normal in 66 (31%) patients in the non-PAH 
group and 4 (33%) patients in the PAH group. The restrictive defect was present in 23 
patients in non-PAH group and 1 patient in PAH group. The obstructive defect was 
found only in non-PAH group in 5 patients. TLCO <55% predicted was found in 2/12 
and 23/206 patients with and without PAH respectively (Fisher’s exact p=0.633). The 
FVC/TLCO ratio >1.4 in 6/12(50%) patients with PAH and 88/201(44%) patients 
without PAH and the difference was not significant between groups (Fisher’s exact 2-
sided test, p value 0.768) 
Association with dyspnoea: There were 3 out of 12 (25%) patients with dyspnoea in 
PAH group and 30 out of 210 (14%) patients with dyspnoea in the non-PAH group. 
The median TLCO predicted was 66% in SLE patients with PAH. Patients with 
symptomatic PAH had median TLCO predicted value of 64% compared to 62% in 
those with asymptomatic PAH and there were no significant difference between them. 
 153 
The difference in the PFT parameters between patients with and without PAH in 
relation to presence or absence of dyspnoea did not reach statistical significance.   
Association with lung disease: There was one patient (8%) in the PAH group and 11 
patients (5%) in the non-PAH group with pre-existing lung disease who underwent 
PFT. Again none of the parameters showed any significant difference between 
patients with and without PAH in relation to presence or absence of lung disease. 
Correlation of TLCO and sPAP: There was no correlation of TLCO predicted % 
with systolic pulmonary artery pressure (sPAP) in patients with SLE, including those 
with and without PAH in SLE. 
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Table 5-8 Pulmonary function test parameters in SLE patients with and without 
PAH. 
 SLE 
 
 
SLE without 
PAH 
(Group I) 
SLE with PAH 
 
(Group II) 
p value 
(Mann 
Whitney test 
comparing 
Group I and II) 
No.of patients 
who had PFT 
222 210 12  
FEV1, % 
predicted 
96 (21-143) 96 (21-143) 90 (43-128) 0.101 
FVC, % 
predicted 
103 (20-157) 103 (20-157) 96 (66-124) 0.435 
TLC, % 
predicted 
94 (36-156) 94 (36-156) 93 (56-127) 0.624 
TLCO, % 
predicted 
74 (16-127) 75 (16-127) 66 (36-100) 0.263 
KCO, % 
predicted 
85.5 (43-130) 85.5 (46-130) 84 (43-106) 0.492 
FEV1: Forced expiratory volume in 1 second. FVC: Forced vital capacity. TLC: Total 
lung capacity. TLCO: Total diffusion capacity. KCO: Transfer coefficient. 
Values are expressed as median and range in brackets. 
 155 
 
Figure 5-3 Box plot analysis of pulmonary function tests in SLE patients with 
and without PAH. 
 
Reference line drawn at 80%; FEV1: Forced expiratory volume in 1 second. FVC: 
Forced vital capacity. TLC: Total lung capacity. TLCO: Total diffusion capacity. 
KCO: Transfer coefficient. 
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Table 5-9 TLCO predicted % in association with normal TLC, FVC and FEV1 
predicted% values. 
 TLCO predicted % 
 SLE without PAH SLE with PAH 
 <80 <70 <60 <80 <70 <60 
No. of patients (%) 122 
(58) 
73 
(35) 
33 
(16) 
8 
(67) 
7 
(58) 
4 
(33) 
With FVC predicted >80%,  
No. of patients (%) 
90 
(43) 
46 
(22) 
13 
(6) 
7 
(58) 
6 
(50) 
3 
(25) 
With TLC predicted >80%,  
No. of patients (%) 
89 
(42) 
46 
(22) 
15  
(7) 
7 
(58) 
6 
(50) 
3 
(25) 
With TLC and FVC predicted 
>80%, No. of patients (%) 
80 
(38) 
40 
(19) 
11  
(5) 
7 
(58) 
6 
(50) 
3 
(25) 
With TLC, FVC and FEV1 
predicted 
 > 80%,  
No. of patients (%) 
73 
(35) 
 
35 
(17) 
10  
(5) 
3 
(25) 
2 
(17) 
1  
(8) 
FEV1: Forced expiratory volume in 1 second. FVC: Forced vital capacity. TLC: Total 
lung capacity. TLCO: Total diffusion capacity. KCO: Transfer coefficient. 
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5.4.3. Six minute walking test 
This test was performed by 11 patients in the PAH group and 266 patients in the non-
PAH group. The median distance walked in 6 minutes (6MWD) in PAH group was 
435 m (range 150-600 m) and in non-PAH group was 440.5m (range 60-729). Six 
patients were unable to perform this test due to walking difficulties, fatigue or refusal 
to perform it. There was no significant correlation between 6MWD and sPAP in 
either group.  
The pre-exercise fatigue score on modified Borg scale [Appendix 5] was 0 (no 
fatigue) in 71 (25%) patients, score 0.5-2 (mild fatigue) in 119 (43%), score 3 
(moderate fatigue) in 54 (19%) and score >4 (severe fatigue) in 34 (12%) patients 
with SLE. The fatigue and dyspnoea scores pre- and post-exercise were not 
significantly different between patients in the PAH and non-PAH group. 
The 6MWD correlated significantly with the total scores from all three respiratory 
questionnaires (modified MRC, BDI and SGRQ) (Figure 5-4, 5-5, 5-6) with spearman 
rank test p value of 0.0 for each questionnaire. Similar significance was also reached 
between 6MWD and NYHA functional classes. 
 158 
Figure 5-4 Scatter plot of correlation between six minute walking distance and 
modified MRC dyspnoea scale. 
 
MRC score 4 refers to sever dyspnoea and 0 refers to being asymptomatic. Spearman 
Rank test p value 0.0 
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Figure 5-5 Correlation of six minute walking distance and Baseline Dyspnoea 
Index (BDI) total score. 
 
BDI score 0 refers to severe dyspnoea and 12 refers to no dyspnoea with ordinary 
activities. Spearman Rank test p value 0.0 
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Figure 5-6 Scatter plot of correlation between six minute walking distance and 
St. George’s respiratory questionnaire (SGRQ) total score. 
 
SGRQ score 100 refers to severe dyspnoea and 0 refers to being asymptomatic. 
Spearman Rank test p value 0.0 
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5.5. Discussion 
 
5.5.1 Pre-existing lung disease  
In this study, the presence of pre-existing lung diseases had no predictive value for 
PAH in SLE. The lung diseases such as interstitial lung disease, pulmonary embolism, 
and pulmonary veno-occlusive disease can result in secondary PH in SLE. The low 
prevalence of these lung diseases (ILD in 2.4%, PE in 2.1% and PVOD in 0%) in this 
lupus cohort could have resulted in the lack of significant association of prior lung 
diseases and PAH in SLE. In a multiethnic US cohort(322). 7.3% had pulmonary 
damage after mean disease duration of 5.3 years based on SLICC/ACR damage scores 
recorded in 626 lupus patients. The pulmonary damage included pulmonary fibrosis 
in 3.9%, pleural fibrosis in 1.2%, pulmonary infarction and shrinking lung syndrome 
in 0.6% patients each and PH in 1.9% patients. Pan et al(169) reported the prevalence 
of secondary PH in SLE due to ILD and/or PE is 1.5% from a retrospective analysis 
on 786 SLE patients and also concluded both PAH and secondary PH in SLE is 
equally common with a prevalence of 3% each. 5/24 patients in that study had PH 
secondary to ILD. But in systemic sclerosis, the prevalence of PH (sPAP>40 mmHg) 
secondary to ILD was 18% and PH without ILD was 22% in a cohort of 197 
patients(324). There was no significant difference in the prevalence of PH between 
limited and diffuse type of systemic sclerosis. There is a lower prevalence of pre-
existing lung diseases in SLE compared to SSc that can predispose to secondary PH, 
and this is reflected in the low PH frequency both in this present study as well as US 
registry report. 
5.5.2 Smoking 
Two thirds of this cohort has never smoked, and there was no significant difference in 
the smoking status between patients with and without PAH. 
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5.5.3 Respiratory muscle strength 
The respiratory muscle weakness was present in 32% in this study cohort which is the 
largest SLE cohort where RMS has been assessed. This finding is of potential interest 
in SLE patients as it is the first time that respiratory muscle weakness has been 
quantified in a large cohort of SLE patients. The subgroup analysis showed 55% of 
patients with PAH and 31% without PAH in SLE had respiratory muscle weakness 
but the difference in MIP or MEP between the groups did not reach statistical 
significance. This is possibly due to small numbers and predominantly mild rise in 
sPAP in the PAH subgroup. Scano et al(325) reported mild reduction in respiratory 
muscle strength in 9 SLE patients, with median MIP 61 cmH2O (range 43-80 cmH2O) 
and median MEP 90 cmH2O (46-139 cmH2O). Jacobelli et al(233) described reduced 
MIP in more than 50% of their study patients In this present study, the corresponding 
values were much lower with median MIP 53 cmH2O (range 5-129 cmH2O) and 
median MEP 61 cmH2O (15-185 cmH2O). Though the median MIP and MEP values 
in this study  did not reach the values we defined for respiratory muscle weakness 
(<40 cmH20), they were much lower than the normal values published in studies 
using mouth flange type pressure meter(242) and relationship to age and sex (326). 
This would suggest our lupus cohort has moderate respiratory muscle weakness. The 
good correlation of BMI with respiratory muscle strength in this study suggests the 
association of low BMI with respiratory muscle weakness previously reported(327). 
Polymyositis, steroid myopathy, myasthenia gravis or myasthenia like condition, and 
peripheral neuropathy are other reasons considered in the respiratory muscle 
weakness in SLE(325). The concept of systemic fatigue and physical deconditioning 
leading to respiratory muscle fatigue can be considered in SLE patients with 
respiratory muscle weakness. In this study, the systemic fatigue score that was 
evaluated by modified Borg scale prior to 6MWT showed moderate or severe fatigue 
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in 32%, mild fatigue in 43% and no fatigue in 25%. The subanalysis (data not shown) 
showed that the correlation between fatigue scores and MIP (Spearman Rho test 
p=0.276) or MEP (Spearman Rho test p=0.215) were not significant. The difference 
in the fatigue scores between those SLE patients with and without inspiratory muscle 
weakness (Mann Whitney U test p=0.758) or expiratory muscle weakness (Mann 
Whitney U test p=0.290) was also not significant. These results in our SLE cohort 
shows there was no association between fatigue and respiratory muscle weakness. 
In our study, the strong correlation between MIP and MEP is irrespective of sPAP, 
exercise capacity or NYHA functional classes. Meyer et al(237) reported that IPAH 
related respiratory muscle weakness was associated with low MIP and low MEP and 
were independent of haemodynamic parameters, exercise capacity and NYHA 
functional class. It was also proposed in IPAH that respiratory muscle weakness could 
either be a cause or consequence of IPAH due to chronic overload of respiratory 
musculature. Congestive cardiac failure has been associated with reduced inspiratory 
muscle strength(328;329). Inspiratory muscle weakness is considered to be a 
prognostic predictor in CCF(238). Our cohort had only 2 patients with LVEF <50% 
and none had RV dysfunction. Overall, the mild nature of PAH in this study could 
have resulted in the lack of association of respiratory muscle weakness with PAH in 
SLE. 
5.5.4 Screening tests for PH  
An ideal screening test for PH in SLE would be a non-invasive test that could be done 
periodically in predisposed patients so that aggressive surveillance to diagnose or 
detect progression of PH is possible at the earliest possible stage. The lung function 
tests, 6MWT and respiratory questionnaires are the screening tests for PH in SLE 
patients discussed below. 
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5.5.4.1. Pulmonary function tests in SLE patients 
 Similar to previous studies(229;330-332), this study also showed an increased 
prevalence of abnormal PFT in SLE patients. Reduction of TLCO was the most 
frequent PFT abnormality noted in 130/222 patients (59%) as found in previous 
studies (discussed below). Seventy-six (34%) patients had isolated TLCO reduction, 
30 (14%) patients also had FVC reduction and 21 (9%) patients also had restrictive 
pattern with both FVC and TLC reduced. Overall in this lupus cohort, only 3/33 
patients with reduced FVC, 5/36 patients with reduced TLC, and 1/24 patients with 
both reduced FVC and TLC had normal TLCO. Any PFT abnormalities without 
reduced TLCO were seen in very few patients in this study. The median %predicted 
TLCO was 74% in this lupus cohort, 63% in those with dyspnoea and surprisingly 
47% in those with pre-existing lupus related lung disease. Other lung function test 
parameters including reduced FEV1, FVC and TLC reached statistical significance in 
those with dyspnoea or prior lung disease in lupus patients compared to those without 
these features. 
Since the early 70s, abnormal PFTs in SLE patients have been reported by several 
investigators. Reduced FVC in up to 60%, mostly accompanied with reduced TLCO 
was observed in earlier studies of smaller lupus cohorts(330;332). But larger cohorts 
and recent studies have reported reduced TLCO in 46-47% and reduced FVC in 8-
32% in unselected SLE cohorts(229;230). Paran et al(333) reported a low KCO of 
<70% was found in 41% of lupus patients who were asymptomatic. Chick et al(334) 
reported from a lupus cohort of 24 SLE patients that 90% had pulmonary dysfunction 
in the presence of lung disease and 71% in the absence of dyspnoea or history of lung 
disease. Grennan et al (330) reported 14/22 lupus patients had abnormal PFT and only 
29% of those  were symptomatic. Groen et al(304) showed that 40% had normal PFT, 
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10% had isolated TLCO reduction and 40% had restrictive defect in a cohort of 48 
SLE patients. Another study (332) on 43 SLE patients reported reduced TLCO in 
72% and reduced lung volumes in 49%. The possibility of subclinical respiratory 
dysfunction associated with reduced TLCO in a non-smoking cohort of SLE has also 
been reported previously(331). In this present study, the median TLCO predicted% 
was 74 (range 16-116) among 139 SLE patients who were non-smokers. 
In 2012, Allen et al reported on 110 SLE patients with abnormal lung function in 
66%, respiratory symptoms in 63% and shrinking lung syndrome in 10%. Previously 
in 2002, Nakano et al(229) reported on a Japanese cohort of 110 lupus patients with 
low TLCO in 47% and restrictive pattern with FVC <80% predicted in 8%. The 
prevalence of pulmonary fibrosis was 13% determined by clinical and/or chest x-ray 
or high resolution CT chest. Over 80% had abnormal PFT in the absence of clinical 
pulmonary disorder. They also noted that impaired TLCO was more prevalent in the 
presence of pulmonary fibrosis (PF) or with restrictive pattern PFT, and isolated 
TLCO reduction was seen in 39% in the absence of PF or restrictive defect. Our study 
results are very similar to that reported by the Nakano et al. The majority of patients 
in this present study were not dyspnoeic (85%) and were non-smokers (64%) and very 
few had prior restrictive lung disease (5%). This raises an important question if this 
subclinical impairment of pulmonary function, particularly in asymptomatic patients, 
has any prognostic value in predicting overt ILD.  
Sant et al(335) found increased prevalence of HRCT abnormalities (72%) in a lupus 
cohort of 29 SLE patients, and they were mostly ILD (38%) who often were 
asymptomatic (31%). Of those who were asymptomatic with a normal CXR and 
normal PFT, 26% were found to have HRCT evidence of ILD. Nakano et al(229) 
performed HRCT in addition to CXR in 110 SLE patients with ILD prevalence of 
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13%. Traynor et al(323) showed 33% prevalence of HRCT proven ILD and 81% of 
these patients were asymptomatic. Only 5 patients in our PFT study group had 
undergone HRCT making it difficult to draw any conclusion in this study. The 
possibility of subclinical ILD in SLE was thus considered highly prevalent in SLE 
which would partly explain the high prevalence of abnormal PFT seen in SLE. It is 
possible that abnormal lung function may contribute to hypoxic muscle fatigue in 
SLE patients. 
Disease activity and PFT in SLE patients: Both in adult(336) and paediatric lupus 
patients(337), disease activity was found to be inversely related to TLCO. In a cohort 
of 34 severe refractory SLE patients(323), improvement of PFT with stem cell 
transplantation was evident. Few other studies neither found this correlation(229;332) 
nor found an improvement with pulmonary function following control of disease 
activity. These variations of low TLCO with SLE disease activity could be due to the 
measure of SLE disease activity index used and the number of patients included in 
these studies.  In this study, we have shown a strong association of BILAG disease 
activity scores for haematologic involvement in patients with low predicted TLCO 
compared to those with normal predicted TLCO.  
Association of TLCO reduction to anti-RNP antibody(229;304) and Raynaud’s 
phenomenon(229) was not found in this study. However, a weak association of anti-
Sm antibody in patients with low TLCO found in this study needs further evaluation 
in a large cohort to confirm this association. 
5.5.4.2. PFT in SLE patients with PAH 
There was no significant reduction of TLCO in those with PAH (median predicted% 
TLCO was 66%) compared to those without PAH. None of the PFT parameters were 
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significantly different between patients with and without PAH in relation to dyspnoea 
or prior lung disease. In this cohort, we have been unable to show the role of PFT as a  
screening test for PH in SLE, but this could just reflect that the PAH cohort is small, 
and the prevalence of dyspnoea and prior lung disease are also minimal. 
Reduction in TLCO has been considered as a screening test for PAH in systemic 
sclerosis(116;117;338) and less often in IPAH(232). Ungerer et al(179) reported 
TLCO <40-55% in association with 87 SSc patients, and Steen et al(339) reported 
reduction in TLCO is a common finding in SSc and only 7% of those developed PH 
over a follow up of 5.4 years. Mukerjee et al(116) found positive predictive accuracy 
of TLCO <55% predicted to be adequate to diagnose advanced PAH but cannot be 
relied to exclude PH where the pre-test probability is high. The same study showed 
cutoff value of TLCO at 60% had sensitivity, specificity, positive predictive value and 
negative predictive value of 74%, 45%, 70% and 50% respectively. Chang et al(340) 
showed TLCO <50% predicted was associated with severe PH in SSc.  The consensus 
from UK PH centres includes DLCO evaluation in the annual screening for PAH in 
SSc and MCTD, and right heart catheterisation should be performed if DLCO <50% 
in absence of ILD. 
An isolated TLCO reduction in patients with SLE has been reported by several 
investigators. The UK PH centres registry reported that the reduction in TLCO is 
much worse in ILD related PH in SSc (mean 29%) and SSc related PAH (mean 41%) 
than SLE-PAH (mean 59%) from a cohort of 56, 259 and 28 patients in each disease 
group respectively. The same registry data showed that 86/484 (18%) patients with 
PH secondary to CTD were due to respiratory disease related and 2/3rds were SSc 
related ILD. In the US PAH registry, the reduction in TLCO was significant in CTD-
PAH compared to IPAH (mean 45% vs 64%), as well as SSc-PAH compared to SLE-
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PAH (mean 41% vs 53%). We have found that TLCO reduction in SLE does not 
differ between patients with and without PAH. This finding supports the previous 
study reports of low TLCO noted in SLE patients but the underlying cause of this and 
the clinical significance remains uncertain. 
Steen et al(338) reported that TLCO %predicted <55 or a ratio of FVC/TLCO (% 
predicted) >1.4 is strongly associated with PH in SSc. They also found serial 
measurements over 15 years prior to diagnosis of PH in limited SSc showed mean 
TLCO %predicted reduced from 80% to 35%. In this present study, we did not find 
any predictive value for TLCO<55% predicted, FVC/TLCO ratio >1.4 or FVC/TLCO 
>2.0 when assessing PAH in this SLE cohort but this may have been due to the 
relatively mild PAH and small numbers of patients with significant PAH. 
5.5.5. Six minute walking test 
Six minute walk test is a useful measure in the evaluation of exercise limitation in 
pulmonary hypertension which might predict the severity of PAH. In this study we 
did not find any correlation between distance walked in 6MWT and sPAP in patients 
with SLE as well as in subgroups with and without PAH. The difference between the 
median distances walked in both subgroups was also not significant. A strong 
association between 6MWD and dyspnoea scores and NYHA functional class was 
found in this SLE cohort. In this study, 85% were asymptomatic in the whole cohort 
and 75% in the PAH subgroup. This partly explains why patients with and without 
PAH do not have significant difference with the distance walked in 6MWT. Another 
plausible reason is the predominance of mild PAH with sPAP <40mmHg in 75% of 
the PAH subgroup. 6MWT is a well standardized and reproducible test. The 
prognostic significance of distance walked and oxygen desaturation in 6MWT has 
been shown in IPAH(341). Walking distance < 332 m(342) or <250 m(147), and 
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oxygen desaturation >10%(343) are considered poor prognostic indicators in PH that 
increases the mortality risk 2-3 times higher. 6MWD is also used to assess response to 
treatment in PH.  
5.5.6. Respiratory symptom questionnaires  
In this study cohort, 85.5% of patients were graded NYHA functional class I as they 
asymptomatic and had no limitations of activity for ordinary tasks. Among those with 
NYHA functional class I, the median modified MRC questionnaire was 1, median 
total BDI score was 10, and median SGRQ total score was 15.1 (median symptom 
score of 13.3, activity score of 29.5 and impact score of 5.95). These results suggest 
that few patients in NYHA functional class I category may have dyspnoea and that 
these respiratory questionnaires are very sensitive in identifying SLE patients with 
respiratory symptoms and/or limitations with activity. All the respiratory symptom 
questionnaires tested in this study did not reach statistical significance in 
differentiating patients with and without PAH. This result is not surprising given the 
low prevalence of PAH and predominantly mild PAH in our study cohort. This 
reflected in the scores calculated by modified MRC scale, BDI and SGRQ 
questionnaires and confirmed that only a minority had significant dyspnoea of severe 
grades. Only 3(25%) patients were dyspnoeic in the PAH group with one in NYHA 
class I and two in NYHA Class II. Modified MRC scale and BDI have been validated 
in COPD, with a change in scale by >1 unit being representative of clinically 
significant change. The SGRQ scores have also shown good correlation with 
spirometry, 6MWD and MRC scale in patients with airways disease(290;291). These 
observations supported our objective to study the screening potential of these 
questionnaires to predict PAH in SLE. In this present study, only few patients were 
dyspnoeic and predominantly had mild degree dyspnoea and patients with PAH were 
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infrequent and had relatively mild PAH. So, it is not possible to evaluate these 
questionnaires as screening tools for PAH in this SLE cohort. 
5.6. Conclusion 
 
 The prevalence of pre-existing restrictive lung disease in lupus was 5%. Two-third 
never smoked, and the patients were predominantly in NYHA functional class I 
(85%). Respiratory muscle weakness was present in one-third and a strong correlation 
existed between inspiratory and expiratory muscle pressures in SLE. There were no 
respiratory risk factors identified for PAH in SLE in this study. Pulmonary function 
tests in patients with SLE revealed low TLCO in 55% and isolated low TLCO in 
33%, and significant difference in all parameters noted between patients with and 
without dyspnoea or pre-existing disease. Pulmonary function test parameters, 6MWT 
distance, and respiratory questionnaires were not useful as screening tests for PAH in 
SLE in this cohort, with mild and infrequent PAH. 
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CHAPTER 6   BIOMARKERS IN SLE ASSOCIATED PAH 
 
6.1 Assessment of NT-proBNP concentration in SLE and PAH 
 
6.1.1 Abstract 
 
Hypothesis: High concentrations of serum NT-proBNP are associated with cardiac 
dysfunction due to pulmonary hypertension in SLE. 
Objective:  
1. To evaluate serum NT-proBNP levels in SLE cohort, and assess characteristics in 
those with high NT-proBNP levels 
2. To evaluate the role of NT-pro BNP as a screening test for PAH in SLE. 
2. To correlate serum NT-proBNP levels with parameters used in assessment of PAH 
severity in SLE including systolic pulmonary artery pressure, six minute walking test 
(6MWT) distance, pulmonary function tests and NYHA functional classes. 
Methods: We performed NT-proBNP assay on 81 lupus patients from our cohort 
including all 12 patients with PAH, 15 patients with systolic pulmonary artery 
pressure (sPAP) 26-30 mmHg, and 54 patients with sPAP <25 mmHg who were age 
and sex matched.  
Results: The median NT-proBNP concentrations in our lupus cohort were 88.3 (range 
5-1413) pg/ml. Five out of 25 patients with high NT-proBNP values had 
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echocardiographic diagnosis of PAH. High NT-proBNP levels were strongly 
associated with SLICC /ACR damage scores >2 (p=0.008) and disease duration (p= 
0.037).There was no statistical difference between the NT-proBNP concentrations in 
lupus patients with and without PAH. The subgroup analysis on patients with systolic 
PAP 26-30mmHg showed higher serum NT-proBNP concentrations in comparison to 
those with sPAP <25mmHg, but was also statistically insignificant. Among the PAH 
subgroup, the correlation between serum NT-proBNP concentration and (i) sPAP (ii) 
6MWT distance and (iii) pulmonary function test parameters were not statistically 
significant. 
Conclusion: Serum NT-proBNP concentration in lupus patients is higher than in 
general population. SLE patients with high NT-proBNP levels are associated with 
longer disease duration and higher cumulative damage scores. Elevated serum NT-
proBNP concentration is neither a significant predictor of PAH in our cohort, nor help 
in monitoring severity of PAH. 
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6.1.2 Introduction and Methods 
N-terminal pro-BNP has been shown to be a useful diagnostic marker of early PAH in 
patients with SSc(344). NT-proBNP is also a valuable prognostic marker in PAH and 
raised levels of NT-proBNP are directly related to severity of PAH in SSc(250) and 
idiopathic PAH(252). According to the manufacturer of the NT-proBNP assay, the 
normal reference range of NT-proBNP in adults is 64.7-278 pg/ml depending on age 
and sex. Please refer to section 1.3.7.1 for detailed introduction and section 2.7.4.1 for 
methods. 
Statistical methods: The variables were not normally distributed and thus non 
parametric tests have been used for statistical analysis. The variables are expressed as 
median and range, or mean and standard deviation (SD). The medians of the groups 
were compared using Mann Whitney U test (MWU test), as the distribution of 
variables were not of normal distribution. The correlation of continuous variables was 
tested with Spearman rank correlation coefficient test. The categorical variables were 
compared using two-sided Fisher’s exact test and Pearson’s chi square test. The 
statistical significance was set at p <0.05. 
6.1.3 Results 
The median serum NT-proBNP concentration in our selected 81 lupus patients was 
88.3pg/ml (range 5-1413pg/ml). The median age of these 81 patients was 44 years 
(range 30-82) and 89% were females. Raynaud’s was ever present in 70%. The racial 
distribution was 59% Caucasian, 22% Asian and 17% Afro-Caribbean. The median 
disease duration was 9.9 years (range 0.4-26.7, mean 10.2 years). 
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6.1.3.1. Comparison of SLE patients with and without high NT-proBNP 
levels 
Twenty five patients with SLE had high concentrations of NT-proBNP for their age 
and sex (median 334.9pg/ml, range 93.1-1413pg/ml). Their median age was 59 years 
(range 30-82) and 92% were females.  The difference in disease duration between 
patients with normal and high NT-proBNP levels reached statistical significance 
(median 9 years vs 11.6 years, p=0.037). The median SLICC/ACR damage score in 
those with high NT-proBNP was 2, range 0-6 (mean + SD: 02.17 + 2.01) compared to 
median 0, range 0-7 (mean + SD 0.87 + 1.33) in those with normal NT-proBNP levels 
(Mann Whitney U test p value 0.008) (Figure 6-1). The median NT-proBNP levels 
was118.9 pg/ml (range 12-1413 pg/ml) in those with SLICC score >2 compared to 
median 63.1 pg/ml (range 5-1387 pg/ml) in those with SLICC scores <2 (Mann 
Whitney U test p value 0.036). The SLICC/ACR damage score >2 was significantly 
associated with high NT-proBNP levels in our cohort (Fisher’s exact test p value 
0.037). There was a significant difference in the SLICC/ACR damage scores for 
cardiovascular system (MWU test p=0.045), respiratory system (MWU test p0.045) 
and premature gonadal failure (MWU test p=0.042) between patients with and 
without high NT-proBNP levels. There were no association between NT-proBNP 
levels and BILAG scores for individual systems including cardiorespiratory and renal 
systems. 
NT-proBNP levels correlated significantly with six minute walk distance (p=0.023), 
but there was weak association with sPAP (p=0.049) and no association with NYHA 
functional classes. In PFT’s, predicted TLCO% (p=0.014) and predicted TLC% 
(p=0.039) were statistically significant with high NT-proBNP levels (data not shown).  
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Figure 6-1 Error bar of SLICC damage score in SLE patients with and without 
high NT-proBNP levels* 
 
*NT-proBNP levels (mean and 95% CI) shown in SLE patients with and without high 
NT-proBNP levels 
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6.1.3.2. Comparison of NT-proBNP concentration in SLE patients with and 
without PAH 
The characteristics of SLE patients with and without PAH are shown in Table 6-1. 
The variables of PAH severity including all lung function test parameters, NYHA 
functional classes, six minute walk test distance, SLICC/ACR damage index scores 
(total and individual systems) and BILAG disease activity scores were not statistically 
different between groups. The scatter plots of NT-proBNP concentration according to 
NYHA subclasses in lupus patients with sPAP< 25mmHg, 26-30mmHg and 
>30mmHg shows most patients had either no dyspnoea or were in NYHA classes I 
and II (Figure 6-2). 
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Figure 6-2 NT-proBNP concentration (pg/ml) according to NYHA symptomatic 
subgroups and systolic pulmonary artery pressure (sPAP) subgroups 
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Table 6-1 Characteristics of SLE patients with and without PAH who underwent 
NT-proBNP assay 
Category SLE patients with PAH 
(n=12) 
SLE patients without 
PAH (n=69) 
Age (years) 45.5 (30-72) 42 (30-82) 
Sex (F:M)    (% of no. of patients)  92:8 88:12 
Disease duration (median, range in 
years) 
9.6 years (1.9-22.1) 9.9 years (0.4-26.7) 
Systolic PAP (median, range in 
mmHg) 
35 (31-59) 10 (5-30) 
NT-proBNP ( median, range in 
pg/ml) 
121.35 (12-878)  83.7 (5-1413) 
NYHA class I (No. of patients) 9 56 
NYHA class II (No. of patients) 1 10 
NYHA class III (No. of patients) 2 2 
NYHA class IV (No. of patients) 0 1 
6MWT ( median, range in meters) 
(n= number of patients) 
435 (150-600) (n=11) 450 (60-609) (n=67) 
FVC % predicted (n=67) 96 (66-124) 102 (23-143) 
TLCO %predicted (n=68) 66 (36-100) 73 (44-112) 
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KCO %predicted (n=68) 84 (43-106) 84 (52-122) 
SLICC damage score (median, 
range) 
1 (0-7) 1.5 (0-5) 
SLICC-CVS Score (no. of patients 
scoring 0/1/2)  
11/0/1  64/4/1  
SLICC-RS Score (no. of patients 
scoring 0/1/2) 
10/1/1  63/5/1  
BILAG cardiorespiratory (no. of 
patients in Group A/B/C/D/E ) 
0/0/4/47/17 
 
0/0/2/8/2 
 
No. of patients with NT-
proBNP>125pg/ml (%) 
6 (50%) 22 (31%) 
No. of patients with NT-
proBNP>150pg/ml (%) 
5 (41%) 16 (23%) 
No. of patients with NT-
proBNP>395pg/ml (%) 
3 (25%) 8 (12%) 
None of the variables were statistically different between groups except the sPAP as 
expected. NYHA- New York Heart association functional class. 6MWT- six minute 
walk test. SLICC- Systemic Lupus International Collaboration clinics damage score. 
BILAG- British Isles Lupus Assessment Group. n: Number of patients. Variables are 
expressed as counts, or median and range. 
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The distribution of NT-proBNP concentrations in patients with and without PAH is 
shown in Figure 6-3. There was no statistical difference between NT-proBNP levels 
in SLE patients with and without PAH (median 121.3pg/ml vs 83.7pg/ml 
respectively). The number of patients with high NT-proBNP levels in each age and 
sex category was also not significant between both groups (Table 6-2). Interestingly, 
the subgroup analysis of those with sPAP 26-30mmHg (n=15) showed higher NT-
proBNP values (median 137.6 pg/ml, range 15.8-642.3 pg/ml) compared to those with 
sPAP <25mmHg (n=54, median 70.75 pg/ml, range 5-1413pg/ml). Patients with high 
NT-proBNP levels were strongly associated with systolic PAP 26-30mmHg compared 
to those with sPAP <=25mmHg (p=0.027). 
PAH was present in 11/72 females and 1/9 males in the cohort for NT-proBNP 
analysis. The difference in NT-proBNP levels in men and women with SLE also did 
not reach statistical significance (Table 6-3). 
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Figure 6-3 NT-proBNP concentration in SLE patients with and without PAH 
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Table 6-2 Analysis of relationship of PAH and NT-proBNP in different sex and 
age groups. 
 BNP normal for age 
(no. of patients) 
BNP high for age 
(no. of patients) 
P value 
 PAH absent PAH present PAH absent PAH present  
Age<50 
female 
(n=50) 
35 5 8 2 0.62 
Age <50 
male (n=4) 
2 0 1 1 1.0 
Age50-59 
female (n=4) 
3 0 0 1 0.25 
Age50-59 
female (n=3) 
3 0 0 0 NS 
Age>60 
female 
(n=18) 
4 2 11 1 0.24 
Age>60 
male (n=2) 
2 0 0 0 NS 
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Table 6-3 NT-proBNP concentrations in male and female patients with SLE. 
 NT-proBNP levels in 
females (n=72),  
Median (range) in pg/ml 
NT proBNP levels in 
males (n=9),  
Median (range) in pg/ml 
SLE without PAH (n=69) 89.1 (5-1413) 48.7 (11.3-118.9) 
SLE with PAH (n=12) 114.4 (12-1878)  197.6  
Number of patients in each subgroup. Mann Whitney U test p value- 0.12 in males, 
and 0.57 in females. 
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6.1.3.3 Correlation of NT-proBNP levels with parameters of PAH severity 
in SLE patients with and without PAH 
The NT-proBNP levels do not correlate with sPAP and ejection fraction calculated by 
echocardiogram, 6MWT distance, NYHA functional class and pulmonary function 
test parameters including FEV1, FVC, TLCO, KCO and TLC (percentage predicted 
values) in both subgroups of lupus patients, with and without PAH (Table 6-1).  
6.1.4 Discussion 
Our study revealed that patients with SLE have higher concentrations of serum NT-
proBNP, similar to findings in other lupus cohorts(253;345) which were published 
after our study period. In comparison to the median NT-proBNP concentration of 
89pg/ml in our SLE cohort, the expected median for age and sex matched healthy 
population is 50pg/ml. Also the median NT-proBNP concentration of the lupus 
patients with high NT-proBNP subgroup was considerably higher at 335pg/ml. In 
comparison, the expected median NT-proBNP level in similar aged females (median 
50-59 years) is 66pg/ml according to assay manufacturer’s evaluation of NT-proBNP 
level in blood donors (Elecsys Systems E170 proBNP assay 03121658122, Roche). 
The limitation of this study is the lack of control group to compare the NT-proBNP 
levels in SLE patients. 
It is well established that plasma NT-proBNP concentration is a diagnostic, 
monitoring and prognostic biomarker for heart failure(346;347). NT-proBNP is also 
shown to be a useful biomarker to stratify cardiovascular risk in general population 
even in those without known cardiac disease(348) or overt clinical heart failure. This 
finding has also been shown in patients with rheumatoid arthritis (349) and SLE 
(253;345;350). In our study there were no significant association between NT-
proBNP levels and echo parameters of cardiac failure such as left ventricular ejection 
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fraction and RV dysfunction (data not shown). With regards to individual system 
scores for cardiac and respiratory system, NT-proBNP level had a weak association 
with SLICC/ACR damage scores (p=0.045) but no association with BILAG disease 
activity scores for these systems. This raises the possibility if lupus patients with high 
NT-proBNP level have in fact undiagnosed cardiac disease or increased susceptibility 
to cardiac disease. Goldenberg et al have recently published the role of NT-proBNP 
as a marker of cardiac disease and not vascular disease in SLE patients (350).   
Chambers et al(351) followed up SLE patients for >10 years and reported 
SLICC/ACR damage accrual is associated with increased risk of mortality. In 
particular, pulmonary and renal damage scores accrual have been shown to predict 
poor outcomes (79). This study has shown a strong association of SLICC/ACR 
damage scores (overall) greater than 2 with high NT-proBNP levels. It is possible that 
NT-proBNP could predict damage accrual and indirectly morbidity and mortality in 
SLE patients but further studies are needed to confirm this finding. Plasma BNP and 
NT-proBNP have potent independent association with mortality in patients with 
IPAH(252) and systemic sclerosis associated PAH(250). 
This study was performed in 2007 and was the first to assess the screening potential 
of NT-proBNP for PAH in SLE, but failed to show any benefit with screening for 
PAH. This could be the effect of smaller group of SLE-PAH patients. Little is known 
about the potential use of BNP and NT-proBNP in lupus, and the literature 
predominantly reports on association of NT-proBNP with cardiac atherosclerotic 
disease in lupus. The significance of NT-proBNP as a diagnostic marker of early PAH 
has been established in systemic sclerosis and IPAH but not for SLE patients. The 
PAH registry from USA compared BNP values (pg/ml)) in a cohort of 59 patients 
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with SLE (263.8+/-338.8) and 179 SSc patients with SSc (552.2+/-977.8pg/ml) and 
the difference was statistically significant (p=0.0004). The markedly elevated levels 
of BNP were specifically seen in SSc associated PAH, unlike other CTD associated 
PAH such as SLE and MCTD as well as IPAH. The high prevalence of myocardial 
fibrosis and renal insufficiency were speculated as reasons for this marked levels of 
BNP in SSC-PAH though not studied specifically in the US registry.  
The correlation of NT-proBNP to pulmonary pressures in IPAH and SSc associated 
PAH has led to the use of NT-proBNP in monitoring progression of PAH. The non-
invasive, inexpensive and convenient testing of NT-proBNP helps to avoid 
unnecessary repeated invasive right heart catheter studies in monitoring PAH. In our 
study, the very weak association in the correlation of NT-proBNP level and sPAP for 
the whole SLE cohort (p=0.049) did not reach statistical significance in the SLE-PAH 
subgroup (data not shown). This could be a reflection of most patients in PAH group 
had mild PAH, with 75% of patients having sPAP 30-40mmHg. Similarly, the 
correlation was significant between NT-proBNP and distance walked in six minute 
test for the whole SLE cohort (p=0.023) but was not significant in subgroup analysis 
of SLE patients with and without PAH. NYHA functional classes help identify 
patients with significant limitation of function secondary to cardio-respiratory 
symptoms. However this limitation in function in SLE could relate not just to cardiac 
and respiratory diseases but also due to musculoskeletal manifestation, fatigue, and 
other systemic involvement. I did not find any significant correlation between NT-
proBNP level and NYHA classes. This could be due to patient numbers in NYHA III 
and IV classes were very few or none. Overall, none of  the PAH severity parameters 
including sPAP, 6MWT distance, NYHA functional classes and lung function test 
parameters do not correlate with NT-proBNP level in our SLE-PAH subgroup 
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analysis. This may reflect the low numbers of PAH patients and the relatively low 
pulmonary artery pressures they had.  
SLE patients are at high risk of atherosclerotic disease despite absence of other 
cardiovascular risk factors. The good correlation of longer disease duration (p=0.037) 
and higher SLICC scores (p=0.017) with high NT-proBNP levels in our whole SLE 
cohort could well be a reflection of longer exposure to inflammatory disease with 
resultant damage accrual and increasing the susceptibility for ischemic myocardial 
disease. It is important to note the absence of BILAG disease activity ‘A’ and 
‘B’scores as well as minimal cardiorespiratory SLICC/ACR damage scores recorded 
in our cohort does not exclude subclinical atherosclerotic disease.  The prevalence of 
high NT-proBNP level is considerably high around 40% both in SLE patients with 
and without PAH in our study.  The interesting and potential question to answer in 
future prospective studies in SLE patients would be to understand the reasons for 
elevated NT-proBNP concentration and its value in identifying cardiac disease earlier 
in SLE. In 2008, Chung et al(253) reported on113 SLE patients comparing with 80 
controls and found high concentrations of NT-proBNP in SLE patient but did not find 
any association with atherosclerotic burden, augmentation index or inflammatory 
state in SLE. In 2012 another report on 124 SLE patients concluded high NT-proBNP 
levels in SLE (median 82.5pg/ml) similar to our study result (median 88.3pg/ml) and 
reported NT-proBNP to be a marker of ventricular dysfunction but not 
atherosclerosis, however in our study the number of patients with ventricular 
dysfunction was very low (see Chapter IV, table 4-2,4-3). 
I have shown that patients with sPAP<25mmHg are different from those with sPAP 
26-30mmHg with regards to normal and high NT-proBNP level. Though patients in 
both subgroups do not fulfil diagnostic criteria for PAH by echocardiogram, the 
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significantly increased number of patients with high NT-proBNP level in the latter 
group (p=0.027) suggests the need for evaluating NT-proBNP in stratifying risk for 
PAH in this borderline group.  Thakkar et al(352) have reported recently on patients 
with systemic sclerosis who are at high risk for PAH and have proposed screening 
algorithm for PAH combining NT-proBNP > 209.8pg/ml, TLCO<70% and 
FVC/TLCO>1.82 as cut-off for high risk for PAH.  
The association of TLCO predicted % and TLC predicted % in patients with high NT-
proBNP levels, especially with only 5 patients in the cohort with SLICC/ACR 
pulmonary damage scores >0 (mean 1.2) is intriguing. Further evaluation of lung 
function test parameters either alone or in combination with NT-proBNP level in a 
larger SLE cohort with PAH or with high risk for PAH would help identify their 
screening potential for PAH.  Allanore et al (353) have reported from a prospective 
cohort of SSc patients that NT-proBNP level and pulmonary function test parameter 
KCO are independent predictors of PAH.  
6.1.5 Conclusion 
Our study confirms high levels of serum NT-proBNP are seen in SLE patients without 
overt cardiac disease or cardiac failure. High NT-proBNP level in SLE have a strong 
association with SLICC damage scores> 2 and longer disease duration. I have shown 
that high levels of NT-proBNP neither have a screening nor monitoring potential in 
mild PAH associated with SLE but this needs further studies in larger cohorts of SLE-
PAH with more severe PAH disease. 
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6.2. Fractalkine in SLE 
 
6.2.1 Abstract 
 
Hypothesis: Inflammation plays a role in the pathogenesis of PAH associated with 
SLE. 
Objective:  
1. To determine soluble Fractalkine(sFkn) concentration in patients with SLE 
2. To compare sFkn concentration in SLE patients with and without PAH 
3. To assess relationship of sFkn levels with BILAG disease activity scores and 
SLICC/ACR organ damage scores 
4. To assess relationship of sFkn concentration with lupus disease activity 
monitoring tests such as dsDNA titre and complement C3 and C4 levels and 
other autoantibodies associated with SLE. 
Methods: We performed sFkn assay by sandwich ELISA method in all our 283 
patients with SLE. The mean cut-off point for detection of plasma sFkn was 
0.57ng/ml, and those below this sFkn concentration were recorded undetectable by 
this assay. 
Results: Forty five patients (15.9%) with SLE had detectable levels of sFkn with 
median concentration of 1.653ng/ml (range 0.559-18.114). The sFkn levels were 
detected in 25% patients with PAH and 15.5% patients without PAH. There was no 
significant difference between sFkn concentration in lupus patients with and without 
PAH.  Though the association of sFkn with BILAG disease activity scores for 
vasculitis (p= 0.036) reached statistical significance, it is unlikely to be of clinical 
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significance because none scored BILAG “A” and 2 patients in each group scored 
BILAG ‘B’. The association of sFkn with anti-Ro antibody (p=0.042) reached 
statistical significance.    
Conclusion: Soluble Fractalkine concentration is increased in patients with SLE and 
maybe a serological biomarker for active vasculitis in SLE but more patients with 
active disease are needed to confirm this finding. sFkn is not associated with PAH in 
SLE. 
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6.2.2 Introduction and Methods 
Please refer to section 1.3.7.2 for detailed introduction and section 2.7.4.2 for 
methods. The reference value of soluble Fractalkine in healthy controls is 
0.003+0.003 ng/ml (mean+standard error of mean) (256). 
Statistical methods 
The continuous variables were expressed as median and ranges, and/or mean +/- 
standard deviation (S.D). Non-parametric tests were used as the variables were not 
normally distributed. The comparison between groups was performed using Mann 
Whitney U test, and the correlation between variables were performed using 
Spearman Rank correlation test. The categorical variables were compared between 
groups using Fisher’s exact (2 sided) or Pearson’s chi-square tests. The p value<0.05 
was considered significant. 
6.2.3. Results 
Among the 283 lupus patients in our study, 91% were females, median age 41 years 
(range 22-75) and median disease duration of 10.2 years (range 0.1-27.6 years) 
Forty-five out of 283 patients with SLE (15.9%) had detectable levels of sFkn. The 
sFkn levels were raised in 42 (25%) and 3 (15.5%) patients with and without PAH 
respectively (p=0.4). The median plasma sFkn concentration for the whole cohort was 
0 ng/ml (range 0-18.1 ng/ml) and mean +S.D was 0.54+0.12 ng/ml. Though the 
median sFkn concentration in lupus patients with and without PAH was 0 ng/ml, the 
mean sFkn concentration in lupus patients were higher in those with PAH (mean 
+SD, 0.79+0.65ng/ml) than without PAH (mean +SD, 0.53+0.12ng/ml; p=0.413). The 
difference in median sFkn concentration between patients with and without PAH was 
not significant (Table 6-4).  
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The detectable sFkn levels were associated with BILAG disease activity scores only 
for vasculitis in SLE (p=0.036), but all other organ system scores did not reach 
statistical significance with sFkn. The overall SLICC/ACR damage score and 
individual organ damage score analysis showed no relationship with sFkn levels.  
The correlation of sFkn levels with dsDNA titre, complement C3 and C4 were also 
not significant. Among the autoantibody associations, anti-Ro antibody was the only 
autoantibody that reached statistical significance with sFkn levels (p=0.042). 
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Table 6-4 Characteristics of SLE patients with and without PAH who underwent 
plasma sFkn assay. 
 SLE 
 
SLE without 
PAH  
SLE-PAH 
 
p value 
(Mann 
Whitney U 
test unless 
specified) 
No. of SLE patients 
underwent sFkn assay , 
no. of patients 
283 271 12 - 
sFkn detected, no. of 
patients(%) 
45 (15.9%) 42 (15.5%) 3 (25%) 0.413 
(Fisher’s) 
Age (years) 41 (18-82) 41 (18-82) 45.5 (30-72) 0.22 
Sex (M:F) 266:17 255:16 11:1 - 
Disease duration (years) 8.7 (0-32) 8.6 (0-32) 9.6 (1.9-
22.1) 
0.95 
sFkn concentration 
,median and range 
(ng/ml)  
[mean+SD in ng/ml) 
0 (0-
18.114) 
 
[0.54+0.12] 
0 (0-18.114) 
 
[0.53+1.2] 
0 (0-7.867) 
 
[0.79+2.25] 
0.433  
Systolic PAP, mmHg 9 (5-46) 8.9 (5-29) 37 (32-46) 0.00 
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C3 (g/l) 1.11  
(0.16-2.68) 
1.11 
(0.16-1.68) 
0.97 
(0.77-1.27) 
0.071  
C4 (g/l) 0.2 
(0.04-0.68) 
0.2  
(0.04-0.68) 
0.17 
(0.11-0.40) 
0.499  
dsDNA titre (kU/l) 20 (7-3887) 20 (7-3887) 109.5 (12-
446) 
0.083  
Variables expressed in median and range and unless specified. sFkn- serum 
Fractalkine 
p value- comparison between groups of SLE patients with and without PAH.  
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Table 6-5 Characteristics of SLE patients with and without raised plasma sFkn 
levels. 
 Plasma SFkn 
elevated 
Plasma sFkn 
undetectable 
p value (Mann 
Whitney U test 
unless 
specified) 
No. of SLE patients (n) 45 238  
Age (years) 41.5 (18-82) 41 (22-75)  
Sex (Male: Female) 41/4 225/13  
Disease duration (years) 10.2 (0.1-27.6) 8.35 (0-32) NS 
Plasma sFkn levels , 
median and range (ng/ml) 
mean + S.D 
1.653 (0.559-
18.114) 
(0.54 + 1.94) 
-  
dsDNA titres 20 (12-245) 20 (7-3887) NS 
Complement C3 (g/l) 1.15 (0.6-1.71) 1.1 (0.16-2.68) NS 
Complement C4 (g/l) 0.23 (0.05-
0.48) 
0.2 (0.04-0.68) NS 
BILAG neurologic disease 
(score A/B/C/D/E) 
0/0/1/30/14 
(n=45) 
0/1/10/150/73 
(n=234) 
NS 
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BILAG vasculitis 
(score A/B/C/D/E) 
0/2/1/29/13 0/2/32/150/50 0.036 (Pearson 
Chi-square 
Anti-Ro antibody, no.of 
patients positive 
23 (51%) 79 (33%) 0.042 (Fisher’s 
exact test) 
Variables expressed as counts, median and ranges; BILAG: British Isles lupus 
assessment group; NS- Not significant 
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6.2.4. Discussion 
In this study, I have shown that raised sFkn levels are not associated with PAH in 
SLE. Thus, sFkn levels do not have a significant role in the screening for PAH risk in 
SLE. As the absolute concentration of sFkn is higher in the PAH group compared to 
the non-PAH group in SLE, I performed sub analysis only on patients with detectable 
sFkn and found that the mean (+SD) levels were 3.15 (+4.1) ng/ml and 3.4(+3.8) 
ng/ml in both groups respectively with no significant difference.  
Fractalkine is considered to play a role in the pulmonary vascular remodelling in 
PAH. This was evidenced in laboratory research by increased expression of 
Fractalkine in the inflammatory cells surrounding pulmonary arterial lesions and 
smooth muscle proliferation(254). A subset of IPAH patients have been shown to 
have circulating autoantibodies as well as elevated levels of circulating  
proinflammatory cytokines and chemokines including sFkn(354). In particular, it is 
thought that inflammation plays a significant role in subsets of PAH associated with 
SLE and human immunodeficiency virus (HIV). Thus I aimed to test the hypothesis 
that inflammatory chemokine Fractalkine is associated with PAH in SLE. But my 
study has not shown a significant association between Fracktalkine and PAH in SLE, 
which could be due to very few patients in the PAH subgroup who predominantly had 
mild PAH. 
Yajima et al(256) reported that serum sFkn levels were higher in SLE compared to 
rheumatoid arthritis or healthy controls, and the sFkn levels among 67 SLE patients re 
452+118 pg/ml (mean + standard error of mean, SEM). Similarly, Sato et al(255) 
reported increased sFkn levels in SLE compared to RA and primary Sjogren’s 
syndrome. In comparison, the mean + SEM in our study with 283 SLE patients were 
540+120 pg/ml confirming similar raised levels of sFkn in SLE. 
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There are only a few studies which have assessed the relationship of sFkn in SLE 
(255;256;355). They have all reported on the significant correlation of sFkn levels in 
cerebrospinal fluid (CSF) but not serum sFkn levels with neuropsychiatric 
involvement in SLE (NPSLE). This follows the evidence that Fractalkine is found in 
inflammatory brain disease(356). Sato et al also reported serum sFkn levels were 
higher in those with NPSLE than those without NPSLE. The role of sFkn as a 
serologic marker of NPSLE disease activity and organ damage in patients with SLE 
as well as the reduction of sFkn levels with treatment of NPSLE are notable(256). In 
this study, I did not find any significant correlation of plasma sFkn level with 
neurologic disease activity scores (BILAG) or SLICC/ACR damage scores for 
NPSLE. This could be due to minimal number of patients having active NPSLE. 
There was only one patient with BILAG “C” score and none in “A” or “B” score in 
neuropsychiatric system in those with raised sFkn (Table 6-5). There were 
approximately 15% who had SLICC/ACR damage scores>0 with NPSLE in patients 
with and without raised sFkn levels (6 and 39 patients with mean score 1.33 vs 1.39 in 
each group respectively).  Interestingly, I found a significant association between 
sFkn levels and BILAG disease activity scores for lupus vasculitis. This fits in with 
active and inflammatory disease in association with sFkn. It has previously been 
shown that active SLE patients have higher sFkn levels compared to inactive SLE 
patients. The BILAG disease activity scores for vasculitis included none with ‘A’ 
score and only 2 patients with “B” score in each group, which would suggest the 
statistical significance noted in our study would need confirmation in a future study 
including more lupus patients with active vasculitis. 
I also found that anti-Ro antibody is significantly associated with raised sFkn levels. 
There has been no previous report of such an association with sFkn. Sato et al showed 
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sFkn levels in serum positively correlated with dsDNA titre, anti-Sm antibody, 
immune complex C1q levels and negatively correlated with CH50((256).  I did not 
find any correlation of sFkn with dsDNA titres or complement C3 and C4 levels. 
6.2.5. Conclusion 
Plasma Fractalkine levels were found to be raised in 15.9% of SLE patients. The 
elevated sFkn level was similar to previous reports on plasma sFkn level in SLE 
which were higher than RA. There was lack of association for plasma sFkn with PAH 
in SLE. The weak statistical association of active lupus vasculitis and anti-Ro 
antibody with sFkn needs confirmation with a larger cohort of active vasculitis 
patients in future. 
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6.3. Vascular Endothelial growth factor (VEGF) in SLE and 
PAH 
6.3.1 Abstract 
Hypothesis: Inflammation plays a role in the pathogenesis of PAH associated with 
SLE. 
Objective:  
1. To evaluate plasma VEGF concentration in patients with SLE 
2. To compare plasma VEGF concentration in SLE patients with and without 
PAH 
3. To assess relationship of VEGF level with BILAG disease activity scores and 
SLICC/ACR organ damage scores 
4. To assess relationship of plasma VEGF concentration with lupus disease 
activity monitoring tests such as anti-dsDNA antibody titre and complement 
C3 and C4 levels, and other autoantibodies associated with SLE. 
Methods: We performed plasma VEGF immunoassay by ELISA method on 81 lupus 
patients from our cohort including all 12 patients with PAH, 15 patients with systolic 
pulmonary artery pressure (sPAP) 26-30 mmHg, and 54 patients with sPAP <25 
mmHg who were age and sex matched.  
Results: The median plasma VEGF concentration in our lupus cohort was 103 pg/ml 
(range 48-610 pg/ml). The median (range) plasma VEGF concentration in patients 
without and with PAH was 103 pg/ml (64-513) and 109 pg/ml (48-610) respectively 
(p=0.26). There was no correlation of VEGF concentration with systolic pulmonary 
artery pressure, anti-dsDNA antibody titres, complement C3 and C4 levels, and 
SLICC/ACR damage scores. The difference between plasma VEGF level in lupus 
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patients with active and inactive disease by BILAG scores was borderline significant 
for musculoskeletal system activity (p=0.033). 
Conclusion: Plasma VEGF concentration in lupus patients is higher than in general 
population. Patients with and without PAH in SLE do not show difference in VEGF 
concentration.  
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6.3.2 Introduction and Methods 
According to the manufacturer of VEGF assay used in this study, the reference range 
of VEGF levels I EDTA plasma is 0-115 pg/ml. Please refer to section 1.3.7.3 for 
detailed introduction and section 2.7.4.3 for methods. 
Statistical Methods: 
The variables tested were not normally distributed. The continuous variables were 
expressed as median and ranges. Thus comparison of continuous variables between 
groups was performed using Mann Whitney U test, and the correlation between 
variables were performed using Spearman Rank correlation test. The categorical 
variables were compared between groups using Fisher’s exact (2 sided) or Pearson’s 
chi-square tests. The p value<0.05 was considered significant. 
6.3.3. Results 
There were detectable levels of plasma VEGF in all lupus patients in this study. The 
median plasma VEGF concentration in our selected 81 lupus patients was 103 pg/ml 
(48-610 pg/ml) and their mean + S.D was 133.9 + 92 pg/ml. The median age of these 
81 patients was 44 years (range 30-82), median disease duration was 9.9 years (range 
0.4-26.7 years) and 89% were females.  
The median plasma VEGF concentration in lupus patients with PAH was109 pg/ml 
(range 48-610 pg/ml) and in patients without PAH was 103 pg/ml (range 64-513 
pg/ml) (Figure 6-4). There was no statistical difference between the plasma VEGF 
level between groups with and without PAH in SLE (p=0.264). The distribution of 
plasma VEGF concentration and sPAP in SLE patients is shown in Figure 6-5. 
The correlation of plasma VEGF level with BILAG disease activity scores and 
SLICC/ACR damage scores in our cohort did not reach statistical significance. In 
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lupus patients with PAH, plasma VEGF level had significant negative correlation 
with BILAG disease activity scores for cardiorespiratory system (Spearman rank test 
p=0.010). In patients without PAH, plasma VEGF has a weak negative correlation 
with BILAG scores for musculoskeletal system (p=0.045). None of the patients 
scored BILAG ‘A’ or ‘B’ in the cardiorespiratory system. One patient scored BILAG 
‘A’ and 8 patients scored BILAG ‘B’ in the musculoskeletal system of which only 
one patient with score ‘B’ had PAH.  To verify these correlation tests between VEGF 
level and BILAG score, I also performed an analysis comparing lupus patients 
grouped together as active (BILAG scores A or B) and inactive (BILAG scores C, D 
or E), and performed sub-analysis in patients with and without PAH. The only 
significant difference in the median plasma VEGF level between active and inactive 
SLE groups was for the musculoskeletal system in the BILAG disease activity scores 
(Table 6-6). However, this significance was weak (Mann Whitney U test p=0.036) 
and the median plasma VEGF level were higher in the inactive group (76 pg/ml) 
compared to the active group (107.19 pg/ml). In the sub-analysis for patients with and 
without PAH, similar weak association was present only for musculoskeletal system 
activity in the non-PAH subgroup (Mann Whitney U test p=0.033) 
The plasma VEGF level did not correlate with systolic PAP (Figure 6-5), anti-dsDNA 
antibody and complement C3 and C4 levels. There was no association of plasma 
VEGF level with autoantibodies related to SLE. 
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Table 6-6 Plasma VEGF level in lupus patients with active and inactive disease 
by BILAG scores. 
Systems involved Inactive SLE 
(BILAG score C,D 
or E) 
Active SLE 
(BILAG score A or 
B) 
p value comparing 
active and inactive 
SLE groups (Mann 
Whitney U test) 
General, median 
pg/ml (range) 
[No .of patients] 
103.96 (49-610) 
[80] 
- 
[0] 
 
Mucocutaneous, 
median pg/ml 
(range)  
[No .of patients] 
103.82 949-610)  
[75] 
104.09 (67-174)  
[5] 
0.796 
Neurological, 
median pg/ml 
(range)  
[No .of patients] 
103.96 (49-610)  
[80] 
- 
[0] 
 
Musculoskeletal, 
median pg/ml 
(range)  
[No .of patients] 
 
107.19 (49-610)  
[71] 
76.34 (64-146)  
[9] 
0.036* 
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Cardiorespiratory, 
median pg/ml 
(range)  
[No .of patients] 
103.96 (49-610)  
[80] 
- 
[0] 
 
Vasculitis, median 
pg/ml (range)  
[No .of patients] 
103.82 (49-610)  
[79] 
- 
[1] 
0.398 
Renal , median 
pg/ml (range)  
[No .of patients] 
103.96 (49-610)  
[74] 
108.18 (92-301)  
[6] 
0.381 
Haematological, 
median pg/ml 
(range)  
[No .of patients] 
106.4 (49-610)  
[66] 
96 (70-322)  
[14] 
0.352 
* p value <0.05 
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Figure 6-4 Box plot graph of plasma VEGF concentration (pg/ml) in SLE 
patients with and without PAH. 
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Figure 6-5 Scatter plot graph of plasma VEGF concentration (pg/ml) and systolic 
pulmonary artery pressure (mmHg) in SLE patients. 
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6.3.4. Discussion 
I have shown that plasma VEGF level in SLE (median103 pg/ml, range 48-610 
pg/ml) are higher than in the general population as described by the VEGF assay 
manufacturer ((R&D systems, Abingdon, UK). The mean (S.D) serum VEGF level in 
10 healthy controls was 330 (84) pg/ml in another study on 15 patients with SLE 
patients with PH(269). In an oncology study with a cohort of 300 patients, the median 
serum VEGF level in 145 healthy individuals were 294 pg/ml (range 30-1752 
pg/ml)(357). I measured plasma VEGF as it has been considered that serum VEGF 
level could be spuriously high due to platelet release of VEGF during blood clotting. 
It has been reported previously that SLE patients have higher level of plasma VEGF 
and serum VEGF compared to controls. Navarro et al (266)showed that the median 
plasma VEGF level in 28 SLE patients was 70 pg/ml (range 5-341pg/ml) compared to 
23 pg/ml in 24 healthy controls. Robak et al(260) reported elevated plasma VEGF 
level in a cohort of 52 SLE with a median of 152.5 pg/ml (range 5-916 pg/ml). In 
another study of children and adolescents with SLE(358), the mean serum VEGF 
level in SLE was 579 pg/ml compared with 113 pg/ml in healthy controls. These 
studies on lupus patients confirm the VEGF levels are higher in serum compared to 
plasma. Our study suggests the high plasma VEGF level seen in SLE patients and is 
in fact higher in our cohort than the levels previously reported by Navarro et al. The 
limitation of this study is the lack of control group to compare the VEGF level seen in 
our SLE cohort. 
However, I have not been able to show any difference in the concentration of VEGF 
levels between lupus patients with and without PAH. It has been debated if VEGF is 
protective or deleterious in PH, given that VEGF levels have been present both in 
normal pulmonary circulation and pathogenic lesions of PAH. Moreover, elevated 
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VEGF has been reported both in patients with PH as well as those receiving 
continuous prostacyclin infusions. In our study, the small numbers of patients in the 
PAH subgroup and that most patients had mild PAH could have been the reason for 
the lack of difference in the median between lupus patients with and without PAH. 
Our study cohort did not have any significant difference in the plasma VEGF 
concentration between active (BILAG score A or B) and inactive (BILAG score C, D 
or E) disease subgroups (Table 6-6). The difference in the plasma VEGF level 
between active and inactive disease in the musculoskeletal system suggested that 
higher VEGF levels were associated with inactive disease. Though this association 
was statistically significant, it is unlikely to be of clinical significance given that 
elevated VEGF level being a marker of inflammation were found to be associated 
with inactive disease. The BILAG scores for the remaining 7 different systems did not 
show any association with plasma VEGF level. Robak et al have shown that serum 
VEGF levels are significantly higher in active (median 238 pg/ml) compared to 
inactive SLE (median 118 pg/ml) using systemic lupus activity measure (SLAM) to 
define disease activity as >15 points. Another study on lupus patients revealed that 
plasma VEGF levels were higher with lupus nephritis compared to those with absent 
renal disease. In this study, I did not find any such associations of plasma VEGF 
levels with lupus disease activity in any system. This could be possible as very few 
patients had BILAG scores A or B in any system. Two patients had BILAG ‘A’ score 
in our cohort with one each in mucocutaneous and musculoskeletal system. There 
were 3,8,1,6 and 14 patients scoring BILAG score ‘B’ in mucocutaneous, 
musculoskeletal, vasculitis, renal and haematologic systems respectively. None of the 
patients scored BILAG A or B in cardiorespiratory system. However, the comparison 
of patients with and without PAH showed that plasma VEGF level negatively 
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correlated with cardiorespiratory scores in the PAH subgroup and plasma VEGF level 
also negatively correlated with musculoskeletal scores in the non-PAH subgroup 
(Spearman Rank correlation test). The scatter plot analysis shows 2 patients in the 
PAH group to have BILAG disease score ‘C’ for cardiovascular system with median 
VEGF concentration of 90pg/ml  compared to 137 pg/ml in the rest of PAH group 
with BILAG score D or E. Thus, the BILAG score associations with plasma VEGF 
level in cardiorespiratory and musculoskeletal systems in subgroups relate to PAH are 
both weak and clinically insignificant. 
The lack of any correlation of plasma VEGF level with lupus disease activity 
monitoring tests such as anti-dsDNA antibody titres, complement C3 and C4 levels 
could also be a reflection of very few patients with active disease in our cohort at the 
time of assessment. None of the lupus associated autoantibodies showed any relation 
to plasma VEGF levels in our analysis. There have been no previous reports of any 
autoantibody association with VEGF in SLE. 
6.3.5 Conclusion 
Patients with SLE may have higher concentrations of plasma VEGF. In a cohort with 
low disease activity and few patients with significant PAH, I did not show any 
significant associations with disease activity or level of PAH. Prospective longitudinal 
studies may be of interest however to address associations reported by others more 
definitively. 
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CHAPTER 7   CONCLUSIONS 
 
7.1 Summary of prevalence of PAH in SLE study 
 
I have shown that the point prevalence of PAH was 4.2% (12 out of 283 patients) in 
our cohort of patients with SLE studied with TTE. This prevalence rate increases to 
7.1% if only cases with detectable TR jet are included (60% of patients). Only 1/12 
patients with PAH was known to have PAH prior to the study. Four other patients 
previously diagnosed with secondary PH did not meet criteria for PAH in this study, 
and 3/109 patients of the cohort who did not participate in the study were diagnosed 
with PAH previously based on TTE. 
As most of the PAH cases (75%) were found to be of mild severity (<40mm Hg) and 
asymptomatic, they would not meet criteria for guidelines-based treatment. Only 1/3 
patients with PAH fulfilled criteria for RHC (sPAP>40mmHg and WHO grade III/IV 
FC) according to study protocol, but refused to undergo RHC.  
There was a weak association of PAH with history of APS but no such association 
was found between PAH and history of Raynaud’s phenomenon or smoking status. 
The BILAG disease activity scores for any system evaluated were not significantly 
different but the total SLICC/ACR DI scores were different between SLE patients 
with and without PAH. Those SLE patients with total SLICC/ACR DI >2 were 
strongly associated with PAH. This suggests the possibility of previous disease 
activity contributing to higher damage scores and PAH.  
The autoantibody that showed a strong significant association with PAH in SLE was 
presence of lupus anticoagulant, and a weak association was found with anti-La 
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antibody. Patients with PAH and SLE were found to be frequently treated with 
warfarin and calcium channel blockers prior to this study. The significant association 
of lupus anticoagulant and presence of antiphospholipid syndrome in PAH cases 
suggests that thrombosis may play an important role in PAH with SLE. This is 
important, as it is treatable. 
It is currently unclear whether establishing the diagnosis of PAH in the pre-
symptomatic phase improves outcome in SLE patients but is likely to be important in 
those contemplating pregnancy due to high risk of maternal mortality in pregnancy 
with PAH. 
7.2 Summary of cardiovascular disease in SLE study 
  
Thickening of the anterior mitral valve was the most common cardiac morphological 
abnormality in our SLE cohort. Valvular regurgitation (tricuspid, mitral and/or aortic 
valve), left ventricular systolic dysfunction (LVSD) and concentric left ventricular 
hypertrophy (LVH) were the other common abnormalities detected on TTE. The 
majority of valvular abnormalities are mild without compromise in cardiac function. 
The benefits of infective endocarditis prophylaxis in patients with mild valvular 
disease who undergo dental surgery are not yet apparent. 
A strong association between MR and combined positive LA and high titre aCL IgG 
and aCL IgM was present similar to previous reports suggesting association of 
valvular disease with antiphospholipid antibodies. In contrast to previous studies, 
acute or chronic pericardial disease was absent in our cohort at the time of 
assessment. Only 1 patients had active disease in cardiorespiratory system with 
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BILAG index score ‘B’, and 4.9% of patients had SLICC/ACR DI cardiovascular 
score of 1 or 2.  
The majority of SLE patients had normal rate, rhythm and axis on ECG and the few 
abnormalities detected on ECG were not associated with BILAG index or 
SLICC/ACR DI. 
The valvular abnormalities are predominantly of mild degree similar to previous 
reports. However, those patients particularly at high risk of infective endocarditis 
should be offered prophylaxis when necessary for gingivo-dental manipulation.  
Left heart morphological and functional compromise was not associated with PAH in 
this cohort. There was no secondary cardiac cause for PH such as left heart 
dysfunction or severe valvular disease with compromised cardiac function detected on 
TTE in this SLE study cohort.  
7.3 Summary of respiratory abnormalities in SLE study 
 
The prevalence of pre-existing restrictive lung disease related to lupus was 5% and 
history of PE was recorded in 6 patients (2 had PAH) in this study. Two-third never 
smoked, and predominantly was in NYHA functional class I (85%). Respiratory 
muscle weakness was present in one-third in SLE patients. A strong correlation 
existed between inspiratory and expiratory muscle pressures as well as BMI and MIP 
in SLE patients. Pulmonary function tests in patients with SLE revealed low TLCO in 
55% and isolated low TLCO in 33%, and significant difference in all parameters 
noted between patients with and without dyspnoea as well as patients with and 
without pre-existing lung disease. 
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The respiratory questionnaires (modified MRC, BDI and SGRQ) showed that a third 
of the patients did not have dyspnoea and less than 10% with severe dyspnoea in the 
whole cohort. In the whole SLE cohort, the median 6MWD was 440m (range 60-
729m), and 6MWD showed significant correlation with total scores from all 
respiratory questionnaires (modified MRC, BDI and SGRQ) suggesting the limitation 
of exercise capacity in those with severe respiratory symptoms. 
The pulmonary risk factors including pre-existing RLD, history of smoking and 
respiratory muscle weakness were not associated with PAH in SLE patients. In 
patients with PAH, the median 6MWD was 435m (range 150-600m), the median % 
predicted TLCO was 66% (range 36-100) and only 17% had severe impairment 
recorded on respiratory questionnaires. Pulmonary function test parameters, 6MWT 
distance, and respiratory questionnaires may not have screening potential for PAH in 
SLE patients. 
The respiratory risk factor/screening test assessment in SLE patients has either 
highlighted a new finding such as respiratory muscle weakness or confirmed the 
presence of findings noted previously in other studies such as reduction of TLCO 
predicted%. There was no evidence of secondary pulmonary cause for PH such as PE, 
ILD or PVOD but the limitation of this study is that patients were not fully 
investigated for these conditions with HRCT or pulmonary vascular imaging at the 
time of study. Though PFT and 6MWT have been recognised as complimentary 
screening and/or monitoring tests for PH in SSc and IPAH patients, it is highly 
possible that these tests did not establish their screening potential role in SLE related 
PAH due to the fact that PAH was infrequent and mostly mild degree disease in this 
cohort. The minimal number of SLE patients with pulmonary damage also led to 
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absent secondary PH from pulmonary interstitial and thromboembolic disease in this 
cohort. 
7.4 Summary of Biomarkers in SLE associated PAH study 
 
NT-proBNP 
Our study confirms high levels of serum NT-proBNP are seen in SLE patients without 
overt cardiac disease or cardiac failure. The high NT-proBNP levels in SLE have a 
strong association with SLICC damage scores> 2 and longer disease duration. This 
may suggest the possibility of longer exposure to recurrent inflammatory disease with 
resultant damage accrual and increasing the susceptibility to ischemic heart disease. I 
have shown that high levels of NT-proBNP neither have a screening nor monitoring 
potential in mild PAH associated with SLE but this needs further studies in larger 
cohorts of SLE-PAH with more severe PAH disease. 
Soluble Fractalkine 
 
Soluble Fractalkine concentration was shown to be increased in patients with SLE. 
The elevated sFkn levels were similar to previous reports on plasma sFkn levels in 
SLE which were higher than RA. Soluble Fkn may be a serological biomarker for 
active vasculitis in SLE. I did not find an association between sFkn levels and PAH in 
SLE patients. The association of anti-Ro antibody with sFkn was a new finding of 
interest. The lack of association of sFkn with active disease markers in lupus reflects 
the minimal activity recorded in these patients at the time of study and/or it is possible 
that the patients chose to attend the study visit only when they felt well and had 
minimal or absent activity of lupus disease. 
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VEGF 
 
Patients with SLE have higher concentrations of plasma VEGF. In a cohort with low 
disease activity and few patients with significant PAH, I did not show any significant 
associations with disease activity or level of PAH. Prospective longitudinal studies 
may be of interest however to address associations reported by others more 
definitively. 
In summary, the role of NT-proBNP, sFkn and VEGF in predicting PAH in this SLE 
cohort is not evident but this is most likely to reflect the mild PAH seen in the few 
PAH cases diagnosed in this cohort. 
 
7.5 Limitations of studies 
 
1. This is an uncontrolled study.  
2. The patients studied might have been biased in only attending the study for 
echocardiogram and assessments while they were not suffering an acute flare. This 
could have reduced the point prevalence rate of PAH estimated in our cohort of SLE 
patients as well as reducing the level of disease activity measured. Certainly some 
patients rebooked their appointments on one or two occasions. 
3. The infrequent and predominantly mild PAH identified in this cohort is potentially 
a major determinant of lack of association with various risk factors and screening tests 
assessed in PAH related to SLE. 
4. The power calculation were performed to detect a significant difference in risk 
factor assessment between the sample sizes in this lupus cohort of 12 PAH cases and 
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271 non-PAH cases. The population value for the prevalence of a specific risk factor 
in lupus patients with and without PAH was assumed in order to perform the power 
calculation. If the prevalence value of a risk factor is 1%, 5%, 10% and 20% in SLE 
patients without PAH and the prevalence value of the same risk factor is at least 23%, 
34%, 43% and 58% respectively for SLE patients with PAH, then there is 80% or 
more power to detect a significant difference at the 5% level between our study 
groups. The statement above holds true whatever the observed prevalence values for 
the risk factor studied. For example, in the general population the reported prevalence 
value for antiphospholipid antibodies in SLE is 30-40% in those without PAH and 
upto 80% in those with PAH. However, such wide differences were not present for all 
the risk factors assessed in this study. 
7.3 Future research 
 
1. A prospective longitudinal long term controlled follow-up study of SLE patients 
with and without diagnosed PAH confirmed by RHC would help recruit a larger 
cohort of moderate and severe PAH associated with SLE. This would enable to assess 
risk factors and screening tests for PAH in patients with SLE in a meaningful and 
detailed manner. 
2. The screening potential of 6MWT in SLE-PAH needs further evaluation in a larger 
cohort of SLE patients with PAH. This could be done either retrospectively 
comparing symptomatic SLE patients with and without PAH or prospectively 
screening symptomatic SLE patients with 6MWT along with periodic PFT and 
Doppler echo evaluation of sPAP and/or RHC evaluation of mPAP. 
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3. It would be useful to conduct a prospective longitudinal study in a large unselected 
SLE cohort to assess the relationship of TLCO to SLE disease activity clinically and 
on blood tests and to determine if low TLCO has any prognostic significance. 
4. A prospective long term follow up study in a large cohort of SLE patients 
comparing PFTs and HRCT in relation to respiratory symptoms. 
5. It would be useful to evaluate the screening potential of biomarkers such as NT-
proBNP in combination with TLCO in a prospective controlled study of SLE patients, 
and also assess their prognostic significance in SLE patients with and without 
symptoms of PH. 
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APPENDIX 1 1997 UPDATE OF THE 1982 ACR 
REVISED CRITERIA FOR CLASSIFICATION OF SLE 
 
 Criterion  Definition  
1. Malar Rash  Fixed erythema, flat or raised, over the malar eminences, 
tending to spare the nasolabial folds  
2. Discoid rash  Erythematous raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring may occur in older lesions  
3. Photosensitivity  Skin rash as a result of unusual reaction to sunlight, by patient 
history or physician observation  
4. Oral ulcers  Oral or nasopharyngeal ulceration, usually painless, observed by 
physician  
5. Nonerosive 
Arthritis  
Involving 2 or more peripheral joints, characterized by 
tenderness, swelling, or effusion  
6. Pleuritis or 
Pericarditis  
1. Pleuritis--convincing history of pleuritic pain or rubbing 
heard by a physician or evidence of pleural effusion  OR  
2. Pericarditis--documented by electrocardiogram or rub or 
evidence of pericardial effusion  
7. Renal Disorder  1. Persistent proteinuria > 0.5 grams per day or > than 3+ if 
quantitation not performed  OR  
2. Cellular casts--may be red cell, hemoglobin, granular, tubular, 
or mixed  
8. Neurologic 
Disorder  
1. Seizures--in the absence of offending drugs or known 
metabolic derangements; e.g., uremia, ketoacidosis, or 
electrolyte imbalance OR  
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2. Psychosis--in the absence of offending drugs or known 
metabolic derangements, e.g., uremia, ketoacidosis, or 
electrolyte imbalance  
9. Hematologic 
Disorder  
1. Hemolytic anemia--with reticulocytosis OR  
2. Leukopenia--< 4,000/mm3 on ≥ 2 occasionsOR  
3. Lymphopenia--< 1,500/ mm3 on ≥ 2 occasions  OR  
4. Thrombocytopenia--<100,000/ mm3 in the absence of 
offending drugs  
10. Immunologic 
Disorder 
1. Anti-DNA: antibody to native DNA in abnormal titer OR  
2. Anti-Sm: presence of antibody to Sm nuclear antigen OR  
3. Positive finding of antiphospholipid antibodies on:  
1. an abnormal serum level of IgG or IgM anticardiolipin 
antibodies,  
2. a positive test result for lupus anticoagulant using a standard 
method, or  
3. a false-positive test result for at least 6 months confirmed by 
Treponema pallidum immobilization or fluorescent treponemal 
antibody absorption test  
11. Positive 
Antinuclear 
Antibody  
An abnormal titer of antinuclear antibody by 
immunofluorescence or an equivalent assay at any point in time 
and in the absence of drugs  
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APPENDIX 2 CLASSIC BILAG INDEX 
 
All features must be attributable to SLE and refer to last 4 weeks compared with 
prior disease activity  
Indicate features which are present: 1) Improving 
 2) same 
 3) worse 
 4) new 
                                                                           or Y/N or value 
(where indicated) 
                                                                               (default is 0 = 
not present) 
  
GENERAL 
1. Pyrexia (documented)  (        ) 
2. Weight loss - unintentional > 5%  (        ) 
3. Lymphadenopathy/splenomegaly  (        ) 
4. Fatigue/malaise/lethargy  (        ) 
5. Anorexia/nausea/vomiting  (        ) 
   
MUCOCUTANEOUS   
6. Maculopapular eruption - severe, active   
      (or discoid/bullous)  (        ) 
7. Maculopapular eruption - mild  (        ) 
8. Active discoid lesions – generalised or   
     extensive  (        ) 
9. Active discoid lesions - localised   
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     Including lupus profundus  (        ) 
10. Alopecia (severe, active)  (        ) 
11. Alopecia (mild)  (        ) 
12. Panniculitis (severe)  (        ) 
13. Angio-oedema  (        ) 
14. Extensive mucosal ulceration  (        ) 
15. Small mucosal ulcers  (        ) 
16. Malar erythema  (        ) 
17. Subcutaneous nodules  (        ) 
18. Perniotic skin lesions  (        ) 
19. Peri-ungual erythema  (        ) 
20. Swollen fingers    Y/N (        ) 
21. Sclerodactyly Y/N (        ) 
22. Calcinosis Y/N (        ) 
23. Telangiectasia Y/N (        ) 
   
NEUROLOGICAL   
24. Deteriorating level of  consciousness  (        ) 
25. Acute psychosis or delirium or  
confusional state 
 (        ) 
26. Seizures  (        ) 
27. Stroke or stroke syndrome  (        ) 
28. Aseptic meningitis  (        ) 
29. Mononeuritis multiplex  (        ) 
30. Ascending or transverse myelitis  (        ) 
31. Peripheral or cranial neuropathy  (        ) 
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32. Disc swelling/cytoid bodies  (        ) 
33. Chorea  (        ) 
34. Cerebellar ataxia  (        ) 
35. Headache severe, unremitting  (        ) 
36. Organic depressive illness  (        ) 
37. Organic brain syndrome including   
       pseudotumor cerebri  (        ) 
38. Episodic migrainous headaches  (        ) 
   
MUSCULOSKELETAL   
39. Definite myositis (Bohan & Peter)  (        ) 
40. Severe polyarthritis - with loss of   
       function  (        ) 
41. Arthritis  (        ) 
42. Tendonitis  (        ) 
43. Mild chronic myositis  (        ) 
44. Arthralgia  (        ) 
45. Myalgia  (        ) 
46. Tendon contractures and   
      fixed deformity Y/N (        ) 
47. Aseptic necrosis Y/N (        ) 
   
CARDIOVASCULAR & RESPIRATORY   
48. Pleuropericardial pain  (        ) 
49. Dyspnoea  (        ) 
50. Cardiac failure  (        ) 
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51. Friction rub   (        ) 
52. Effusion (pericardial or pleural)  (        ) 
53. Mild or intermittent chest pain  (        ) 
54. Progressive cxr changes-lung fields Y/N (        ) 
55. Progressive cxr changes-heart size Y/N (        ) 
56. ECG evidence of pericarditis or   
      myocarditis Y/N (        ) 
57. Cardiac arrhythmias including tachycardia   
      > 100 in absence of fever Y/N (        ) 
58. Pulmonary function fall by > 20% Y/N  
59. Cytohistological evidence of   
      inflammatory lung disease Y/N (        ) 
   
VASCULITIS   
60. Major cutaneous vasculitis incl.ulcers  (        ) 
61. Major abdominal crisis due to vasculitis  (        ) 
62. Recurrent thromboembolism (excluding  (        ) 
      strokes)   
63. Raynaud’s  (        ) 
64. Livido reticularis  (        ) 
65. Superficial phlebitis  (        ) 
66. Minor cutaneous vasculitis   
      (nailfold vasculitis, digital vasculitis,   
      purpura, urticaria)  (        ) 
67. Thromboembolism (excl. stroke)   
      - 1st episode Y/N (        ) 
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RENAL   
68. Systolic blood pressure (mm Hg) value (        ) 
69. Diastolic blood pressure (mm Hg) value (        ) 
70. Accelerated hypertension Y/N (        ) 
71. Urine dipstick protein (+ = 1, ++ = 2, value (        ) 
        +++ = 3)   
72. 24 hour urinary protein (g) value (        ) 
73. Newly documented proteinuria > 1g / 24hrs Y/N (        ) 
74. Nephrotic syndrome Y/N (        ) 
75. Creatinine (plasma/serum) value (        ) 
76. Creatinine clearance/GFR  ml/min value (        ) 
77. Active urinary sediment Y/N (        ) 
78. Histological evidence of active nephritis   
       - within 3 months Y/N (        ) 
   
HAEMATOLOGY   
79. Haemoglobin g/dl value (        ) 
80. Total white cell count x 109/l value (        ) 
81. Neutrophils x 109/L value (        ) 
82. Lymphocytes x 109/L value (        ) 
83. Platelets x 109/L value (        ) 
84. Evidence of active haemolysis Y/N (        ) 
85. Coomb’s test positive Y/N (        ) 
86. Evidence of circulating anticoagulant Y/N (        ) 
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APPENDIX 3 SLICC/ACR DAMAGE INDEX FOR SLE 
 
Damage (non-reversible change, not related to active inflammation) occurring 
since diagnosis of lupus, ascertained by clinical assessment and present for at least 
6 months unless otherwise stated.  Repeat episodes must occur at least 6 months 
apart to score 2.  The same lesion cannot be scored twice. 
 
OCULAR  
Any cataract ever (documented by ophthalmoscopy)   
Retinal change OR Optic atrophy (documented by ophthalmoscopy) 
  
Score 
1 
1 
NEUROPSYCHIATRIC 
Cognitive impairment (eg memory deficit, difficulty with calculation, poor 
concentration, difficulty in spoken or written language, impaired performance 
level) OR Major psychosis    
Seizures requiring therapy for 6 months      
Cerebrovascular accident or surgical resection (for non-malignant causes)         
(score 2 if >1) 
Cranial or peripheral neuropathy (excluding optic)     
Transverse myelitis        
  
 
 
 
1 
1 
1     2 
 
1 
1 
RENAL 
Estimated/Measured GFR < 50%       
Proteinuria ≥ 3.5g/24 hours       
OR  
End-stage renal failure (regardless of dialysis or transplantation) 
   
 
1 
1 
 
3 
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PULMONARY 
Pulmonary hypertension (right ventricular prominence or loud P2)   
Pulmonary fibrosis (physical & radiograph)      
Shrinking lung (radiograph) 
Pleural fibrosis (radiograph) 
Pulmonary infarction (radiograph) or resection (for non-malignant causes) 
 
 
1 
1 
1 
1 
1 
CARDIOVASCULAR 
Angina OR Coronary artery bypass 
Myocardial infarction                                                                       (score 2 if 
> 1)                                                                                                            
Cardiomyopathy (ventricular dysfunction) 
Valvular disease (diastolic, murmur, or systolic murmur > 3/6) 
Pericarditis for 6 months OR Pericardiectomy 
 
 
1 
1     2 
1 
1 
1 
PERIPHERAL VASCULAR 
Claudication for 6 months 
Minor tissue loss (pulp space) 
Significant tissue loss (eg loss of digit or limb)                               (score 2 if 
> 1)                                                   
Venous thrombosis with swelling ulceration OR Venous stasis (clinical) 
 
1 
1 
1     2 
1 
GASTROINTESTINAL 
Infarction or resection of bowel below duodenum, spleen, liver or gallbladder 
for any cause                                                                                          (score 2 
if > 1)                                                                                                                           
Mesenteric insufficiency 
Chronic peritonitis 
Stricture OR Upper gastrointestinal surgery 
 
1     2 
 
1 
1 
1 
1 
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Pancreatic insufficiency requiring enzyme replacement 
 
MUSCULOSKELETAL 
Muscle atrophy or weakness 
Deforming or erosive arthritis (including reversible deformities, excluding 
avascular necrosis) 
Osteoporosis with fracture or vertebral collapse (excluding avascular 
necrosis) 
Avascular necrosis (imaging)                                                     (score 2 if > 1)                                                                           
Osteomyelitis (supported by culture evidence) 
Tendon rupture 
 
 
1 
1 
 
1 
1     2 
1 
1 
SKIN 
Scarring chronic alopecia 
Extensive scarring or panniculum other than scalp and pulp space 
Skin ulceration for > 6 months (excluding thrombosis)  
 
 
1 
1 
1 
PREMATURE GONADAL FAILURE (secondary amenorrhoea before age 
40) 
 
1 
DIABETES MELLITUS (regardless of treatment) 
 
1 
MALIGNANCY (exclude dysplasia)                                      (score 2 if > 1 
site)                                                            
1     2 
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APPENDIX 4 PAH IN SLE- STUDY PROTOCOL 
SYNOPSIS 
 
Protocol synopsis for the study on PAH in SLE submitted to multi-centre research 
ethics committee, UK 
TITLE Determination of the prevalence and risk factors for PAH in 
patients with systemic lupus (SLE)).   
OBJECTIVES To evaluate the prevalence of patients with symptomatic 
Pulmonary Arterial Hypertension (PAH) diagnosed by 3D 
ECHO Doppler / right heart cardiopulmonary catheterisation in 
a group of patients with systemic lupus erythematosus. 
To assess the prevalence of PAH in the different subtypes of 
SLE defined by autoantibodies (including overlap syndrome 
such as mixed connective tissue disease). 
To determine risk factors for PAH in the total population and 
the different sub groups of patients with SLE. 
To evaluate the influence of DLCO on the sensitivity and the 
specificity of the PAH screening algorithm in patients with SLE 
To assess the frequency of cardiac valve abnormalities and right 
and left ventricular dysfunction in patients with SLE and their 
risk factors 
To assess the correlation between the sPAP determined by 
Doppler echocardiogram and the resting mPAP measured by 
 230 
right cardiac catheterisation, where medically indicated, such as 
in patients with moderate/severe PAH (>40 mm Hg).   
INDICATION  SLE 
METHODOLOGY Prospective observational study 
NUMBER OF 
PATIENTS 
400 patients 
POPULATION 
STUDIED 
Inclusion criteria: 
Male or female > 18 years 
SLE or mixed connective tissue disease 
Informed consent.   
Exclusion criteria: 
Pregnancy 
DURATION OF 
STUDY 
January 2004 to December 2005: cross-sectional study 
Follow up of patients with confirmed pulmonary hypertension 
for 5 years total (yearly assessment) 
OUTLINE OF 
STUDY 
The following data will be recorded: 
Clinical data (defined clinical criteria for disease activity and 
damage, SF36, and serology) 
Full lung function tests including DLCO (base hospital) 
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Electrocardiogram 
Doppler Echocardiogram (Wellcome Trust CRF) 
Echocardiographic assessment of cardiac function to determine: 
Left ventricular systolic function 
Left ventricular diastolic function 
Left atrial and aortic measurements 
Aortic – valve, sinuses, sinotubula, ascending aorta 
Right ventricular systeolic function 
Right ventricular diastolic function 
Valvular morphometry and dynamics 
Pulmonary valve – PA root dimension, PA – pressures 
Tricuspid valve 
Aortic valve 
Mitral valve 
Cardiac catheterisation (when clinically indicated). (Wellcome 
Trust CRF)   
Walking test (6 minutes)  
Respiratory muscle strength measurement 
Questionnaire assessing shortness of breath on exertion on a 
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scale of 1-10 (Borg scale) and transient dyspnoea index and/or a 
respiratory QOL score such as SGRQ.  
Detailed symptom questionnaire and history re smoking history 
will be included. 
TREATMENT NA – Non therapeutic study (but therapy taken by the patients 
will be recorded, in particular, calcium channel blockers, ACE 
inhibitors and related drugs, aspirin and warfarin) 
DEFINITIONS PAH: resting mPAP > 25 mm Hg (echocardiogram) 
STATISTICAL 
ANALYSIS 
 
Prevalence of PAH amongst the patients screened 
Prevalence of PAH for SLE (autoantibody subtypes) 
Correlation between ECHO Doppler and PAH confirmed on 
right heart catheter 
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APPENDIX 5 MODIFIED BORG DYSPNOEA SCALE 
 
  0  Nothing at all 
  0.5  Very, very slight (just noticeable) 
  1  Very slight 
  2  Slight 
  3  Moderate 
  4 Somewhat severe 
  5 Severe   
  6 
  7  Very severe 
  8 
  9   Very, very severe (almost maximal) 
10  Maximal     
 
Patient Instructions for Borg Dyspnoea Scale 
“This is a scale that asks you to rate the difficulty of your breathing. It starts at 
number 0 where your breathing is causing you no difficulty at all and progresses 
through to number 10 where your breathing difficulty is maximal. How much 
difficulty is your breathing causing you right now?” 
Modified Borg Fatigue scale: The same scale is used to score Fatigue level with 
appropriate instructions. 
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APPENDIX 6 MODIFIED MRC DYSPNOEA SCORE 
 
Grade 
0 “I only get breathless with strenuous exercise” 
 
1 “I get short of breath when hurrying on the level or walking up a slight hill” 
 
2 “I walk slower than people of the same age on the level because of 
breathlessness or have to stop for breath when walking at my own pace on the 
level” 
 
3 “I stop for breath after walking about 100 yards or after a few minutes on the 
level” 
 
4 “I am too breathless to leave the house” or “I am breathless when dressing” 
 
 
NB: This is the modified MRC (Medical Research Council) scale that uses the same 
descriptors as the original MRC scale in which the descriptors are numbered 1-5.  
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APPENDIX 7  St.GEORGE’S RESPIRATORY 
QUESTIONNAIRE 
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APPENDIX 8 PREVALENCE OF PAH IN SLE 
(PUBLICATION) 
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